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 Hedgehog (HH) signaling is a conserved mode of cell-cell communication that is 
indispensible for embryogenesis. HH proteins are secreted ligands that travel over long distances 
within a developing tissue to induce distinct cellular responses in a concentration- and time-
dependent manner. These properties necessitate precise spatial and temporal control of HH 
ligand production, distribution, and reception at the cell surface. Failure to properly regulate HH 
ligands during development produces debilitating congenital disorders. Moreover, deregulated 
HH pathway activity in adult tissues causes several human diseases. In particular, overactive HH 
signaling underlies many devastating pediatric and adult cancers. Therefore, understanding the 
mechanisms that restrain HH signaling will provide key insights into human development and 
disease pathogenesis.  
A highly conserved negative feedback loop involving the canonical HH receptor Patched 
(Ptc in Drosophila; PTCH1 in vertebrates) limits the magnitude and range of HH signaling by 
binding and sequestering HH ligands. While Ptc up-regulation is essential during Drosophila 
embryogenesis, PTCH1-feedback inhibition plays only a limited role in mammals. In this 
dissertation, I have resolved this discrepancy by demonstrating redundant roles between PTCH1 
and two additional vertebrate-specific HH-binding antagonists that are induced by HH signaling, 
PTCH2 and HHIP1. Importantly, I define PTCH1, PTCH2, and HHIP1 as a core network of HH 
pathway antagonists that play overlapping and essential roles to restrict HH signaling during 
mammalian embryogenesis. While any single antagonist is largely dispensable for normal 
	   xi	  
development, the combined loss of all three inhibitors yields unrestrained HH pathway activity in 
the mouse embryo. Moreover, I find that these vital HH antagonists function through distinct 
molecular mechanisms. In particular, I present evidence to define HHIP1 as a secreted inhibitor 
of vertebrate HH signaling. Surprisingly, secreted HHIP1 protein is enriched in epithelial 
basement membranes due to a direct, high affinity interaction with heparan sulfate. Intriguingly, 
HHIP1 also controls the tissue distribution of endogenous HH ligands within the basement 
membrane during development. Overall, these data provide novel insights into the mechanisms 
that restrain vertebrate HH signaling and establish a foundation for further investigation into the 
role of HH inhibitors during development, tissue homeostasis, and disease processes. 
	  
 






Restricting the Hedgehog response in development and disease: mechanisms that 
antagonize Hedgehog signaling at the cell surface 
 
1.1 Abstract 
Hedgehog (HH) signaling plays essential and diverse roles during invertebrate and 
vertebrate embryogenesis. HH ligands are dually lipidated signaling molecules that are 
distributed over long distances in developing tissues to impact cellular behavior. In several 
contexts, HH proteins act as morphogens, where a gradient of HH ligands produce distinct 
functional consequences in a concentration- and time-dependent manner. These properties 
necessitate precise spatial and temporal control of HH ligand production, distribution, and 
reception at the cell surface. This is largely accomplished by a diverse array of molecules at the 
cell surface and in the extracellular matrix that directly bind to HH ligands to regulate HH 
signaling in a developing tissue. Of particular interest is a class of ligand-binding HH pathway 
antagonists that are critical for restricting HH signaling during embryogenesis; however, little is 
known concerning the molecular and cellular mechanisms employed by these structurally diverse 
proteins to antagonize HH pathway activity. Beyond the role for HH signaling during 
development, dysregulation of the HH pathway post-natally underlies many devastating pediatric 
and adult cancers. In several contexts, HH ligands produced by tumor cells mediate critical 
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interactions with the surrounding cancer microenvironment to support disease progression. Thus, 
elucidating the mechanisms that regulate HH ligand activity is not only crucial to understand the 
molecular basis of tissue development, but will also unveil novel strategies to therapeutically 
manipulate HH signaling for a growing number of HH-dependent diseases. In this chapter, I 
review the basic mechanisms that regulate HH signaling at the cell surface with an emphasis on 
molecules that function to antagonize HH pathway activity during vertebrate embryogenesis. 
 
1.2 Hedgehog signaling: from Drosophila development to human pathophysiology  
1.2.1 Discovery of Core Hedgehog Pathway Components in Drosophila 
The HH ligand derives its name from a Nobel prize-winning genetic screen to identify 
mutations that affect embryonic patterning in Drosphila melanogaster embryos (Nüsslein-
Volhard and Wieschaus, 1980). The Hedgehog mutation produced embryos with a lawn of spiny 
denticle bands, reminiscent of hedgehog spines (Nüsslein-Volhard and Wieschaus, 1980). 
Cloning of the Hh gene a decade later revealed HH to be a secreted signaling molecule that acted 
to pattern the developing embryo (Mohler and Vani, 1992; Lee et al., 1992; Tabata et al., 1992; 
Taylor et al., 1993). HH ligands were subsequently identified in mouse, chicken, and zebrafish, 
demonstrating conservation of the HH pathway from flies to vertebrates (Krauss et al., 1993; 
Chang et al., 1994; Roelink et al., 1994; Riddle et al., 1993; Echelard et al., 1993). In fact, three 
HH ligands were identified in mice: Sonic Hedgehog (SHH), Indian Hedgehog (IHH), and 
Desert Hedgehog (DHH), demonstrating an expansion of the HH family in vertebrates (Echelard 
et al., 1993). 
The receptor for the HH pathway remained controversial due to the identification of two 
putative cell surface receptors, Patched (Ptc) and Smoothened (Smo). Smo is a 7-pass 
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transmembrane protein with homology to G-protein coupled receptors (GPCRs) (Alcedo et al., 
1996). Smo was an attractive candidate due to its structural homology to other cell surface 
receptors and because Smo mutants resembled a loss of HH pathway function (Alcedo et al., 
1996). Ptc encodes for a 12-pass transmembrane protein that is found at the plasma membrane 
(Capdevila et al., 1994a; Hooper and Scott, 1989; Nakano et al., 1989). In contrast to Smo 
mutants, loss of Ptc leads to ectopic activation of HH target genes downstream of HH ligand 
while Ptc overexpression inhibits HH pathway activity (Martizez Arias et al., 1988; Hidalgo and 
Ingham, 1990; Capdevila et al., 1994b; Johnson et al., 1995; Schuske et al., 1994; Ingham et al., 
1991); thus, Ptc is a negative regulator of the HH pathway. The controversy was resolved when 
three groups independently verified that Ptc was indeed the HH receptor through genetic and 
biochemical studies demonstrating direct binding of HH ligands to Ptc, but not to Smo (Stone et 
al., 1996; Marigo et al., 1996; Chen and Struhl, 1996). Although not the definitive HH receptor, 
Smo is an essential transducer of the HH signal that acts downstream of Ptc to indirectly regulate 
the activity of Cubitus Interruptus (Ci), the transcriptional effector of HH signaling in flies 
(Alexandre et al., 1996; Chen and Struhl, 1996). Three GLI transcription factors are the 
vertebrate homologues of Ci [reviewed in (Hui and Angers, 2011; Aberger and Ruiz i Altaba, 
2014; Falkenstein and Vokes, 2014)]. 
Overall, these initial studies in Drosphila demonstrated that HH signaling is a profoundly 
unique and unusual mode of cell-cell communication where the receptor, Ptc, acts as an 
antagonist of the pathway. In the absence of HH ligand, Ptc represses HH signaling through 
constitutive inhibition of Smo activity (Fig. 1-1, left panel). Ligand-binding to Ptc relieves this 
inhibition enabling Smo to transduce the HH signal (Fig. 1-1, right panel). Importantly, these 
relationships are conserved in vertebrates. 
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1.2.2 Processing, Release, and Distribution of HH Ligands 
 To understand the molecular strategies that regulate HH ligand activity, it is important to 
discuss the mechanisms that govern the biogenesis, packaging, release, and distribution of HH 
proteins in a developing tissue. HH ligands are synthesized as 45 kDa precursors that undergo an 
autocatalytic cleavage reaction generating the bioactive N-terminal 19 kDa ligands (Bumcrot et 
al., 1995; Lee et al., 1994; Porter et al., 1995; Martí et al., 1995). Two lipophilic moieties are 
covalently added to produce the active HH ligand. A C-terminal cholesterol is attached as a 
byproduct of the autocatalytic cleavage reaction and an N-terminal palmitate residue is added by 
the acyltransferase, Skinny Hedgehog (Ski) (Pepinsky et al., 1998; Chamoun et al., 2001; Porter 
et al., 1996a; b; Micchelli et al., 2002; Amanai and Jiang, 2001; Lee and Treisman, 2001). In 
Drosophila, HH ligand lacking the cholesterol modification exhibits an extended range of HH 
target gene activation in the developing embryo and wing imaginal disc, suggesting that the 
cholesterol moiety restricts the distribution of HH ligands within a target field (Porter et al., 
1996b; Burke et al., 1999). While the evidence in vertebrates is mixed, the role of cholesterol in 
restricting HH ligand distribution is likely conserved (Lewis et al., 2001; Li et al., 2006). In 
contrast, the palmitic acid residue is required for the full signaling potency of HH ligands both in 
vitro and in vivo, based on phenotypic analysis of Ski mutants in both Drosophila and mice and 
through analysis of mutant forms of HH ligands that are not receptive to palmitoylation 
(Chamoun et al., 2001; Chen et al., 2004; Kohtz et al., 2001; Lee and Treisman, 2001; Lee et al., 
2001c).  
In general, these lipid modifications impart significant hydrophobic character to HH 
ligands, promoting a strong association with cell membranes (Porter et al., 1995; Bumcrot et al., 
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1995; Porter et al., 1996b). This presents two key challenges: (1) a significant energetic barrier 
exists in the release of HH ligands from producing cells and (2) the solubility of HH proteins 
must be maintained as they distribute within a target field. The first challenge is overcome in part 
by Dispatched (DISP), a 12-pass transmembrane protein that is structurally similar to Patched, 
which is required for the release of HH ligands from producing cells (Burke et al., 1999; Caspary 
et al., 2002; Ma et al., 2002; Kawakami et al., 2002). Initial studies in flies demonstrated that 
DISP is required for the release of cholesterol-modified HH ligands from producing cells while 
HH ligand lacking the cholesterol modification is secreted independent of DISP (Burke et al., 
1999). Vertebrates possess two DISP homologues, DISP1 and DISP2, with DISP1 being the 
predominant actor as Disp1-/- mice demonstrate a near complete loss of HH activity similar to 
Smo-/- embryos (Caspary et al., 2002; Ma et al., 2002; Kawakami et al., 2002; Tian et al., 2005; 
Zhang et al., 2001). Recent biochemical evidence demonstrates that DISP directly binds to the 
cholesterol moiety of HH ligands, which then catalyzes the release of HH proteins from the 
plasma membrane (Tukachinsky et al., 2012; Creanga et al., 2012). In vertebrates, DISP activity 
is not sufficient to liberate HH ligands from the cell surface; release also depends on the activity 
of the Signal sequence, CUB domain, EGF-related (SCUBE) family of proteins (Kawakami et 
al., 2005; Woods and Talbot, 2005; Hollway et al., 2006; Tukachinsky et al., 2012; Creanga et 
al., 2012). These secreted molecules directly bind to the cholesterol moiety of HH proteins in a 
manner distinct from that of DISP to shield this hydrophobic adduct and maintain the solubility 
of HH ligands in the extracellular space (Tukachinsky et al., 2012; Creanga et al., 2012). 
Importantly, combined loss of all three SCUBE family members leads to a complete loss of HH 
signaling in zebrafish (Johnson et al., 2012); however no SCUBE homologue has been identified 
in Drosophila. 
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Another key strategy to maintain the solubility and signaling capacity of HH proteins is 
the assembly of higher order, multivalent HH ligand complexes. One key observation is that HH 
proteins are often visualized by immunofluorescence within large punctate structures (LPS) 
(Gallet et al., 2003; 2006). The assembly of HH ligand into these LPS requires cholesterol 
modification in addition to interactions with Heparan Sulfate Proteoglycans (HSPGs, see below 
for in-depth discussion of HSPGs in HH signal transduction) and is thought to be important for 
the magnitude and range of HH signaling (Gallet et al., 2006; 2003; Vyas et al., 2008). 
Moreover, biochemical studies of purified, soluble HH proteins demonstrate the presence of HH 
ligands in both high molecular weight complexes in addition to monomeric species, with the 
multimeric HH ligands possessing significantly greater signaling potency (Zeng et al., 2001; 
Chen et al., 2004; Feng et al., 2004). The assembly of HH ligands into these multimeric 
complexes depends on both the cholesterol and palmitate moieties (Chen et al., 2004). The exact 
nature of these higher-order HH particles is controversial and may involve packaging into 
exosomes, lipoprotein complexes, or soluble HH multimers [reviewed in (Therond, 2012)]. More 
recently, data in Drosophila and vertebrates suggest that HH ligands may be transported along 
the membranes of specialized filopodia extended from producing cells, bypassing the need for 
long-range diffusion of HH proteins (Rojas-Ríos et al., 2012; Sanders et al., 2013; Bischoff et al., 
2013; Kornberg and Roy, 2014); however, these various mechanisms of HH ligand dispersal are 
not mutually exclusive and organisms may employ several means to distribute HH proteins 
within a target field. 
 
1.2.3 The Vertebrate Central Nervous System as a Model for Hedgehog Ligand Function 
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 HH ligands play diverse roles in nearly every tissue during mammalian embryogenesis 
[reviewed in (McMahon et al., 2003)]; however, the neural tube represents one of the best-
studied systems for the role of HH signaling during vertebrate development. In the embryonic 
spinal cord, HH signaling is directly required to induce five unique ventral neuronal progenitor 
populations (Wijgerde et al., 2002; Zhang et al., 2001). Towards this end, Sonic Hedgehog 
(SHH) ligand functions as a morphogen, acting over long distances to specify distinct cell fates 
in a concentration- and time-dependent manner [reviewed in (Ribes and Briscoe, 2009; Dessaud 
et al., 2007)]. Shh is initially expressed in the notochord, a mesodermal structure underlying the 
neural tube, which induces a secondary source of SHH production in the ventral midline of the 
neural tube known as the floor plate (Fig. 1-2 A) (Echelard et al., 1993; Roelink et al., 1994; 
Riddle et al., 1993). This establishes a ventral-to-dorsal gradient of SHH ligand that acts on 
neural progenitors by inducing (Class II genes: Nkx6.1, Nkx2.2, Olig2, FoxA2, etc.) and 
repressing (Class I genes: Pax3, Pax7, etc.) a series of transcriptional determinants depending on 
the concentration and duration of exposure to HH signaling (Fig. 1-2 A) (Briscoe et al., 2000; 
1999; Ericson et al., 1997).  
Combinatorial expression of these transcription factors along the dorsal-ventral (D-V) 
axis defines five distinct ventral neuronal progenitor domains; each of these domains give rise to 
unique mature neuronal cell populations (Briscoe et al., 2000). For example, ventral progenitors 
closest to the source of SHH production that are exposed to the highest levels of HH signaling 
are specified as v3 interneuron progenitors through expression of Nkx2.2 (Briscoe et al., 1999). 
Progenitors situated further away from the source of HH production that are exposed to slightly 
lower SHH concentrations adopt an OLIG2+ motor neuron progenitor identity (Novitch et al., 
2001; Briscoe et al., 2000). The induction of these distinct cell fates at different concentration 
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thresholds of SHH ligand is supported by early studies demonstrating that naïve neural plate 
explants isolated from chicken embryos exposed to varying concentrations of SHH ligand adopt 
unique cell identities (Roelink et al., 1995; Martí et al., 1995; Briscoe et al., 2000; Ericson et al., 
1997). Importantly, the amount of HH ligand that is required to specify these distinct neuronal 
identities correlates to their dorsal-ventral position within the neural tube, with increasing 
concentrations of ligand inducing progressively more ventral cell types (Roelink et al., 1995; 
Martí et al., 1995; Briscoe et al., 2000; Ericson et al., 1997). Strikingly, as little as a two-fold 
change in HH ligand concentration is sufficient to specify unique cell fates (Briscoe et al., 2000; 
Ericson et al., 1997). 
Moreover, increasing the duration of HH signaling also induces a ventral shift in 
progenitor cell identity, underscoring the importance of timing in HH-dependent ventral neural 
patterning (Dessaud et al., 2007; Stamataki et al., 2005). This is supported in vivo as ventral cells 
initially express the low level HH target Olig2 at the onset of SHH exposure whereas induction 
of the higher threshold HH targets requires a longer duration of active HH signaling (Fig. 1-2 B) 
(Jeong and McMahon, 2005; Dessaud et al., 2007). Critically, a temporal adaptation mechanism 
de-sensitizes cells to ongoing HH pathway activity; thus, greater concentrations of HH ligand are 
required to maintain active HH signaling to induce a progressive shift form dorsal to ventral cell 
fates (Dessaud et al., 2007). The boundaries between these progenitor domains are subsequently 
refined through cross-repressive interactions between transcription factors expressed in 
neighboring populations (Fig. 1-2 B) (Briscoe et al., 2000; 1999; Ericson et al., 1997; Balaskas et 
al., 2012).  
This graded nature of the HH response suggests that neural progenitors must possess 
exquisitely sensitive mechanisms to precisely interpret the extracellular concentration of HH 
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ligands and to integrate these signals over time to ensure proper positional specification of 
ventral cell domains. Moreover, the extracellular distribution of HH ligands must be carefully 
controlled in order to establish the morphogenetic gradient. Several lines of evidence suggest that 
this is accomplished, in part, through feedback regulation of a diverse array of HH ligand-
binding proteins that have both positive and negative influences over HH pathway activity 
(Tenzen et al., 2006; Allen et al., 2007; 2011; Jeong and McMahon, 2005; Holtz et al., 2013; 
Chen and Struhl, 1996). In particular, negative feedback at the level of HH ligand is essential to 
limit HH signaling to the ventral aspect of the neural tube to preserve the requisite diversity of 
neuronal cell types (Milenkovic et al., 1999; Jeong and McMahon, 2005; Holtz et al., 2013). A 
diverse set of HH-binding molecules function to restrict the activity of HH ligands during 
embryogenesis (discussed below); however, the precise molecular mechanisms that antagonize 
HH signaling during ventral neural patterning remain poorly understood. 
 
1.2.4 Hedgehog Signaling in Human Cancers: From Bench to Bedside 
In addition to its role in development, HH signaling has been implicated in a diverse 
range of human diseases. Consistent with data in mice, mutations in HH pathway components in 
humans produce a broad spectrum of clinical developmental abnormalities in the limbs, face, 
brain, and skeleton, demonstrating an essential role for HH signaling in human embryogenesis 
(Gao et al., 2001; McCready et al., 2002; Bosse et al., 2000; Radhakrishna et al., 1997; Belloni et 
al., 1996; Roessler et al., 1996; 2003; Nanni et al., 1999; Bae et al., 2011). Importantly, 
overactive HH signaling post-natally is a driving force behind several devastating pediatric and 
adult cancers [reviewed in (Teglund and Toftgård, 2010)]. Broadly speaking, there are two 
distinct mechanisms that lead to pathologic HH pathway activation in the context of cancer. 
	   10	  
Classically, mutations in HH pathway components can lead to high levels of ligand-independent 
pathway activation that cell autonomously drives HH signaling to promote cancer growth (Scales 
and de Sauvage, 2009). However, there is an emerging class of cancers where tumor cells 
aberrantly re-express HH ligands that signal to the surrounding tumor microenvironment to 
foster tumor development (Scales and de Sauvage, 2009). 
 
Ligand-independent HH pathway activation drives Basal Cell Carcinoma, Medulloblastoma, 
and Rhabdomyosarcoma 
Simultaneous with the identification of Ptc as the canonical HH receptor, mutations in the 
human Ptch1 locus were identified as the driving mutation in hereditary basal cell nevus 
syndrome, or Gorlin’s syndrome (Johnson et al., 1996; Hahn et al., 1996; Chidambaram et al., 
1996; Wicking et al., 1997). Gorlin’s syndrome is a dominantly inherited condition characterized 
by a severe predisposition to basal cell carcinomas (BCCs), a largely benign skin tumor (Gorlin 
and Goltz, 1960). Affected individuals can possess dozens to thousands of BCCs in addition to 
other abnormalities including palmar pitting in the hands and feet, odontogenic keratocysts, 
central nervous system calcifications, polydactyly, enlarged body size (similar to acromegaly) 
and a variety of skeletal defects (bifid ribs, enlarged skull, vertebral anomalies) (Gorlin and 
Goltz, 1960; Evans et al., 1993; Athar et al., 2014). In addition, Gorlin’s syndrome patients are 
predisposed to a variety of other cancers, including medulloblastoma, meningiomas, ovarian 
tumors, and rhabdomyosarcomas (Evans et al., 1991; 1993; Athar et al., 2014). These 
observations suggested that PTCH1 functions as a tumor suppressor in several contexts. 
Consistent with this idea, inactivating mutations in PTCH1 have been isolated in sporadic BCCs, 
medulloblastomas, and rhabdomyosarcomas, demonstrating that PTCH1 is a key tumor 
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suppressor for a variety of human cancers (Hettmer et al., 2013; Johnson et al., 1996; Gailani et 
al., 1996; Hahn et al., 1996; Vorechovsky et al., 1997; Tostar et al., 2006). Since PTCH1 is 
required to antagonize HH pathway activity in the absence of ligand, these data suggest that 
ligand-independent HH signaling is a potent driver of tumorigenesis in several contexts. 
 Similar to Gorlin’s syndrome patients, Ptch1+/- mice are predisposed to developing 
several forms of cancers. While Ptch1 heterozygotes do not spontaneously develop BCCs, these 
tumors arise in response to ionizing radiation (Aszterbaum et al., 1998). Ptch1+/- mice do, 
however, develop medulloblastoma and rhabdomyosarcoma at varying frequencies depending on 
the genetic background, which is greatly enhanced after exposure to ionizing radiation (Goodrich 
et al., 1997; Svärd et al., 2006; Wetmore et al., 2000). BCCs and medulloblastomas can also be 
induced by conditional inactivation of Ptch1 in the skin and cerebellum, respectively (Yang et 
al., 2008; Adolphe et al., 2006; 2014). Moreover, overexpression of a constitutively active form 
of SMO can drive BCC-like tumors, medulloblastomas, and rhabdomyosarcomas while BCCs 
have also been produced through overexpression of GLI2 in the skin (Grachtchouk et al., 2003; 
Xie et al., 1998; Mao et al., 2006; Wong et al., 2009; Schüller et al., 2008; Grachtchouk et al., 
2000; Hutchin et al., 2005). Collectively, these data from mouse models confirm that ligand-
independent HH pathway activation underlies tumor development.  
  
Ligand-dependent HH signaling controls pancreatic tumorigenesis 
 While HH-dependent tumors classically arise through ligand-independent HH pathway 
activation, an emerging role for HH ligands has been described in several diseases, including 
pancreatic, intestinal, colorectal, and ovarian cancers (Yauch et al., 2008; Berman et al., 2003; 
Thayer et al., 2003; Theunissen and de Sauvage, 2009). In this context, cancer cells produce HH 
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ligands to signal to their surrounding microenvironment to promote tumor growth (Scales and de 
Sauvage, 2009). Pancreatic cancer represents the best example of this mode of HH signaling. 
Pancreatic ductal adenocarcinoma (PDA) is a terrible illness with an extremely poor prognosis. 
PDA tumors are surrounded by a dense desmoplastic stroma and are often metastasized at the 
time of diagnosis (Erkan et al., 2012). While pancreatic ducts do not normally express HH 
ligands, both pancreatic intraepithelial neoplasias (PanINs), the precursor lesions to pancreatic 
cancer, and PDAs aberrantly express SHH ligand, which activates HH target genes in the 
surrounding pancreatic mesenchyme (Berman et al., 2003; Thayer et al., 2003). 
In this context, HH pathway activity is limited to the stromal environment while the 
tumor epithelial cells are largely refractory to HH ligands (Thayer et al., 2003; Tian et al., 2009; 
Yauch et al., 2008). In xenograft models where PDA cell growth is supported by co-injection of 
stromal fibroblast cells, deletion of SMO in the stromal compartment significantly impaired 
tumor growth, suggesting that this tumor-stromal cross-talk is critical for PDA development 
(Yauch et al., 2008). Moreover, pharmacologic inhibition of HH signaling in a mouse model of 
PDA sensitized tumors to gemcitabine treatment, likely through disruption of the desmoplastic 
environment to facilitate drug delivery (Olive et al., 2009). These data suggested that HH 
signaling is a promising drug target for PDA; however, clinical trials with HH pathway inhibitors 
in pancreatic cancer patients have not been successful (Amakye et al., 2013).  
This failure in the clinic is consistent with recent reports suggesting that reducing HH 
pathway activity can actually accelerate pancreatic tumor growth (Mathew et al., 2014; Rhim et 
al., 2014; Lee et al., 2014). In PDA mouse models, both pharmacologic inhibition of HH 
signaling and conditional deletion of Shh in pancreatic epithelial cells lead to increased tumor 
growth and decreased overall survival. This was correlated with a reduction in the stromal 
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compartment, suggesting that the desmoplastic response might actually act to restrain PDA 
growth (Rhim et al., 2014; Özdemir et al., 2014; Lee et al., 2014). In these models, however, 
only a partial reduction in HH signaling is likely achieved, leading to accelerated disease. 
Consistently, using a PDA cell/fibroblast xenograft model, it was demonstrated that while partial 
loss of HH signaling in the stromal compartment enhanced tumor growth, complete inactivation 
of HH signaling lead to reduced tumor size (Mathew et al., 2014). These data underscore the 
critical need for novel strategies to manipulate ligand-dependent HH pathway activity to better 
treat a growing number of HH-dependent diseases. 
 
HH pathway inhibitors in the clinic 
 The first small molecule inhibitor of HH signaling was isolated as the active component 
of the corn lily Veratrum californicum (BINNS et al., 1963; Cooper et al., 1998). This compound 
was named cyclopamine since pregnant sheep who ingested this plant produced offspring with 
severe holoprosencephaly, similar to mouse embryos lacking Shh (BINNS et al., 1963; Chiang et 
al., 1996). Cyclopamine is a cholesterol-like molecule that directly binds to SMO to antagonize 
HH signaling and can be used to reverse tumor growth in cancers driven by loss of Ptch1 or by 
oncogenic SMO mutations (Chen et al., 2002b; Cooper et al., 1998; Taipale et al., 2000). These 
data suggested that pharmacologic inhibition of SMO may be a useful therapeutic to combat HH-
dependent cancers. Additional SMO-binding HH pathway antagonists were identified in a small 
molecule screen, one of which was optimized for potency and pharmacokinetic properties in 
humans, leading to the development of GDC-0449 (Chen et al., 2002a; Robarge et al., 2009). 
 Initial phase I clinical trials with GDC-0449 yielded promising results. In patients with 
locally advanced or metastatic BCC, more than half of patients demonstrated a significant 
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clinical response (Hoff et al., 2009). Moreover, GDC-0449 induced dramatic tumor regression in 
a 26 year old man with metastatic medulloblastoma; however, drug-resistant tumors appeared 
within 3 months of therapy due to a point mutation in SMO that disrupted drug binding (Yauch 
et al., 2009; Rudin et al., 2009). Phase II trials in patients with Gorlin’s syndrome or with 
advanced basal cell carcinomas also showed promising results leading to the FDA approval of 
GDC-0449, or vismodegib, for treatment of BCCs (Tang et al., 2012; Sekulic et al., 2012). While 
clinical trials are currently ongoing, GDC-0449 has not proven effective in treating other solid 
tumors (LoRusso et al., 2011; 2013; Italiano et al., 2013; Amakye et al., 2013).  
These observations in the clinic demonstrate the challenges of treating patients with HH 
pathway inhibitors. Current approaches rely almost solely on targeting and inactivating SMO 
activity. Unfortunately, acquired resistance to these drugs rapidly develops in several clinical 
models (Rudin et al., 2009; Yauch et al., 2008; Chang and Oro, 2012); thus, novel approaches to 
antagonize HH pathway activity are desperately needed to combat the growing list of cancers 
driven by overactive HH signaling. In particular, there is a critical need to therapeutically target 
HH ligand-dependent signaling in several contexts, such as pancreatic cancer. Encoded within 
the vertebrate genome are highly effective HH inhibitors that function to restrict HH ligand 
activity during embryogenesis. Unfortunately, the molecular mechanisms underlying HH 
pathway inhibition by these endogenous antagonists remain largely undefined. One of the long-
term goals of this dissertation research is to identify novel mechanisms that function to 
antagonize HH signaling during vertebrate embryogenesis to reveal additional strategies for 
therapeutic HH pathway inhibition. Since these endogenous HH antagonists reside at the cell 
surface, they may provide attractive drug targets in certain disease contexts, especially in 
pancreatic cancer where recent evidence suggests that activation of HH signaling could provide 
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therapeutic benefit (Lee et al., 2014). This could be achieved through pharmacologic inhibition 
of these endogenous HH antagonists. 
 
1.3 Diverse Molecular Mechanisms Restrict HH Ligand Activity at the Cell Surface   
 Complex mechanisms exist to restrict the activity of HH ligands during embryogenesis 
and to maintain normal tissue homeostasis in adulthood. This involves a set of diverse molecules 
that reside at the cell surface and in the extracellular matrix that directly bind to HH ligands to 
regulate their HH protein distribution and activity within a developing tissue. These structurally 
divergent proteins act through distinct molecular mechanisms to antagonize HH signaling during 
embryogenesis. The following section will delineate the key molecules that act to inhibit HH 
ligand activity during embryogenesis. 
 
1.3.1 Two Distinct Forms of Patched-Mediated Inhibition of HH Signaling 
Seminal studies in Drosophila defined two distinct forms of Ptc-mediated inhibition of 
HH signaling (Chen and Struhl, 1996). In the absence of HH ligand, Ptc represses HH target 
genes through constitutive inhibition of SMO (Ingham et al., 1991; Tabata and Kornberg, 1994; 
Chen and Struhl, 1996). This basal inhibition of SMO activity is termed ligand-independent 
antagonism (LIA, Fig. 1-3, top panel). Ligand-binding to Ptc relieves this inhibition, culminating 
in modulation of HH target genes, including Ptc-itself (Alexandre et al., 1996; Forbes et al., 
1993). Accumulation of Ptc at the cell surface in response to HH signaling unveils a second role 
for Ptc– to bind and sequester HH ligands, restricting their distribution away from the source of 
HH production (Chen and Struhl, 1996). HH ligand sequestration by Ptc is termed ligand-
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dependent antagonism (LDA, Fig. 1-3, bottom panel). These distinct activities of Ptc are 
functionally separable and mediated by unique molecular mechanisms. 
 
Ligand Independent Antagonism of SMO Activity and Localization Involves the Transporter 
Function of Patched 
 The mechanism underlying PTCH1-mediated inhibition of SMO (LIA) remains largely 
undefined. This activity is essential for embryogenesis as Ptch1-/- mouse embryos die at E9.5 and 
exhibit constitute activation of HH signaling throughout the embryo (Goodrich et al., 1997). 
Initial models postulated that PTCH1 and SMO could form a complex that sequesters and 
inactivates SMO activity (Stone et al., 1996). Ligand-binding to PTCH1 would cause 
dissociation and release of SMO from this inhibitory complex to activate downstream signaling 
(Stone et al., 1996). This model was called into question by a careful examination of the 
stoichiometric relationship between PTCH1 and SMO in relation to HH pathway activation 
(Taipale et al., 2002). The heteromeric PTCH1/SMO complex model relies upon a direct 
relationship between PTCH1 and SMO levels where roughly equal amounts of PTCH1 are 
required to suppress SMO activity. However, it was determined that PTCH1 sub-
stoichiometrically inhibits SMO activity with one molecule of PTCH1 capable of inhibiting up to 
40 molecules of SMO (Taipale et al., 2002). These data support a catalytic model wherein 
PTCH1 possesses enzymatic activity that restricts SMO function. 
 Clues as to the underlying catalytic nature of LIA come from structural homology of 
PTCH1 to the Resistance Nodular Division (RND) family of molecular transporters (Taipale et 
al., 2002). RND permeases are 12-pass transmembrane proteins that function as trimeric, protein-
dependent antiporters that transport small molecules across lipid bilayers (Tseng et al., 1999). 
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The transport activity of RND efflux pumps rely on a conserved GxxxD motif present in the 4th 
transmembrane domain that is thought to form the proton-binding domain of the pore complex 
(Tseng et al., 1999). Similar to RND permeases, PTCH1 is a 12-pass transmembrane protein that 
possesses this conserved GxxxD motif (Hooper and Scott, 1989; Nakano et al., 1989; Johnson et 
al., 1996; Hahn et al., 1996; Taipale et al., 2002). Moreover, PTCH1 forms a stable trimeric 
complex, consistent with other RND permeases (Lu et al., 2006; Tseng et al., 1999). Missense 
mutations in the conserved glycine and aspartic acid residues within the GxxxD domain severely 
compromise PTCH1-mediated inhibition of SMO and have been identified as the causative 
mutation in several families with Gorlin’s syndrome (Taipale et al., 2002; Chidambaram et al., 
1996; Wicking et al., 1997; Aszterbaum et al., 1998). These data support the idea that the 
catalytic basis for LIA involves the RND transporter activity of PTCH1. 
 The substrate transported by PTCH1 remains elusive, yet likely involves transport and 
depletion of a molecule that is required for SMO activity. Pharmacologic and genetic evidence 
demonstrate that cholesterol is required for SMO activation (Cooper et al., 2003; Stottmann et 
al., 2011). Additionally, several oxysterols directly bind to SMO leading to potent activation of 
HH signaling (Nachtergaele et al., 2012; Corcoran and Scott, 2006; Nachtergaele et al., 2013; 
Myers et al., 2013; Nedelcu et al., 2013). These observations invoke a model where PTCH1 
transports and depletes a sterol-like molecule that is required for SMO activation. Ligand-
binding to PTCH1 would de-activate this transport activity, enabling accumulation of the SMO 
activator to stimulate HH pathway activity. Whether PTCH1 directly transports sterols remains 
unknown. PTCH1 possesses a conserved sterol sensing domain (SSD) that binds sterols in 
several proteins that regulate cholesterol synthesis and trafficking, including HMGCoA 
reductase, SREBP cleavage-activating protein (SCAP), and Niemann-Pick C1 (NPC1) (Carstea 
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et al., 1997; Loftus et al., 1997). While some mutations within the SSD of Drosophila Ptc lead to 
a loss of SMO inhibition, these do not affect the LIA activity of vertebrate PTCH1 (Strutt et al., 
2001; Martín et al., 2001; Johnson et al., 2002). Interestingly, overexpression of Ptc in 
Drosophila wing imaginal disc cells increases sterol mobilization from endosomal 
compartments, which was not observed upon expression of a Ptc SSD mutant (Khaliullina et al., 
2009). Moreover, overexpression of vertebrate PTCH1 in fibroblasts and yeast cells enhances 
cellular efflux of BODIPY-labeled cholesterol (Bidet et al., 2011); however, no direct evidence 
exists demonstrating direct cholesterol transport by Ptc/PTCH1. Importantly, evidence in 
Drosophila has also implicated lipoprotein-derived lipids and phosphatidylinositol-4 phosphate 
as candidate molecules involved in Ptc-mediated regulation of SMO (Callejo et al., 2008; Yavari 
et al., 2010; Khaliullina et al., 2009), suggesting that Ptc may possess several substrates, 
consistent with the broad specificity of other RND permeases (Tseng et al., 1999). 
 Another key aspect of LIA involves the regulation of SMO subcellular localization by 
Patched. In Drosophila, Ptc resides at the cell surface in the absence of HH ligand, where it 
destabilizes SMO accumulation at the plasma membrane (Denef et al., 2000; Zhu et al., 2003). 
HH-binding induces Ptc internalization, leading to the stabilization of SMO at the cell surface to 
activate downstream signaling (Denef et al., 2000; Zhu et al., 2003). SMO molecules with 
activating mutations that render it refractory to Ptc-mediated inhibition are constitutively present 
at the cell surface even in the absence of HH ligand (Zhu et al., 2003). This reciprocal 
localization of PTCH1 and SMO is conserved in vertebrates with respect to the membrane of the 
primary cilium (Rohatgi et al., 2007; Corbit et al., 2005). The primary cilium is a microtubule-
based cellular protrusion that is essential for HH signal transduction (Huangfu et al., 2003). 
Many HH pathway components exhibit dynamic trafficking through the ciliary compartment, 
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including PTCH1, SMO, SUFU, and the GLI transcription factors (Rohatgi et al., 2007; Corbit et 
al., 2005; Haycraft et al., 2005; Tukachinsky et al., 2010). In the absence of HH ligand, PTCH1 
is present within the ciliary membrane to prevent SMO ciliary entry (Rohatgi et al., 2007). 
Ligand-binding prevents PTCH1 ciliary accumulation, enabling SMO to enter the primary cilium 
to initiate the HH signal transduction cascade (Rohatgi et al., 2007). Importantly, SMO ciliary 
entry is necessary, but not sufficient for HH pathway activation and likely involves a two step 
process including translocation to the ciliary membrane and subsequent activation (Rohatgi et al., 
2009; Corbit et al., 2005; Milenkovic et al., 2009). Collectively, these data support a model for 
LIA where PTCH1 controls the local distribution of small molecules that are required for both 
SMO trafficking and activation. 
 
Ligand-Dependent Antagonism by Patched Limits the Magnitude and Range of Hedgehog 
Signaling 
Ptc was initially defined as a target of HH signaling in Drosophila (Forbes et al., 1993; 
Alexandre et al., 1996). Induction of vertebrate Ptch1 by HH signaling is conserved in mice; 
thus, feedback up-regulation of Patched represents a fundamental aspect of HH signal 
transduction (Goodrich et al., 1996). Moreover, Ptch1 appears to be directly regulated by HH 
signaling based on ChIP-Chip and ChIP-Seq studies that demonstrate binding of GLI1 and GLI3 
at the Ptch1 locus (Vokes et al., 2007; 2008; Peterson et al., 2012).  
The function of Patched feedback-upregulation was first demonstrated in the Drosophila 
wing imaginal disc, where HH ligands produced in the posterior compartment induce HH target 
gene expression in cells within the anterior aspect of the tissue. As expected, Ptc mutant clones 
in the anterior compartment exhibited active HH signaling independent of their distance from the 
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HH source due to loss of SMO repression (Chen and Struhl, 1996). Strikingly, HH target genes 
were also inappropriately up-regulated in wildtype cells distal to these Ptc mutant clones (Chen 
and Struhl, 1996), suggesting that Ptc not only antagonizes SMO activity cell autonomously, but 
also sequesters HH ligands and prevents signaling in cells further away from the HH source. 
Similarly, Smo mutant cells were incapable of HH ligand sequestration due to loss of PTC-
feedback up-regulation (Chen and Struhl, 1996). Critically, a transgene expressing constitutive, 
low levels of Ptc from the Tubulinα1 promoter was sufficient to restore SMO inhibition in cells 
distal to the HH source, suggesting that the low levels of Ptc provided by the transgene are 
capable of antagonizing SMO activity in the absence of HH ligand (Chen and Struhl, 1996). 
However, this transgene failed to restore the ability of Ptc mutant cells to sequester HH ligand, 
leading to constitutive HH pathway activation throughout the anterior compartment (Chen and 
Struhl, 1996). Collectively, these data demonstrated two critical aspects of Ptc function: (1) that 
low levels of Ptc are sufficient to inhibit SMO activity, which was later confirmed by the sub-
stoichiometric relationship between PTCH1 and SMO as discussed above (Taipale et al., 2002) 
and (2) that feedback up-regulation of Ptc plays an essential role in Drosophila to bind and 
sequester HH ligands to restrict signaling in cells distal to the HH source (Chen and Struhl, 
1996). Importantly, this also established an experimental paradigm to separate LIA and LDA by 
Ptc. 
The molecular mechanism underlying LDA by Ptc likely involves endocytosis and 
degradation of liganded receptor complexes, clearing HH proteins from the extracellular space. 
Early immunohistochemical studies demonstrated that Ptc was present at both the cell surface 
and within intracellular punctate structures (Tabata and Kornberg, 1994). In Drosphila, HH 
ligand induces the internalization of Ptc in a dynamin-dependent manner (Denef et al., 2000; 
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Martín et al., 2001; Torroja et al., 2004). The internalized Hh-Ptc complexes are destined for 
lysosomal degradation, a mechanism that is likely conserved in vertebrates (Torroja et al., 2004; 
Incardona et al., 2002). However, recent evidence suggests that PTCH1-SHH complexes can be 
rerouted to a recycling endocytic pathway by the LRP2 receptor to promote HH signaling in the 
developing forebrain (Christ et al., 2012); thus, the subcellular trafficking of Ptc/PTCH1 in 
response to HH ligand is likely governed in a context-specific manner.  
The role of LDA to restrict HH signaling in vertebrates is less clear. A similar genetic 
strategy as used in Drosophila was developed in mice to rescue the early lethality of Ptch1-/- 
embryos caused by a loss of LIA (Fig. 1-4 A) (Milenkovic et al., 1999). In this model, Ptch1 was 
expressed ubiquitously, at low levels from the metallothionein promoter (MT-Ptch1) 
(Milenkovic et al., 1999). Tonal expression of Ptch1 from the transgene is sufficient to inhibit 
SMO activity; however, there is no feedback up-regulation of Ptch1 in response to HH signaling 
in MT-Ptch1;Ptch1-/- mice, which lack Ptch1 expression from the endogenous locus (Fig. 1-4 A). 
While Ptch1-/- mice die at E9.5 and exhibit constitutive HH signaling throughout the embryo 
(Fig. 1-4 B), MT-Ptch1;Ptch1-/- embryos demonstrate dramatic rescue of the Ptch1-/- phenotype 
and are nearly indistinguishable from wildtype embryos at E10.5 (Fig. 1-4, C and D). Depending 
on the transgenic line used in these rescue experiments, MT-Ptch1;Ptch1-/- embryos either 
survive to E15.5 with no apparent defects in HH-dependent patterning or perish at E12.5 and 
exhibit exencephaly and polydactyly, consistent with elevated HH pathway activity (Milenkovic 
et al., 1999). A closer examination of early ventral neural patterning in MT-Ptch1;Ptch1-/- at 
E10.5 demonstrated a subtle expansion of HH-dependent FOXA2+ floor plate cells and 
NKX2.2+ v3 interneuron progenitors, consistent with a mild increase in the magnitude and range 
of HH ligand activity in the developing neural tube (Jeong and McMahon, 2005). This mild 
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phenotype was surprising considering the constitutive de-repression of HH signaling observed in 
analogous experiments in the Drosophila wing imaginal disc, calling into question the role of 
PTCH1-feedback inhibition in vertebrate development.  
 
1.3.2 An Expansion of Cell Surface Hedgehog Pathway Antagonists in the Vertebrate Lineage 
The apparent limited role for negative feedback by PTCH1 in mice sharply contrasts with 
the essential role for Ptc-feedback inhibition in Drosophila. Unique to vertebrates are two 
additional cell surface HH pathway antagonists: the PTCH1-homologue, Patched 2 (PTCH2), 
and an unrelated membrane-anchored glycoprotein, Hedgehog interacting protein 1 (HHIP1) 
(Chuang and McMahon, 1999; Motoyama et al., 1998b; Carpenter et al., 1998; Koudijs et al., 
2008; 2005). Like Ptch1, both Ptch2 and Hhip1 are direct targets of the HH pathway that are up-
regulated in proximity to the source of HH ligand production (Fig. 1-3) (Chuang and McMahon, 
1999; Vokes et al., 2008; 2007; Motoyama et al., 1998a; Peterson et al., 2012; Holtz et al., 2013). 
To date, no PTCH2 or HHIP1 homologues have been described in Drosophila; thus, one 
explanation for the discordance between the role of LDA in mice and flies involves 
compensation between PTCH1 and the vertebrate specific HH feedback inhibitors. However, the 
roles for PTCH2 and HHIP1 during vertebrate embryogenesis are just beginning to unravel. 
Moreover, the molecular and cellular mechanisms employed by the vertebrate specific 
antagonists remain largely unexplored. The following sections will delineate the current 
understanding of PTCH2 and HHIP1 in vertebrate HH signal transduction. 
 
PTCH2: a PTCH1-homologue induced by HH Signaling 
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 A second Patched gene was initially cloned from the adult newt eye and subsequently 
identified in mouse, humans, and zebrafish (Takabatake et al., 1997; Motoyama et al., 1998b; 
Carpenter et al., 1998; Zaphiropoulos et al., 1999; Koudijs et al., 2008; 2005). Ptch2 is expressed 
in largely overlapping domains with Ptch1, consistent with Ptch2 as a target of HH signaling; 
however, Ptch2 is co-expressed with Shh in several contexts, which is not observed with Ptch1 
(Motoyama et al., 1998a; b). The direct regulation of Ptch2 by HH was later confirmed by ChIP-
Chip and Chip-Seq studies (Vokes et al., 2007; 2008; Peterson et al., 2012; Holtz et al., 2013). 
 PTCH2 is a 12-pass transmembrane protein that shares 56% amino acid identity with 
PTCH1 (Motoyama et al., 1998b; Carpenter et al., 1998). The major structural divergence 
between PTCH1 and PTCH2 is a truncated C-terminal tail in PTCH2. This leads to increased 
stability of PTCH2 compared to PTCH1, as ubiquitylation of the PTCH1 C-terminus by 
NEDD4- and SMURF-ubiquitin ligases targets the protein for endocytosis and degradation 
(Kawamura et al., 2008; Huang et al., 2013; Yue et al., 2014). Despite these structural 
differences, PTCH2 binds to all three mammalian HH ligands with similar affinity to PTCH1 
(Carpenter et al., 1998) and can complex with PTCH1 (Rahnama et al., 2004). While PTCH2 can 
inhibit HH ligand-dependent signaling in cell-based assays, there are conflicting reports as to 
whether PTCH2 possesses the ability to directly inhibit SMO activity in Ptch1-/- mouse 
embryonic fibroblasts (MEFs), which exhibit high levels of ligand-independent HH pathway 
activity (Rahnama et al., 2004; Nieuwenhuis et al., 2006). 
Ptch2 mutant mice were generated to test the functional role for PTCH2 during vertebrate 
embryogenesis (Nieuwenhuis et al., 2006; Lee et al., 2006). Surpisingly, Ptch2-/- mice are viable 
and fertile and exhibit no apparent defects in HH-dependent organ development (Nieuwenhuis et 
al., 2006; Lee et al., 2006). This is in stark contrast to Ptch1-/- mutants, which die at E9.5 and 
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display constitutive HH signaling throughout the embryo due to a loss of LIA. While Ptch2 
mutants do display a subtle expansion of Ptch1 and Gli1 expression in the developing limb bud 
consistent with elevated HH signaling, these defects do not alter HH-dependent digit 
specification (Nieuwenhuis et al., 2006). Interestingly, aged Ptch2+/- and Ptch2-/- male mice 
develop alopecia and skin lesions characterized by epidermal and dermal hyperplasia, ulceration, 
and loss of hair follicles (Nieuwenhuis et al., 2006); thus, PTCH2 may perform an important role 
to maintain normal skin homeostasis in adulthood.  
Beyond embryonic development, loss of Ptch2 enhances tumorigenesis in Ptch1+/- mice 
(Lee et al., 2006). Ptch1+/- mice exposed to ionizing radiation develop tumors in several organs 
and have been used as a model for BCC, medulloblastoma, and rhabdomyosarcoma (Pazzaglia et 
al., 2002; Zurawel et al., 2000; Pazzaglia, 2006; Mancuso et al., 2004). While Ptch2-/- mice 
exposed to ionizing radiation are not predisposed to cancer, Ptch2-/-;Ptch1+/- mice show a 
decreased tumor latency and decreased overall survival compared to Ptch1+/- animals after 
radiation exposure (Lee et al., 2006). Moreover, mutations in Ptch2 have been linked to Gorlin’s 
syndrome, suggesting that PTCH2 may function as a tumor suppressor in humans (Fujii et al., 
2013; Fan et al., 2008). These data demonstrate that PTCH2 plays overlapping roles with PTCH1 
to restrict tumorigenesis; thus, a similar functional redundancy between PTCH2 and PTCH1 may 
explain the lack of overt HH phenotypes in Ptch2-/- embryos. However, this idea has yet to be 
formally tested. 
 
HHIP1 plays overlapping and distinct roles with PTCH1 during vertebrate embryogenesis 
HHIP1 was first isolated in a screen to identify novel HH ligand-binding proteins 
(Chuang and McMahon, 1999). HHIP possesses several conserved functional domains including 
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an N-terminal cysteine rich domain (CRD), a 6-bladed β-propeller domain, two membrane 
proximal EGF repeats, a C-terminal hydrophobic region, and 4 N-linked glycosylation sites 
(Chuang and McMahon, 1999). This initial study described HHIP1 as a membrane-anchored 
protein based on its retention at the cell surface when expressed in COS-7 cells (Chuang and 
McMahon, 1999). Deletion of the C-terminal 22 amino acids stimulated significant secretion of 
HHIP from cells, suggesting that HHIP1 was a type-I transmembrane protein with a C-terminal 
membrane spanning helix (Chuang and McMahon, 1999). However, a subsequent report 
identified the presence of a secreted form of HHIP1 when overexpressed in HEK293T cells 
(Coulombe et al., 2004); thus, there is controversy surrounding the exact nature of the interaction 
between HHIP1 and the cell membrane. 
HHIP1 binds to all three mammalian HH ligands with high affinity (Chuang and 
McMahon, 1999; Pathi et al., 2001; Bishop et al., 2009; Bosanac et al., 2009). A crystal structure 
of HHIP1 in complex with SHH ligand implicated the β-propeller domain as the site of HH 
binding (Bishop et al., 2009; Bosanac et al., 2009). Overexpression of HHIP1 in the developing 
mouse skeleton using the Colα1 promoter produced shortened limbs similar to phenotypes 
observed in Ihh-/- embryos, demonstrating that HHIP1 can function to antagonize HH pathway 
activity (Chuang and McMahon, 1999). Hhip1 was initially described as a HH target gene due to 
its expression near the sources of HH ligand production (Chuang and McMahon, 1999). ChIP-
Chip and Chip-Seq studies demonstrated GLI binding at the Hhip1 locus, confirming direct 
regulation of Hhip1 expression by HH signaling (Vokes et al., 2007; 2008; Peterson et al., 2012); 
however, additional inputs that control Hhip1 expression have been demonstrated in Xenopus, 
including the BMP, WNT, and FGF signaling pathways (Cornesse et al., 2005). 
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These similarities between PTCH1 and HHIP1 as membrane-associated HH pathway 
antagonists induced by HH signaling led to the idea that HHIP1 might cooperate with PTCH1 in 
LDA of HH signaling during nervous system development (Jeong and McMahon, 2005). This 
idea was tested in mice by examining neural patterning in embryos lacking the combined 
feedback activities of PTCH1 and HHIP1 (Jeong and McMahon, 2005). Hhip1-/- mice are 
indistinguishable from wildtype embryos based on the number and distribution of HH-dependent 
ventral neuronal cell populations (Chuang, 2003; Jeong and McMahon, 2005). While MT-
Ptch1;Ptch1-/- embryos displayed a subtle increase in HH signaling in the ventral neural tube, 
MT-Ptch1;Ptch1-/;Hhip1-/- mice exhibited a dramatic expansion of HH-dependent ventral cell 
fates and a concomitant retraction of dorsal neuronal cell types at E10.5 (Jeong and McMahon, 
2005). These double mutant embryos also displayed an expansion of the SHH-producing floor 
plate; however, this severe ventralization phenotype was also observed at E8.5 prior to the 
induction of floor plate Shh expression, suggesting that this expansion of HH signaling is not 
secondary to increased HH ligand production (Jeong and McMahon, 2005). These data support a 
model where PTCH1 and HHIP1 play overlapping roles in LDA of HH signaling during ventral 
neural patterning.  
Interestingly, dorsal neural identity persists to an extent in MT-Ptch1;Ptch1-/-;Hhip1-/- 
embryos. These dorsal progenitors are competent to respond to HH signaling based on the 
expression of high level HH target genes throughout the dorsal-ventral axis observed in Ptch1-/- 
and Sufu-/- embryos, which exhibit constitutive HH pathway activation downstream of HH ligand 
(Cooper et al., 2005; Goodrich et al., 1997). This discrepancy suggests that additional 
mechanisms may contribute to LDA of HH signaling during neural pattering.  
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While HHIP1 is functionally redundant with PTCH1 in the developing nervous system, 
HHIP1 does display unique requirements in different tissues during embryogenesis. Most 
notably, Hhip1-/- mice die at birth due to severe defects in lung branching morphogenesis 
resulting from unrestrained HH pathway activity in the lung mesenchyme (Chuang, 2003). 
During lung development, Shh is expressed by the lung epithelium and activates HH signaling in 
the underlying mesenchyme to repress expression of Fgf10, a key mediator if epithelial 
outgrowth (Bellusci et al., 1997b; a; Sekine et al., 1999; Pepicelli et al., 1998; Litingtung et al., 
1998). Shh-/- embryos display a near complete absence of secondary branching morphogenesis 
with high levels of Fgf10 expression (Pepicelli et al., 1998; Litingtung et al., 1998). 
Counterintuitively, Fgf10 expression is maintained in the mesenchyme proximal to the growing 
epithelial bud tips, which are the sites of highest Shh expression in the lung endoderm (Bellusci 
et al., 1997b; a). It has been proposed that the high levels of SHH production at branch tips 
induces expression of Hhip1 in the surrounding mesenchyme to inhibit HH signaling and 
maintain the localized expression of Fgf10 to stimulate epithelial outgrowth (Chuang, 2003). 
Consistent with this model, Hhip1-/- lungs exhibit a loss of Fgf10 expression in the lung 
mesenchyme (Chuang, 2003).  
This unique requirement for HHIP1 during lung branching morphogenesis contrasts with 
the redundant role with PTCH1 in the developing nervous system. This is not simply a 
consequence of expression differences since Ptch1-feedback upregulation occurs in the lung 
mesenchyme (Chuang, 2003; Pepicelli et al., 1998; Bellusci et al., 1997b). These data suggest 
that HHIP1 performs a unique, non-redundant activity that is essential for lung branching 
morphogenesis that cannot be fulfilled by PTCH1; however, the features that distinguish HHIP1 
from PTCH1 in this context remain unknown. Importantly, Hhip1-/- embryos also display 
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developmental defects in other organ systems including the pancreas, stomach, and duodenum 
(Kawahira et al., 2003). In the developing pancreas, loss of HHIP1 produces a decrease in organ 
mass and endocrine cell numbers through a reduction in Fgf10 expression (Kawahira et al., 
2003); thus, HHIP1 likely plays a key role to protect Fgf10 expression by inhibiting HH 
signaling in multiple organs derived from the endoderm. 
In addition to its role in lung development, HHIP1 has been implicated in a variety of 
human lung diseases including COPD, lung cancer, and asthma (Wilk et al., 2009; Hancock et 
al., 2010; Van Durme et al., 2010; Young et al., 2010; Li et al., 2011b; Zhou et al., 2012; 
Castaldi et al., 2014). These SNPs that associate with COPD are not found within the Hhip1 
coding sequence, but instead largely reside in a distal enhancer region upstream of the Hhip1 
gene that contributes to Hhip1 expression (Zhou et al., 2012). Consistent with a role for HHIP1 
in COPD, lung tissue from COPD patients exhibited ~50% decrease in HHIP1 protein levels 
compared to control samples (Zhou et al., 2012). Importantly, PTCH1 and PTCH2 have not been 
associated with lung disease; therefore, HHIP1 appears to play a unique role to regulate both 
lung morphogenesis and to maintain lung physiology in adult life. However, the role for HHIP1 
in the adult lung is unknown. 
 
Blurring the lines: HH co-receptors play dual roles to promote and antagonize HH signaling 
 In addition to feedback up-regulation of PTCH1, PTCH2, and HHIP1, another essential 
component of negative feedback regulation of HH ligands involves downregulation of the 
positive-acting cell surface HH co-receptors, CDON (CAM-related/downregulated by 
oncogenes), BOC (brother of CDON), and GAS1 (growth arrest-specific 1) (Tenzen et al., 2006; 
Lee et al., 2001a; Allen et al., 2007). Drosophila possess the CDON/BOC homologues, Ihog 
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(interference Hedgehog) and Boi (brother of Ihog); however, no GAS1 homologue as been 
identified in flies (Lum et al., 2003; Yao et al., 2006). While these cell surface components are 
largely thought to promote HH signal transduction by functioning as essential HH co-receptors, 
recent evidence suggests that these molecules can play dual roles as HH pathway antagonists. 
CDON and BOC are transmembrane-anchored proteins within the Ig superfamily, 
possessing a series of Ig repeats followed by three fibronectin type III (FNIII) domains (Kang et 
al., 1997; 2002). In contrast, GAS1 is a GPI-anchored protein that has homology to GDNF 
receptor family (Cabrera et al., 2006; Stebel et al., 2000). All three proteins directly bind to HH 
ligands and can promote HH signaling in a ligand-dependent manner when overexpressed in the 
developing chicken neural tube (Tenzen et al., 2006; Lee et al., 2001a; Allen et al., 2011; 2007). 
GAS1, CDON, and BOC can also bind to PTCH1 and form distinct receptor complexes (Izzi et 
al., 2011). Importantly, Gas1, Cdon, and Boc are all under negative regulation by HH signaling 
(Tenzen et al., 2006; Allen et al., 2007). 
The essential role for GAS1, CDON, and BOC to promote HH signaling during 
development was largely defined through loss-of-function studies in mice. While Boc-/- mice are 
viable and fertile, Cdon-/- embryos display a mild loss of HH-dependent ventral cell fates in the 
neural tube and develop holoprosencephaly to varying degrees depending on the genetic 
background, consistent with a role for CDON to promote HH signaling (Tenzen et al., 2006; 
Zhang et al., 2006; Allen et al., 2011; Okada et al., 2006). GAS1 was initially characterized as a 
HH pathway antagonist through overexpression studies in the developing somite and tooth (Lee 
et al., 2001a; Cobourne et al., 2004); however, Gas1-/- embryos display prominent loss-of-
function HH phenotypes in the cerebellum, limb, eye, face, and neural tube, demonstrating a 
positive role for GAS1 in HH signal transduction (Lee et al., 2001b; Liu et al., 2002; 2001; Allen 
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et al., 2007; 2011; Izzi et al., 2011; Martinelli and Fan, 2007). Analysis of compound mutant 
embryos suggested that GAS, CDON, and BOC cooperate to promote HH signaling. For 
example, Gas1-/-;Cdon-/-, Gas1-/-;Boc-/-, and Cdon-/-;Boc-/- embryos exhibit more severe loss-of-
function phenotypes in the developing neural tube than loss of any single component (Tenzen et 
al., 2006; Allen et al., 2007; 2011). Strikingly, Gas1;Cdon;Boc triple mutant embryos display a 
near complete loss of HH signaling throughout the embryo, similar to Smo-/- animals. These data 
suggest that GAS1, CDON, and BOC play overlapping and essential roles to transduce HH 
ligand-based signaling (Allen et al., 2011; Izzi et al., 2011). Similar results were observed in 
Drosophila, where Ihog;Boi double mutants display a complete loss of HH signaling (Camp et 
al., 2010; Zheng et al., 2010).  
 In addition to their role to promote HH signaling, recent evidence suggest that the HH co-
receptors can function to antagonize HH pathway activity in certain contexts. In the developing 
Drosophila ovary, where HH signaling stimulates the proliferation of follicle stem cells (FSC), 
Boi binds and sequesters HH ligands to antagonize FSC divisions in a manner analogous to Ptc 
(Hartman et al., 2010). Interestingly, this mechanism acts in times of nutritional deprivation to 
restrict FSC proliferation and can be reversed in response to feeding through S6 kinase-
dependent phosphorylation of the Boi intracellular domain (Hartman et al., 2010). In zebrafish, 
morpholino-mediated knockdown of Cdon caused an expansion of HH signaling in the 
developing eye, suggesting that CDON can antagonize HH signaling in this context (Cardozo et 
al., 2014). Rescue experiments demonstrated that this antagonistic activity depends on the ability 
of CDON to bind to HH ligands, but was independent of PTCH1-binding (Cardozo et al., 2014). 
A similar tissue-specific role for BOC to antagonize HH signaling in the lower jaw of zebrafish 
has also been proposed (Bergeron et al., 2011). 
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 Collectively, these data demonstrate that the role for cell surface HH pathway 
components can vary in a context-dependent manner. The precise mechanisms that govern these 
divergent activities remain elusive. This likely does not involve the mode of ligand binding, 
since most cell surface HH pathway components bind to overlapping domains on the surface of 
HH ligands (Bishop et al., 2009; Bosanac et al., 2009; McLellan et al., 2008; Whalen et al., 
2013; Beachy et al., 2010). Instead, this phenomenon may be related to tissue-specific factors 
that govern the trafficking and assembly of distinct HH receptor complexes. Future studies will 
be needed to determine the molecular characteristics that define HH-binding activators and 
antagonists. 
 
1.3.3 Heparan Sulfate Proteoglycans Play Diverse Roles in Hedgehog Signal Transduction 
 Another critical regulator of HH pathway activity at the cell surface involves heparan 
sulfate proteoglycans (HSPGs). HSPGs are proteins found at the cell surface and within the 
extracellular matrix (ECM) that are decorated with heparan sulfates (HS), a glycosaminoglycan 
(GAG) composed of repeating disaccharide units of glucuronic acid and N-acetylglucosamine 
(Esko and Lindahl, 2001). HS can be differentially modified through variable sulfation, 
deacetylation, and epimerization of glucuronic acid to iduronic acid (Esko and Lindahl, 2001). 
Moreover, these modifications vary between tissue types and over developmental times, 
producing a great diversity of HS species that can differentially influence several cell signaling 
pathways (Esko and Lindahl, 2001; Allen and Rapraeger, 2003). There are two major classes of 
cell surface HSPGs including the transmembrane-anchored syndecans and the GPI-linked 
glypicans while Perlecan is a secreted HSPG found in the ECM (Lin, 2004). HSPGs are key 
regulators of morphogen signaling during embryogenesis (Yan and Lin, 2009; Häcker et al., 
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2005). Both HS and the HSPG core proteins play critical roles in the production, processing, 
distribution, and reception of HH ligands at the cell surface (Yan and Lin, 2009; Bandari et al., 
2015). HS and several associated core proteins directly interact with HH ligands in addition to 
other cell surface HH pathway components (Lee et al., 1994; Bumcrot et al., 1995; Chang et al., 
2011; Whalen et al., 2013; Rubin et al., 2002; Zhang et al., 2007; Capurro et al., 2008; Williams 
et al., 2010). Moreover, certain HSPGs function to antagonize HH signaling during 
embryogenesis, similar to PTCH1, PTCH2, and HHIP1 (Capurro et al., 2008). 
 
A critical role for HS to mediate HH ligand distribution 
 The role for HS to regulate HH signaling came from an analysis of the Drosophila tout 
velu (ttv) mutant (Bellaiche et al., 1998). Ttv is the Drosophila homologue of the mammalian 
hereditary multiple exostoses (EXT) family of proteins, mutation of which causes an autosomal 
dominant disorder characterized by benign bone tumors (exostoses) and short stature (Ahn et al., 
1995; Stickens and Evans, 1997). EXT proteins are glycosyltransferases that are essential for HS 
biosynthesis (Lind et al., 1998; McCormick et al., 1998). In the Drosophila wing imaginal disc, 
ttv was found to be required for the cell-to-cell movement of HH ligands within responding cells, 
but was not required to initiate the HH response in cells immediately adjacent to the source of 
HH production (Bellaiche et al., 1998; The et al., 1999; Han et al., 2004b). Moreover, loss of ttv 
caused retention of HH ligand within producing cells in the developing embryo (The et al., 
1999). These data demonstrated that HS is required to distribute HH ligands within a target field.  
Disruption of HS biosynthesis in mice causes lethality during gastrulation due to defects 
in FGF signaling (García-García and Anderson, 2003; Lin et al., 2000). However, a hypomorphic 
allele of Ext1 bypassed this early lethality and resulted in enhanced IHH signaling in the 
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developing bone through an increased range of HH ligand diffusion (Koziel et al., 2004). A 
similar defect was observed in Ext1+/- mice (Hilton et al., 2005). In contrast to studies in 
Drosophila, these data demonstrate that HS-interactions with HH ligands can also act to restrict 
HH ligand diffusion within a target field. Importantly, these models only lead to a partial 
disruption of HS-biosynthesis; therefore, conditional ablation of Ext genes in the developing 
bone will help to determine whether the requirement for HS in the cell-to-cell movement of HH 
ligands is conserved from flies to mice (Mundy et al., 2011). It is also important to consider how 
HS modifications might affect HH ligand distribution within a target field as HS sulfation can 
affect HH protein production and distribution in flies, zebrafish, chickens, and mice (Danesin et 
al., 2006; Oustah et al., 2014; Touahri et al., 2012; Wojcinski et al., 2011). 
 
Glypican family members play diverse roles to regulate HH signal transduction 
Members of the glypican family of core proteins are the predominant HSPGs that 
regulate HH signal transduction during embryogenesis. Drosophila possess two glypican core 
proteins, Dally and Dally-like protein (Dlp), while vertebrate have an extended family of 6 
glypicans (GPC1-6) (Filmus et al., 2008). Glypicans play complex and diverse roles to regulate 
HH signal transduction in both Hh producing and receiving cells. The role for glypicans in HH 
signaling was first identified in an RNAi screen to define novel regulators of the HH pathway in 
Drosophila, which demonstrated an essential role for Dlp in HH signal transduction (Lum et al., 
2003). Dlp mutants phenocopy a loss of HH signaling in the Drosophila embryo (Desbordes and 
Sanson, 2003; Han et al., 2004a; Williams et al., 2010); however, the requirement for Dlp is less 
pronounced in the wing imaginal disc due to redundancy with Dally (Gallet et al., 2008; Han et 
al., 2004a). Interestingly, the un-modified Dlp core protein is sufficient to rescue Dlp mutants, 
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demonstrating that these effects are HS-independent and instead rely on the core protein 
(Williams et al., 2010; Yan et al., 2010). The exact molecular mechanism underlying this effect 
remains unclear. While there are conflicting reports as to whether the Dlp core protein can 
interact with HH ligand (Williams et al., 2010; Yan et al., 2010), Dlp does associate with Ptc and 
can stimulate the endocytosis of Ptc-Hh complexes to promote HH activation (Yan et al., 2010; 
Gallet et al., 2008). Similarly, Dally promotes HH signaling through endocytosis of Ptc in 
receiving cells, an activity that requires cleavage of Dally by the GPI-hydrolase, Notum 
(Giraldez et al., 2002; Ayers et al., 2012).  
In addition to the role of glypicans in responding cells, Dally plays a distinct role in Hh-
producing cells to promote the formation of a long-range apical signaling gradient in the wing 
imaginal disc (Ayers et al., 2012). This activity depends on cleavage of Dally by Notum and is 
consistent with the role for HSPG-mediated assembly of HH ligands into signaling competent, 
multivalent structures (Ayers et al., 2010; Vyas et al., 2008; Eugster et al., 2007). Interestingly, 
this mechanism is thought to promote an apical distribution of HH ligands, which produces 
distinct functional consequences in HH receiving cells compared to a separate, Dally-
independent basolaterally-distributed pool of HH proteins (Ayers et al., 2010). In addition to 
packaging HH proteins into higher order structures, HS promotes the release of soluble HH 
ligand complexes from producing cells by promoting metalloprotease-dependent shedding of 
SHH in vitro (Dierker et al., 2009; Ohlig et al., 2012); however, the in vivo significance of this 
mechanism remains unclear. 
Mammalian glypicans have also been implicated in HH signal transduction [reviewed in 
(Yan and Lin, 2008)]. This was first demonstrated for Glypican-3 (GPC3), which is the causative 
mutation underlying Simpson-Golabi-Behmel syndrome, an X-linked disorder characterized by 
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developmental overgrowth (tall stature) and defects in digit specification, cleft palate, cardiac 
defects, cystic kidneys, in addition to rib and vertebrae fusions (Pilia et al., 1996; Neri et al., 
1998). Many of these phenotypes were recapitulated in a Gpc3-/- mouse model and are 
reminiscent of defects in HH signal transduction in multiple organ systems (Cano-Gauci et al., 
1999). Consistently, Gpc3-/- mice display overactive HH signaling in multiple contexts during 
embryogenesis (Capurro et al., 2008; 2009); thus, GPC3 functions as an antagonist of HH 
signaling.  
In contrast to the inhibitory activity of GPC3, Glypican-5 (GPC5) functions to promote 
HH signaling. This was initially defined in the context of rhabdomyosarcoma, which exhibit 
overexpression of GPC5 in some instances (Williamson et al., 2007). Overactive HH signaling is 
a potent driver of rhabdomyosarcoma in both mice and humans, leading to the idea that GPC5 
may potentiate HH signaling to drive tumor growth (Hahn et al., 1998; Bridge et al., 2000; 
Rajurkar et al., 2014; Nitzki et al., 2011). This was formally demonstrated in rhabdomyosarcoma 
cell lines, where GPC5 promotes tumor proliferation in response to HH signaling (Li et al., 
2011a). Moreover, GPC5 enhances HH-dependent expansion of cerebellar granule cell 
precursors in vitro, suggesting that GPC5 can promote HH signaling in several contexts (Witt et 
al., 2013); however, these data have yet to be confirmed in Gpc5 knockout mouse model. 
The opposing roles for GPC3 and GPC5 to antagonize and promote HH signaling, 
respectively, are reflected in their distinct mechanisms of action. GPC3 competes with PTCH1 
for HH ligand binding at the cell surface (Capurro et al., 2008). This is mediated through direct 
interaction between the GPC3 core protein and SHH, while the HS-chains interact with the LRP1 
receptor to promote endocytosis and degradation of GPC3-HH complexes (Capurro et al., 2008; 
2012). GPC5 also binds to HH ligand in addition to interacting with PTCH1 through its HS side 
	   36	  
chains (Li et al., 2011a). This HS-dependent interaction also promotes the localization of GPC5 
to the primary cilium, suggesting that GPC5 may function as a co-receptor for HH signaling (Li 
et al., 2011a; Witt et al., 2013). These distinct interactions might be related to the higher degree 
of HS sulfation present on GPC5 compared to GPC3 (Li et al., 2011a). Intriguingly, preventing 
convertase-dependent cleavage of GPC3 leads to a higher degree of HS sulfation and promotes 
interactions with PTCH1 (Capurro et al., 2015). Surprisingly, this abolishes the antagonistic 
activity of GPC3, which instead promotes HH signaling similar to GPC5 (Capurro et al., 2015); 
therefore, the degree of HS-sulfation may determine the identity of an HSPG as an HH activator 
or antagonist.  
Overall, these data demonstrate that vertebrate glypicans play diverse roles to regulate 
HH signaling; however, these data mostly focus on the role of glypicans in HH-responding cells. 
Conditional mouse mutants will be essential to tease out the precise roles of GPC3 and GPC5 in 
different developmental contexts. Moreover, preliminary evidence suggests that GPC1, GPC2, 
GPC4, and GPC6 can also modulate HH signaling (Williams et al., 2010; Wilson and Stoeckli, 
2013); thus, it will be critical to determine the role of the entire glypican family in HH signal 
transduction. 
 
Complex interactions between HS and HH ligands 
 HH ligands possess a conserved Cardin-Weintraub sequence (C-W, XBBBXXBX, where 
B is a basic amino acid), which is a common HS-interaction motif (Cardin and Weintraub, 1989). 
Mutation of basic residues within the C-W sequence in SHH reduced interactions with HS and 
diminished the ability of SHH to stimulate proliferation in cerebellar granule neuronal precursors 
(CGNPs) (Rubin et al., 2002). A knock-in mouse model mutating two of these C-W residues at 
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the endogenous Shh locus (Shhala/ala) produced mice that were viable and fertile (Chan et al., 
2009). Interestingly, while HH-dependent patterning was largely preserved in Shhala/ala mice, 
these animals exhibited smaller body size and reduced HH-dependent proliferative responses 
(Chan et al., 2009). These data suggested that the patterning and proliferative responses to HH 
signaling could be dissociated through proteoglycan interactions; however, these data need to be 
interpreted with caution since additional motifs within SHH can mediate interactions with HS 
(Chang et al., 2011; Whalen et al., 2013). Recently, a crystal structure of SHH in complex with 
different species of HS demonstrated an expanded mode of GAG binding employed by SHH and 
implicated a direct role for HS in the multimerization of HH ligands (Whalen et al., 2013). This 
may provide a mechanism to understand the role for HS to promote the assembly of higher order, 
multivalent HH ligand complexes (Vyas et al., 2008; Eugster et al., 2007; Whalen et al., 2013). 
While most of the focus to date has been on the interactions between HS and HH ligands, 
additional HH pathway components interact with HS in vitro, including Ihog and CDON (Zhang 
et al., 2007); however, the functional consequences of these interactions are unknown. It will be 
important to determine whether additional HH pathway components associate with HS and how 
these interactions contribute to HH signal transduction.  
 
1.4 Conclusions 
Regulation of HH signaling at the cell surface is a dynamic process involving a diverse 
array of HH-binding proteins. These molecules precisely control the magnitude and range of HH 
pathway activity to ensure normal tissue development in both flies and humans. Moreover, many 
of these cell surface HH pathway components continue to play critical roles into adulthood to 
maintain proper tissue homeostasis and function as tumor suppressors in a variety of contexts. In 
	   38	  
particular, feedback up-regulation of HH ligand-binding antagonist is a highly conserved process 
that plays a critical role to restrict the activity of HH ligands (Jeong and McMahon, 2005; 
Milenkovic et al., 1999; Chen and Struhl, 1996). This likely functions through two distinct 
mechanisms: (1) to cell autonomously decrease the sensitivity of cells to HH signaling by 
competing with productive ligand-receptor interactions at the cell surface and (2) to inhibit 
signaling non-cell autonomously in cells distal to the HH source by sequestering HH ligands and 
restricting their distribution within a tissue (Chen and Struhl, 1996; Jeong and McMahon, 2005).  
While Drosophila Ptc is the sole feedback HH inhibitor in flies, vertebrates possess three 
cell surface HH antagonists that are direct targets of the pathway, including PTCH1, PTCH2, and 
HHIP1 (Chen and Struhl, 1996; Goodrich et al., 1996; Motoyama et al., 1998; Carpenter et al., 
1998; Chuang and McMahon, 1999; Vokes et al., 2007; 2008; Holtz et al., 2013). The central 
focus of this dissertation involves this expansion of HH feedback inhibitors in vertebrates to 
include PTCH2 and HHIP1. While HHIP1 and PTCH1 play overlapping roles to restrict HH 
signaling during vertebrate embryogenesis, there is no described role for PTCH2 in vivo (Jeong 
and McMahon, 2005). In Chapter II, I use a combinatorial genetic approach to explore the role 
for PTCH2 in HH-dependent ventral neural patterning by addressing the potential redundancy 
between PTCH2, PTCH1, and HHIP1. Moreover, I set out to determine how all three vertebrate 
antagonists cooperate to restrict HH signaling by analyzing neural patterning in the complete 
absence of PTCH2-, HHIP1-, and PTCH1-feedback inhibition. Importantly, I also explore the 
cellular and molecular mechanisms of PTCH2-mediated inhibition of HH signaling including: 
(1) whether PTCH2 possesses similar catalytic activity as PTCH1 to directly antagonize SMO 
function; (2) if PTCH2 functions in the context of a receptor complex by exploring interactions 
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between PTCH2 and the HH co-receptors, GAS1, CDON, and BOC; and (3) whether PTCH2 
localizes to the primary cilium similar to other HH pathway components. 
Another key question is: why vertebrates possess additional feedback antagonists if they 
play largely redundant roles with PTCH1? While HHIP1 plays overlapping roles with PTCH1 in 
the developing nervous system, HHIP1 plays a non-redundant role to antagonize HH signaling in 
the developing lung (Chuang, 2003). However, the mechanisms underlying this unique activity 
of HHIP1 remain undefined. In Chapter III, I explore the biochemical and molecular 
mechanisms employed by HHIP1 to antagonize HH pathway activity that are distinct from 
PTCH1 and PTCH2. In particular, I define a novel role for HHIP1 as a secreted antagonist of 
vertebrate HH signaling. Moreover, I explore a critical interaction between HHIP1 and HS that 
governs the surface association and tissue distribution of HHIP1 protein. Finally, I examine 

















Figure 1-1. Basic mechanisms of HH signal transduction. (Left) In the absence of HH ligand, 
PTC constitutively inhibits the activity of SMO, a key transducer of the HH pathway. This leads 
to processing of the CI (GLIs in vertebrates) transcription factor into a repressor form that 
inhibits HH target gene activation. (Right) Ligand-binding to PTC relieves this inhibition 
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Figure 1-2. Graded HH signaling specifies distinct neuronal progenitor domains in the 
ventral neural tube.  (A) In the developing spinal cord, SHH ligand produced from the 
notochord and floor plate establish a gradient of HH ligand within the neural tube. This gradient 
of HH signaling leads to the induction (Class II; Nkx6.1, Olig2, Nkx2.2, FoxA2, Dbx1, Dbx2) and 
repression (Class I; Pax7, Pax3) of HH target genes in a concentration-dependent manner. 
Combinatorial expression of these transcription factors along the dorsal-ventral axis specifies 
five distinct ventral neuronal progenitor domains. (B) The duration of exposure to HH signaling 
is also critical for HH target gene activation, with initiation of low threshold targets (Olig2, 
green) at the onset of exposure to HH ligands, while higher threshold targets (Nkx2.2, blue; 
FoxA2, red) are induced at later time points. Subsueqent cross-repressive interactions between 
transcription factors in neighboring domains establishes a complex gene regulatory network that 
sharpens the boundaries between progenitor domains and prevents co-expression of these fate-
determinants, which is observed at earlier time points (blue-green nuclei).   
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Figure 1-3. Distinct mechanisms of HH pathway inhibition by cell surface molecules. (Top 
panel) In the absence of HH ligand, PTCH1 inhibits the activity of SMO to prevent HH pathway 
activity in a process termed ligand-independent antagonism (LIA). (Bottom panel) Ligand-
binding to PTCH1 relieves this inhibition, culminating in HH target gene expression including 
feedback up-regulation of Ptch1. High levels of PTCH1 at the cell surface binds ands sequesters 
HH ligands to restrict HH protein diffusion within a target field. Vertebrates possess two 
additional cell surface HH pathway antagonists, PTCH2 and HHIP1, that bind to HH ligands and 
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Figure 1-4. An experimental model to dissociate LIA and LDA. (A) A hypothetical model for 
the expression of Ptch1 over time in a HH-responsive tissue during embryogenesis. (Red line) 
While low levels of Ptch1 are required to inhibit SMO activity (LIA), initiation of HH signaling 
(dotted line) leads to feedback up-regulation of Ptch1 to bind and sequester HH ligands (LDA). 
While there is no Ptch1 expression in Ptch1-/- embryos (green line), LIA can be restored by a 
transgene expressing tonic levels of Ptch1 from the metallothionein promoter (blue line). In MT-
Ptch1;Ptch1-/- embryos, there are sufficient levels of Ptch1 for LIA of SMO, but no feedback up-
regulation of Ptch1 occurs in response to HH signaling (LDA, blue line). (B-D) Whole mount 
images of Ptch1-/- (B), MT-Ptch1;Ptch1-/- (C), and wildtype embryos (D) at E9.5 (B) and E10.5 
(C, D). While Ptch1-/- embryos die at E9.5 and exhibit severe developmental defects due to 
constitutive HH signaling (B), MT-Ptch1;Ptch1-/- animals are nearly indistinguishable from 
wildtype embryos at E10.5 (compare C, D). This demonstrates sufficient rescue of LIA by the 
MT-Ptch1 transgene and suggests that LDA of HH signaling might play a limited role to restrict 
HH signaling in vertebrates. Image in B was provided by Irene Althaus. Scale bar (B) 1000 µm. 
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Essential role for ligand-dependent feedback antagonism of vertebrate Hedgehog signaling 




Hedgehog (HH) signaling is essential for vertebrate and invertebrate embryogenesis. In 
Drosophila, feedback up-regulation of the HH receptor, Patched (PTC; PTCH in vertebrates), is 
required to restrict HH signaling during development. In contrast, PTCH1 up-regulation is 
dispensable for early HH-dependent patterning in mice. Unique to vertebrates are two additional 
HH-binding antagonists that are induced by HH signaling, HHIP1 and the PTCH1 homologue, 
PTCH2. While HHIP1 functions semi-redundantly with PTCH1 to restrict HH signaling in the 
developing nervous system, a role for PTCH2 remains unresolved. Data presented here define a 
novel role for PTCH2 as a ciliary-localized HH pathway antagonist. While PTCH2 is 
dispensable for normal ventral neural patterning, combined removal of PTCH2- and PTCH1-
feedback antagonism produces a significant expansion of HH-dependent ventral neural 
progenitors. Strikingly, complete loss of PTCH2-, HHIP1-, and PTCH1-feedback inhibition 
results in ectopic specification of ventral cell fates throughout the neural tube, reflecting 
constitutive HH pathway activation. Overall, these data reveal an essential role for ligand-
dependent feedback inhibition of vertebrate HH signaling governed collectively by PTCH1, 
PTCH2, and HHIP1. 
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2.2 Introduction 
During embryogenesis, complex gene expression patterns arise within fields of initially 
equivalent cells to form the tissues that comprise a fully developed organism (Perrimon and 
McMahon, 1999). A small number of conserved signaling pathways act via secreted ligands to 
establish these embryonic patterns, producing distinct cellular responses in a concentration and 
time dependent manner (Freeman, 2000; Ulloa and Briscoe, 2007; Kutejova et al., 2009). These 
pathways require precise spatial and temporal control of ligand production and distribution to 
preserve the requisite diversity of cellular responses and to limit signaling within the appropriate 
domains. Thus, feedback antagonism of secreted ligands plays a critical role in regulating the 
level and spatial distribution of signaling within a target field (Perrimon and McMahon, 1999; 
Freeman, 2000). 
Hedgehog (HH) proteins are secreted molecules that play critical roles in both vertebrate 
and invertebrate development (McMahon et al., 2003). Negative feedback at the level of HH 
ligand is governed by the canonical receptor, Patched (PTC; PTCH in vertebrates) (Chen and 
Struhl, 1996). Seminal studies in Drosophila identified two distinct forms of PTC-mediated 
antagonism (Chen and Struhl, 1996). In the absence of ligand, PTC inhibits the activity of 
Smoothened (SMO) (Ingham et al., 2000), a key effector of the pathway, in a process termed 
ligand-independent antagonism (LIA) (Jeong and McMahon, 2005). Ligand binding to PTC 
relieves SMO inhibition and culminates in modulation of HH target genes, including ptc itself. 
Consequently, PTC is highly up-regulated near the source of HH production to bind and 
sequester ligand and limit the level and the range of signaling within a responding tissue (Hooper 
and Scott, 1989; Nakano et al., 1989). This negative feedback by PTC at the level of ligand is 
known as ligand-dependent antagonism (LDA) (Jeong and McMahon, 2005). 
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Evidence from Drosophila suggests that PTC up-regulation is dispensable for SMO 
inhibition (LIA), but is required to sequester HH ligand and prevent pathway activation in cells 
more distal to the HH source (LDA) (Chen and Struhl, 1996). Feedback up-regulation of the 
vertebrate PTCH1 receptor is conserved in mammals (Goodrich et al., 1996); however, similar 
experiments that abrogate PTCH1-feedback up-regulation in mice do not dramatically alter HH 
signaling during early embryogenesis (Milenkovic et al., 1999; Jeong and McMahon, 2005). In 
this model, tonal levels of PTCH1 are produced from a transgene using the metallothionein 
promoter (MT-Ptch1) (Milenkovic et al., 1999). In MT-Ptch1;Ptch1-/- embryos, basal levels of 
PTCH1 are sufficient for LIA, but surprisingly given the Drosophila studies, these embryos 
display a largely normal body plan at E10.5 with relatively minor disturbances of HH-dependent 
patterning (Milenkovic et al., 1999; Jeong and McMahon, 2005). 
In contrast to Drosophila, vertebrates possess two additional cell surface HH-binding 
proteins that are induced by HH signaling: Hedgehog interacting protein 1 (HHIP1; (Chuang and 
McMahon, 1999), a membrane anchored glycoprotein, and Patched 2 (PTCH2; (Motoyama et 
al., 1998b), a structural homolog of PTCH1 that arose from a gene duplication event. HHIP1 acts 
partially redundantly with PTCH1 to antagonize HH signaling in the developing mouse central 
nervous system (CNS); embryos lacking both HHIP1 and PTCH1-feedback inhibition generate 
cell fates within the normal HH signaling domain that are more ventral than expected, and HH-
responses extend into dorsal regions that do not normally exhibit active signaling (Jeong and 
McMahon, 2005). In comparison, mutant embryos such as Ptch1-/-, where LIA is removed, and 
Sufu-/-, where the pathway is activated downstream of ligand, have an even more ventralized 
phenotype with a significant extent of the neural tube adopting a Sonic HH (SHH)-secreting 
floorplate fate (Goodrich et al., 1997; Cooper et al., 2005). The differences in the severity of 
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these patterning defects suggest that other mechanisms limit ligand-dependent vertebrate HH 
pathway activity. 
The contribution of PTCH2 in feedback antagonism during CNS patterning has not been 
addressed. Mouse PTCH1 and PTCH2 share 56% amino acid identity; a key difference is that 
PTCH2 is more stable than PTCH1 due to a truncated C-terminal region (Kawamura et al., 
2008). Although PTCH2 antagonizes HH signaling in cell-based assays (Rahnama et al., 2004), 
Ptch2-/- mice are viable and fertile, whereas Ptch1-/- mice die at E9.5 with ectopic HH signaling 
throughout the embryo (Nieuwenhuis et al., 2006; Goodrich et al., 1997). Ptch2-/- embryos do, 
however, exhibit subtle changes in gene expression consistent with increased HH pathway 
activation, including a slight expansion of Ptch1 and Gli1 expression in the developing limb bud 
and the embryonic hair follicle (Nieuwenhuis et al., 2006). These transcriptional changes 
ultimately resolve to produce normally patterned HH-responsive tissues although aged male 
Ptch2+/- and Ptch2-/- mice develop epidermal hyperplasia and alopecia (Nieuwenhuis et al., 
2006). That PTCH1 action may mask PTCH2 activity is a reasonable hypothesis especially given 
the observation that the loss of Ptch2 enhances tumorigenesis in a Ptch1+/- background (Lee et 
al., 2006). 
Here, we demonstrate that PTCH2 is a critical component of LDA in the developing 
neural tube. While embryos lacking PTCH2 alone or in combination with HHIP1 display normal 
neural patterning, combined loss of PTCH2 and PTCH1-feedback inhibition results in a 
significant expansion of SHH dependent-ventral cell populations. In addition, complete loss of 
PTCH2, HHIP1, and PTCH1-feedback inhibition results in a neural tube composed entirely of 
ventral cell populations, similar to Ptch1-/- and Sufu-/- embryos. Overall, these data demonstrate 
an essential role for negative feedback at the level of HH ligand during vertebrate development 
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Ptch2 is a direct HH target that antagonizes SHH-mediated pathway activation in vivo. 
Genomic characterization of GLI1 and GLI3 binding profiles highlight HH pathway 
components, including Ptch1, Ptch2 and Hhip1, as direct transcriptional targets of HH signaling 
(Vokes et al., 2008; 2007; Peterson et al., 2012). Previously, a promoter proximal GLI1 binding 
region (GBR) associated with Ptch1 recapitulated the majority of Ptch1 expression, including in 
the CNS (Vokes et al., 2007). Similarly, Ptch2 possesses a conserved promoter proximal GBR 
(Ptch2(-0.5kb); Fig. 2-1 A); however, the regulatory potential of this region remains unexplored. To 
determine the enhancer activity associated with Ptch2(-0.5kb) , we isolated a highly conserved 459 
base pair region and assayed reporter expression in transient transgenic mouse embryos at E10.5 
(Fig. 2-1 B). The Ptch2(-0.5kb) enhancer displays a ventral distribution throughout the entire CNS 
consistent with Ptch2 as a direct readout of SHH signaling (Fig. 2-1, C and D) and in line with 
previous reports of Ptch2 expression in the neural tube (Motoyama et al., 1998a). 
To examine PTCH2-mediated antagonism of HH signaling, and to directly compare 
PTCH2 to other cell surface HH pathway antagonists, we expressed PTCH2, PTCH1, and 
HHIP1 in HH-responsive NIH/3T3 fibroblasts. Cells transfected with a HH-responsive luciferase 
reporter (Chen et al., 1999) and treated with SHH show robust induction of luciferase activity 
compared to untreated cells (Fig. 2-1 E). Consistent with previous reports, expression of PTCH1, 
HHIP1, or PTCH2 inhibits NSHH-mediated pathway activation (Fig. 2-1 E; (Rahnama et al., 
2004). 
	   76	  
 To extend these results, we utilized chick in ovo electroporations to determine whether 
PTCH2 could antagonize SHH-dependent ventral neural patterning. During nervous system 
development, a gradient of SHH directly induces (class II genes: Nkx6.1, Nkx2.2, FoxA2, etc.) or 
indirectly represses (class I genes: Pax7, Pax3, etc.) expression of a series of transcriptional 
regulators in a concentration-dependent manner (Dessaud et al., 2008). The combinatorial 
activity of these transcriptional determinants along the dorsal-ventral (D-V) axis specifies unique 
neural progenitor domains that generate distinct classes of mature neurons (Briscoe et al., 2000). 
These targets quantitatively readout HH pathway activity in vivo. 
Ectopic expression of EGFP (pCIG) in the chick neural tube does not affect neural 
patterning (Fig. 2-1, F-I) based on expression of NKX6.1 (class II target) and PAX7 (class I 
target). In contrast, over-expression of either PTCH1 or PTCH2 represses NKX6.1 (Fig. 2-1, J, 
K, N, and O, arrows) and de-represses PAX7 expression in the ventral neural tube (Fig. 2-1, L, 
M, P, and Q, arrows) consistent with PTCH1 and PTCH2 acting as HH pathway antagonists. 
Importantly, NKX6.1 is maintained and PAX7 remains repressed in more ventral cells 
electroporated with either PTCH1 or PTCH2 (Fig. 2-1, J-Q, arrowheads), suggesting that 
Patched-mediated antagonism can be overcome by higher ligand concentrations. In contrast, a 
ligand-insensitive PTCH1 (PTCH1ΔL2) that acts as a constitutive SMO antagonist (Briscoe et al., 
2001) inhibits NKX6.1 and enables PAX7 expression in a position-independent manner (Fig. 2-
1, R-U). Taken together, these data are consistent with PTCH2 acting as a HH pathway 
antagonist. 
 
Ptch2-/- and Ptch2-/-;Hhip1-/- embryos display normal ventral neural patterning 
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 To determine the endogenous actions of PTCH2, we analyzed SHH-dependent ventral 
neural patterning in Ptch2-/- embryos. Consistent with other published alleles, Ptch2-/- mice are 
viable and fertile (Nieuwenhuis et al., 2006) and display a grossly normal body plan at E10.5 
(Fig. 2-2 A and B). As reported for Hhip1 mutants (Jeong and McMahon, 2005), Ptch2-/- 
embryos exhibit no overt defects in ventral neural patterning at E10.5 (Fig. 2-3; Fig. 2-4, B and 
G). 
 To address possible redundancy between PTCH2 and HHIP1 functions, we analyzed 
neural patterning in Ptch2;Hhip1 double mutant embryos at E10.5 (Fig. 2-4); however, Ptch2-/-
;Hhip1-/- embryos are grossly normal and exhibit no defects in ventral neural patterning at this 
stage (Fig. 2-2, A-C; Fig. 2-4, E and J). 
 
Expansion of ventral neural progenitors in embryos lacking PTCH1 and PTCH2 feedback 
antagonism 
 Given the previously identified redundancy between PTCH1 and HHIP1, we reasoned 
that PTCH1-feedback inhibition is sufficient to antagonize SHH signaling in Ptch2;Hhip1 
double mutants. Thus, to uncover a role for PTCH2, we utilized an MT-Ptch1 transgene that 
produces sufficient levels of PTCH1 for LIA of SMO (Milenkovic et al., 1999), to compare the 
phenotypes of MT-Ptch1;Ptch1-/- embryos that lack PTCH1-mediated LDA with MT-
Ptch1;Ptch1-/-;Ptch2-/- embryos, incapable of both PTCH1 and PTCH2-dependent LDA. 
As previously reported, MT-Ptch1;Ptch1-/- embryos display a grossly normal body plan at 
E10.5 (Fig. 2-2 D) (Milenkovic et al., 1999; Jeong and McMahon, 2005), although a subtle 
expansion of ventral cell identities is detected when compared to wildtype embryos at E10.5 
(Fig. 2-5, A, B, E, and F). This is in stark contrast to analogous experiments performed in 
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Drosophila, where removal of PTC-feedback inhibition completely abrogates receptor-mediated 
feedback antagonism (Chen and Struhl, 1996). Intriguingly, MT-Ptch1;Ptch1-/-;Ptch2-/- embryos 
exhibit midbrain and hindbrain exencephaly (Fig. 2-2 E)– similar to mutants lacking GLI3 
repressor activity (Hui and Joyner, 1993) and consistent with overactive HH pathway activity. 
Compared to MT-Ptch1;Ptch1-/- embryos, MT-Ptch1;Ptch1-/-;Ptch2-/- embryos also exhibit 
significant expansion of SHH-dependent NKX6.1 (Fig. 2-5 D), FOXA2, NKX2.2, and OLIG2 
(Fig. 2-5 H) expression at E10.5 indicative of an increased range of HH signaling in the absence 
of PTCH2. In particular, NKX2.2+ cells, which require a high threshold for induction (Ericson et 
al., 1997), are dorsally extended in MT-Ptch1;Ptch1-/-;Ptch2-/- embryos (Fig. 2-5 H, arrows, see 
insets). The ventral expansion is accompanied by retraction of the dorsal PAX3+ domain in MT-
Ptch1;Ptch1-/-;Ptch2-/- embryos (Fig. 2-5 D). Quantitation demonstrates a significant increase in 
FOXA2+ floorplate cells (Fig. 2-5 I), NKX2.2+ v3 interneuron progenitors (Fig. 2-5 J), and the 
proportion of the neural tube that is NKX6.1+ in MT-Ptch1;Ptch1-/-;Ptch2-/- embryos compared 
to MT-Ptch1;Ptch1-/- animals (Fig. 2-5 K).  
These results, in combination with previous studies (Jeong and McMahon, 2005), 
demonstrate that PTCH2 and HHIP1 functionally compensate for the absence of PTCH1-
feedback inhibition during ventral neural patterning. To determine whether transcriptional up-
regulation of Ptch2 or Hhip1 occurs in the absence of PTCH1-mediated LDA, we examined 
Ptch2 and Hhip1 expression patterns in the neural tube of MT-Ptch1;Ptch1-/- embryos using 
RNA in situ hybridization (Fig. 2-6). Both Hhip1 and Ptch2 are transcriptionally up-regulated in 
the ventral neural tube of MT-Ptch1;Ptch1-/- compared to wildtype embryos at E9.5 and E10.5 
(Fig. 2-6). We also observe significant up-regulation of Hhip1 transcripts in the paraxial 
mesoderm in embryos lacking PTCH1-feedback inhibition (Fig. 2-6, M-P). 
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Together the data suggest that PTCH1, PTCH2 and HHIP1 all contribute to LDA of SHH 
signaling. Further, when PTCH2 or HHIP1 is absent, the normal patterning response is 
dependent on PTCH1-mediated LDA. 
 
Severe neural tube ventralization in E10.5 embryos lacking combined PTCH1, PTCH2 and 
HHIP1 feedback antagonism 
 In both MT-Ptch1;Ptch1-/-;Ptch2-/- and MT-Ptch1;Ptch1-/-;Hhip1-/- embryos, a persistent 
PAX3+; NKX6.1- dorsal domain suggests that SHH signaling is largely absent from the dorsal 
neural tube (Fig. 2-5; Fig. 2-7, B and J). The cells in this region are HH-responsive, as evident 
from Ptch1-/- embryos where NKX6.1 extends the length of the D-V axis and only a small 
number of PAX3+ cells remain (Goodrich et al., 1997). This disparity could be explained by the 
residual functions of HHIP1 or PTCH2 in MT-Ptch1;Ptch1-/-;Ptch2-/- or MT-Ptch1;Ptch1-/-
;Hhip1-/- embryos, respectively. 
To test this, we reduced the gene dosage of Hhip1 in MT-Ptch1;Ptch1-/-;Ptch2-/- embryos. 
Consistent with this view, MT-Ptch1;Ptch1-/-;Ptch2-/-;Hhip1+/- embryos display a more severe 
expansion of ventral cell populations than MT-Ptch1;Ptch1-/-;Ptch2-/- embryos (Fig. 2-7, B, F, C, 
and G). Additionally, MT-Ptch1;Ptch1-/-;Hhip1-/-;Ptch2+/- embryos exhibit a further expansion of 
ventral cell identities compared to MT-Ptch1;Ptch1-/-;Hhip1-/- embryos (Fig. 2-7, J, K, N, and O). 
Thus, both HHIP1 and PTCH2 play significant roles when PTCH1/PTCH2 or PTCH1/HHIP1 
feedback responses are removed, respectively. Of note, there is significant variability in the 
degree of patterning defects in these embryos, which likely reflects the large effects from 
fluctuations in near threshold levels of dorsal SHH signals (Fig. 2-7, K and O, insets). 
Interestingly, we also observed significant mixing amongst different cell populations indicating 
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that LDA is essential to generate discrete boundaries between progenitor domains (Fig. 2-7, F 
and G, arrows). 
These data support the notion that PTCH1, PTCH2, and HHIP1 together comprise a 
feedback network of cell surface HH antagonists. To test this hypothesis, we generated embryos 
that completely lack cell surface feedback antagonism (MT-Ptch1;Ptch1-/-;Ptch2-/-;Hhip1-/-). 
Grossly, triple mutant embryos display severe exencephaly throughout most of the 
anterior-posterior axis, CNS overgrowth, craniofacial abnormalities, and enlarged somites (Fig. 
2-2 G). Remarkably, MT-Ptch1;Ptch1-/-;Ptch2-/-;Hhip1-/- embryos exhibit neural patterning 
defects comparable to those described in Ptch1-/- embryos (Fig. 2-7, D, H, L, and P) (Goodrich et 
al., 1997): a small dorsal midline cluster of PAX3+ cells, NKX6.1 expression along the entire D-
V axis (Fig. 2-7, D and L), OLIG2+ motor neuron progenitors confined to the dorsal neural tube, 
and NKX2.2+ v3 progenitors extending to the dorsal limits of the neuraxis (Fig. 2-7, H and P; 
Fig. 2-8). 
FOXA2 is critical for induction of SHH at the ventral midline and its activation there 
requires the highest level of HH signaling (Roelink et al., 1995; Ribes et al., 2010). In MT-
Ptch1;Ptch1-/-;Ptch2-/-;Hhip1-/- embryos, FOXA2 production extends throughout the D-V axis 
with high levels of expression ventrally and low levels dorsally (Fig. 2-7, H and P; Fig. 2-8), 
resulting in a dramatically enlarged SHH producing floorplate (Fig. 2-7, Q-U). However, 
persistent NKX2.2 expression in these cells demonstrates incomplete floorplate maturation (Fig. 
2-7, H and P; Fig. 2-8).  
As an expected outcome of progenitor misspecification, we also observed a severe 
reduction in post-mitotic descendants of specific progenitor classes in the absence of all LDA, 
including motor neurons (ISL1 and MNR2), V1 interneurons (EN1), and V0 interneurons 
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(EVX1; Fig. 2-9). Overall, these data demonstrate a collective requirement for PTCH2, HHIP1, 
and PTCH1-feedback inhibition to restrict HH signaling in order to ensure the appropriate 
diversity of both ventral and dorsal neural progenitor types. 
Beyond the severe neural patterning defects observed in the embryos, we also detected 
significant deficits in the size and cellularity of MT-Ptch1;Ptch1-/-;Ptch2-/-;Hhip1-/- neural tubes 
as well as aberrant neuroepithelial outgrowths (Fig. 2-10, A-E, arrows) and cells budding off of 
the epithelium into the lumen (Fig 2-10, F-J, arrowheads). These morphologic defects are 
accompanied by reduced proliferation and increased apoptosis, as assessed by Phospho-Histone 
H3 (PH3) and Cleaved Caspase-3 (CC3) staining, respectively, in triple mutants (Fig. 2-11). 
Notably, apoptotic cells are most prominent in the paraxial mesoderm surrounding the neural 
tube (Fig. 2-11) and the distal extent of apoptotic mesodermal cells from the notochord increases 
with the severity of the LDA mutations, suggesting that the cell death is dependent on SHH 
ligand. Additionally, the loss of paraxial mesoderm could contribute to the lack of mature 
neurons (Fig. 2-9) due to compromised retinoic acid production from the somites, which is 
required for neuronal differentiation in the neural tube (Diez del Corral et al., 2003; Novitch et 
al., 2003; Sockanathan et al., 2003). 
 
Severe neural tube ventralization in E8.5 MT-Ptch1;Ptch1-/-;Ptch2-/-;Hhip1-/- embryos is 
independent of floorplate-derived SHH 
The extended SHH domain in MT-Ptch1;Ptch1-/-;Ptch2-/-;Hhip1-/- embryos raises the 
possibility that the observed patterning defects are secondary to enhanced SHH ligand 
production rather than due to a direct deficiency of LDA. To resolve these conflicting 
interpretations, we examined neural patterning at E8.5, where SHH-dependent ventral patterning 
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derives solely from notochord-expressed ligand. While FOXA2 expression begins around the 8-
somite stage, floorplate SHH expression does not initiate until the 16-somite stage (Jeong and 
McMahon, 2005).  Thus, patterning defects prior to this time reflect direct readouts of the loss of 
LDA uncomplicated by ectopic SHH from an expanded floorplate.   
In Ptch2-/-;Hhip1-/- embryos at E8.5, neural patterning is normal as indicated by the dorsal 
restriction of PAX3, and NKX6.1 expression in the ventral neural tube (Fig. 2-12, A and F). In 
addition, FOXA2 expression initiates in the ventral midline with SHH synthesis limited to the 
notochord (Fig. 2-12 K). As expected, MT-Ptch1;Ptch1-/- embryos exhibit a slight expansion of 
NKX6.1 and FOXA2 compared to Ptch2-/-;Hhip1-/- embryos (Fig. 2-12, B, G, and L). However, 
MT-Ptch1;Ptch1-/-;Ptch2-/- embryos demonstrate a dramatic expansion of NKX6.1 and FOXA2 
expression compared to MT-Ptch1;Ptch1-/- embryos (Fig. 2-12, C, H, and M) at E8.5. 
Interestingly, the magnitude of this early difference is more marked than at E10.5, with FOXA2 
expression at the dorsal most extent of the neural tube in E8.5 MT-Ptch1;Ptch1-/-;Ptch2-/- and 
MT-Ptch1;Ptch1-/-;Ptch2-/-;Hhip1+/- embryos (Fig. 2-12, M and N, arrows), a phenotype never 
observed at E10.5. In some instances, we also observed reduced PAX3 (Fig. 2-12, H and I) and 
induction of FOXA2 (Fig. 2-12, M and N) in the somites of LDA mutants at E8.5, suggesting 
that ligand-mediated feedback antagonism also functions to restrain HH signaling in other HH-
responsive tissues. Finally, MT-Ptch1;Ptch1-/-;Ptch2-/-;Hhip1-/- embryos exhibit severe neural 
tube ventralization nearly indistinguishable from Ptch1-/- embryos at E8.5 (Fig. 2-12, J and O). In 
each instance, immunostaining for SHH confirmed that the patterning defects arise solely from 
notochord-derived ligand (Fig. 2-12, K-O). Collectively, these results are consistent with a direct 
requirement for LDA in neural progenitors to limit HH signaling at the onset of ventral neural 
patterning. 
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PTCH2 is a ciliary-localized SMO antagonist 
While the ectopic signaling observed in MT-Ptch1;Ptch1-/-;Ptch2-/-;Hhip1-/- embryos is 
likely ligand-dependent, loss of inhibition downstream of ligand could also contribute to this 
phenotype. To address this, we tested whether PTCH1, PTCH2 or HHIP1 could antagonize 
signaling downstream of SMO. In NIH/3T3 cells, co-transfection of PTCH1, PTCH2, or HHIP1 
with constitutively active SMOM2 (Xie et al., 1998) does not reduce HH pathway activity 
compared to cells transfected with SMOM2 alone (Fig. 2-13 A); thus, these cell surface 
molecules act upstream of SMO. 
We next explored whether PTCH1, PTCH2, and HHIP1 can directly antagonize SMO 
activity (LIA). Towards this end, we employed mouse embryonic fibroblasts (MEFs) isolated 
from Ptch1-/- embryos that lack LIA and exhibit high levels of HH signaling. While PTCH1 can 
directly inhibit SMO, there are conflicting reports concerning LIA by PTCH2 (Rahnama et al., 
2004; Nieuwenhuis et al., 2006). As previously reported, expression of PTCH1 in Ptch1-/- MEFs 
causes robust inhibition of HH-responsive luciferase reporter activity even at low concentrations 
of transfected DNA (Fig. 2-13 B; (Taipale et al., 2002). While PTCH1 and PTCH2 function 
equivalently at high DNA concentrations, PTCH2 displays significantly reduced activity at lower 
concentrations, even though PTCH2 protein is highly stable compared to PTCH1 (Fig. 2-13 B; 
(Kawamura et al., 2008). In contrast, HHIP1 is unable to inhibit SMO at any DNA concentration 
tested (Fig. 2-13 B). Overall, these results suggest that PTCH2 is capable of LIA of SMO but 
that PTCH2 activity is weaker than PTCH1. 
PTCH1 and PTCH2 are structurally related to the RND permease superfamily, which 
consists of 12-pass transmsembrane proteins that function by proton-antiport to efflux small 
molecules across lipid bilayers (Tseng et al., 1999). This transporter activity is dependent on a 
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conserved RND domain and missense mutations within the PTCH1 RND motif result in 
impaired LIA, consistent with PTCH1 functioning catalytically as an RND transporter (Tseng et 
al., 1999; Taipale et al., 2002). To determine whether LIA by PTCH2 involves a similar catalytic 
activity, we generated two analogous PTCH2 RND mutants: PTCH2G465V and PTCH2D469Y. 
As previously reported, PTCH1G495V and PTCH1D499Y exhibit reduced ability to inhibit 
SMO in Ptch1-/- MEFs (Fig. 2-13 C). Similarly, PTCH2G465V and PTCH2D469Y display 
impaired LIA at all concentrations tested (Fig. 2-13 D), consistent with PTCH2 functioning as an 
RND permease. PTCH2 binds all three mammalian HH ligands with similar affinity as PTCH1 
(Carpenter et al., 1998); however, previous work suggested that PTCH2-mediated inhibition of 
SMO is only relieved after treatment with Desert Hedgehog (DHH) ligand and does not respond 
to SHH (Rahnama et al., 2004). We next determined whether PTCH2 could respond to SHH in 
Ptch1-/- MEFs. Interestingly, both PTCH1- and PTCH2-mediated inhibition of SMO is partially 
relieved upon treatment with SHH (Fig. 2-13 E), suggesting that PTCH2 is responsive to SHH 
ligand. In contrast, a ligand-insensitive PTCH1 construct (PTCH1ΔL2) is refractory to SHH 
treatment (Fig. 2-13 E). 
During vertebrate embryogenesis, the HH co-receptors GAS1, CDON, and BOC are 
collectively required to initiate HH ligand-mediated responses (Allen et al., 2011). 
Gas1;Cdon;Boc triple mutant embryos are nearly identical to Smo-/- mutants (Allen et al., 2011), 
yet HH signaling can be activated downstream of ligand using small molecule SMO agonists in 
co-receptor deficient cerebellar granule neuron precursors (Izzi et al., 2011). Consistent with 
their role in mediating HH ligand-dependent signaling, GAS1, CDON, and BOC interact with 
PTCH1 and can form distinct receptor complexes (Bae et al., 2011; Izzi et al., 2011). Based on 
the ability of PTCH2 to respond to SHH, we assessed whether PTCH2 interacts with the HH co-
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receptors by co-immunoprecipitation. Similar to PTCH1, HA-tagged PTCH2 interacts with 
GAS1, CDON, and BOC in COS7 cells (Fig. 2-13 F), suggesting that PTCH2 can also form 
complexes with the HH co-receptors. 
SMO transduces the HH signal at the primary cilium, an organelle critical for vertebrate 
HH signal transduction (Corbit et al., 2005; Huangfu et al., 2003). In the absence of ligand, 
PTCH1 localizes to the primary cilium to prevent SMO ciliary accumulation and activation. 
Ligand-binding to PTCH1 delocalizes LIA from the ciliary membrane, enabling downstream 
signaling through SMO (Rohatgi et al., 2007). To determine whether PTCH2 and HHIP1 also 
localize to the primary cilium, we expressed HA-tagged PTCH2 and HHIP1 in NIH/3T3 cells to 
examine co-labeling of HA with the ciliary marker, Acetylated Tubulin (ACTUB). Consistent 
with previous studies, PTCH1 localizes to the primary cilium (Fig. 2-13, G-I). Strikingly, we 
also detect PTCH2 within the ciliary membrane of transfected cells (Fig. 2-13, J-L). This 
localization is not dependent on a physical interaction with endogenous PTCH1 as PTCH2::HA 
also localizes to the primary cilium in Ptch1-/- MEFs (Fig. 2-13, J-L, insets). In contrast, 
HHIP1::HA does not localize to the primary cilium (Fig. 2-13, M-O). Taken together these data 
suggest that ciliary localization is a shared feature between PTCH1 and PTCH2, but that ciliary 
localization is not a universal requirement for ligand-dependent HH pathway antagonism. 
 
2.4 Discussion 
A novel role for PTCH2 as a HH pathway antagonist during vertebrate neural patterning 
While initial studies suggested that PTCH2 plays little to no role in antagonizing HH 
signaling in vivo (Nieuwenhuis et al., 2006), data presented here support an important role for 
PTCH2 in restricting HH pathway activity during vertebrate embryogenesis. First, embryos 
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lacking both PTCH1 and PTCH2 feedback inhibition (MT-Ptch1;Ptch1-/-;Ptch2-/-) display more 
severe patterning defects than those lacking only PTCH1 feedback antagonism (MT-
Ptch1;Ptch1-/-). This inhibitory role is most evident at E8.5, when HH-dependent ventral 
patterning initially occurs unopposed by antagonistic roof plate signals, including Wnts and 
BMPs (Parr et al., 1993; Dudley and Robertson, 1997). Second, the severe ventralization 
observed in MT-Ptch1;Ptch1-/-;Ptch2-/-;Hhip1-/- embryos compared to MT-Ptch1;Ptch1-/-;Hhip1-/- 
animals suggests that PTCH2 limits HH activity in the absence of both HHIP1 and PTCH1 LDA. 
Lastly, chick electroporation studies and cell signaling assays confirm that PTCH2 directly 
antagonizes HH ligand function. This finding is particularly important in light of the potential 
role for PTCH2 in human cancers and congenital disorders (Fan et al., 2008; 2009).  
We also present evidence that both PTCH1 and PTCH2 restrict HH signaling using 
similar molecular mechanisms. Like PTCH1, PTCH2 can antagonize ligand-dependent HH 
pathway activation and directly inhibit SMO activity. Moreover, PTCH2-mediated LIA depends 
on a conserved RND motif, implicating PTCH2 as a novel RND-permease within the HH 
pathway. Emerging evidence suggests that the cell surface HH machinery functions in the 
context of a complex interaction network (Izzi et al., 2011; Bae et al., 2011). Similar to PTCH1, 
data presented here show that PTCH2 may function as a receptor complex with the obligate HH 
co-receptors, GAS1, CDON, and BOC. This is consistent with the ability of PTCH2 to respond 
to SHH ligand, but future studies will be needed to define the functional significance of these 
interactions and to determine how HHIP1 participates in the cell surface HH interactome.  
PTCH1 is thought to function within the membrane of the primary cilium to prevent 
ciliary entry and subsequent activation of SMO (Rohatgi et al., 2007). Consistent with this idea, 
we detect PTCH2 within primary cilium, implicating PTCH2 as a novel, ciliary localized HH 
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pathway component. However, the lack of ciliary localized HHIP1 suggests that ciliary 
localization is not a general requirement for ligand-dependent HH pathway antagonism, and that 
diverse mechanisms exist to restrict the activity of HH ligands during embryogenesis. 
 
Collective requirement for PTCH2, HHIP1, and PTCH1 during feedback antagonism of 
vertebrate HH signaling 
Our data support a model where PTCH2, HHIP1, and PTCH1 comprise a semi-redundant 
feedback network of cell surface antagonists that collectively act to restrict ligand-dependent HH 
pathway activity (LDA). Removal of any single cell surface antagonist produces little to no 
defects in ventral cell specification, while combined removal of PTCH1-feedback inhibition and 
either PTCH2 or HHIP1 produces a significant expansion of ventral cell populations. 
Intriguingly, complete loss of feedback inhibition by all three cell surface antagonists yields a 
neural tube composed entirely of ventral cell populations, including expression of the highest-
level HH targets, NKX2.2 and FOXA2, throughout the D-V axis.  
Patterning defects of this magnitude have thus far only been described for mutations that 
activate HH signaling downstream of ligand, such as Ptch1-/- and Sufu-/- embryos (Goodrich et 
al., 1997; Cooper et al., 2005). In contrast, the severe ventralization observed in MT-
Ptch1;Ptch1-/-;Ptch2-/-;Hhip1-/- embryos likely results from loss of inhibition at the level of HH 
ligand (LDA) and not simply from loss of SMO inhibition (LIA). First, only PTCH1 and PTCH2 
are capable of LIA; thus, the lack of ectopic signaling in the dorsal neural tube of MT-
Ptch1;Ptch1-/-;Ptch2-/- embryos confirms that PTCH1 levels provided by the MT-Ptch1 transgene 
are sufficient for LIA. Since HHIP1 is incapable of LIA, the severe ventralization observed upon 
further removal of HHIP1 likely results from enhanced ligand-dependent signaling. That HHIP1 
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is indirectly required for LIA is unlikely due to the normal patterning observed in Hhip1-/- and 
Ptch2-/-;Hhip1-/- embryos. Collectively, these results suggest an essential role for negative 
feedback at the level of HH ligand to restrict HH signaling during ventral neural patterning. Of 
note, this mechanism is likely more global as we also observe defects in somite patterning and 
craniofacial development. 
Despite the overall similarities in patterning defects, there are some clear differences 
between MT-Ptch1;Ptch1-/-;Ptch2-/-;Hhip1-/- (total LDA mutant) and Ptch1-/- (complete or near 
complete LIA mutant) embryos. The floorplate, as demarcated by the highest levels of FOXA2 
and SHH synthesis, extends to the dorsal limits of the latter, but only to mid regions of the neural 
tube in the former. This may reflect the importance of timing in HH-dependent patterning 
(Dessaud et al., 2008; Balaskas et al., 2012; Dessaud et al., 2007). In Ptch1-/- embryos, ectopic 
signaling occurs once cells gain competence to initiate a HH response. Conversely, the ectopic 
pathway activity observed in complete LDA mutants is dependent on the kinetics of SHH ligand 
production and distribution. Dorsal progenitors in LDA mutants ultimately experience high 
levels of SHH as evident by FOXA2 and NKX2.2 expression; however dorsal cells may not 
receive this signal within the narrow early competence window required for definitive floorplate 
specification (Ribes et al., 2010). Lastly, additional HH binding proteins may limit the time and 
range of SHH ligand-based responses, including the HH co-receptors GAS1, CDON, and BOC 
(Allen et al., 2011; Izzi et al., 2011), glypicans (Capurro et al., 2008; Li et al., 2011), megalin 
(LRP2) (Christ et al., 2012), or other cell surface proteins. 
 
Feedback regulation of SHH is required to establish discrete neural progenitor domain 
boundaries 
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 At the onset of ventral neural patterning, the SHH gradient induces or represses 
expression of transcriptional determinants along the D-V axis to establish distinct progenitor 
fates. This initial pattern established by SHH ligand is thought to be inherently disorganized and 
must be refined by cross-repressive interactions between transcription factors expressed in 
neighboring domains, resulting in sharp boundaries between neural progenitor populations 
(Briscoe et al., 1999; Briscoe et al., 2000; Ericson et al., 1997). In fact, mathematical models of 
the downstream gene regulatory network (GRN) initiated by HH signaling can recapitulate the 
graded and discrete patterns established in the ventral neural tube independent of threshold 
responses to HH ligand (Balaskas et al., 2012). This suggests that precise interpretation of a SHH 
gradient is not required to establish distinct progenitor domains in the ventral neural tube 
(Balaskas et al., 2012). However, our observation of significant mixing of pV3 and pMN 
populations in embryos with compromised LDA demonstrates the importance of feedback 
inhibition at the level of HH ligand to produce sharp boundaries between progenitor populations 
and suggests that the downstream GRN is not sufficient to properly pattern the ventral neural 
tube in the context of deregulated HH ligand. 
 A recent study in zebrafish suggests that the initial noisy pattern established by HH 
ligand is corrected by dramatic cell rearrangements. These migratory events lead to clustering 
and positioning of neural progenitors to establish discrete boundaries between domains (Xiong et 
al., 2013). Strikingly, ectopic motor neurons induced in the zebrafish neural tube migrate into the 
appropriate region independent of their initial position (Xiong et al., 2013). Conservation of this 
mechanism in mice would predict that ectopic ventral progenitors in embryos with disrupted 
LDA should migrate into their appropriate positions and produce discrete boundaries. However, 
this is not the case as our analysis reveals significant mixing of ectopic pMN and pV3 cells. This 
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discrepancy suggests that mouse and zebrafish could have fundamentally different mechanisms 
to achieve HH-dependent ventral patterning. Alternatively, the ectopic progenitors in LDA 
mutants could have been specified after cells are epithelialized and therefore unable to migrate. 
One intriguing possibility is that the proper regulation of HH ligands is required to direct these 
coordinated cell movements, despite an apparent lack of a role for downstream signaling in this 
process (Xiong et al., 2013). 
 
Complexity of cell surface regulation of HH signaling during vertebrate embryogenesis 
Together, the data presented here demonstrate that Drosophila and mammals have 
fundamentally similar feedback responses, though the unique role of Drosophila PTC has been 
distributed amongst three partially redundant proteins in mammals (PTCH1, PTCH2 and 
HHIP1), each of which are direct transcriptional targets of the SHH pathway and each of which 
participates in direct LDA of SHH signaling (Fig. 2-14). The presence of additional antagonists 
may provide essential robustness to HH-dependent patterning processes during vertebrate 
development, where HH ligands act over significantly larger distances and greater developmental 
times in a broader variety of tissue contexts than during invertebrate embryogenesis. 
Notably, the collective action of PTCH1, PTCH2, and HHIP1 to restrict HH pathway 
activity is analogous to the general requirement for the HH co-receptors, GAS1, CDON, and 
BOC, to activate HH signaling (Allen et al., 2011; Izzi et al., 2011). Similarly, removal of a 
single co-receptor produces only minor defects in ventral neural patterning while combined 
removal of GAS1, CDON, and BOC reveals their collective requirement in ligand-mediated HH 
pathway activation (Allen et al., 2011). The results presented in this study define an equally 
important network of cell surface antagonists that are collectively required to antagonize ligand-
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dependent HH signaling. However, it remains unclear what characteristics distinguish GAS1, 
CDON, and BOC as HH pathway activators compared to the HH pathway antagonists examined 
in this study. Future studies will be needed to elucidate the mechanisms that regulate the balance 
between HH pathway activation and inhibition at the cell surface in different HH-responsive 
tissues during embryogenesis, organ homeostasis, and HH-dependent disease processes. 
 
2.5 Materials and Methods 
Mice 
Ptch2 mice were generated and provided by Curis. The absence of Ptch2 mRNA was confirmed 
by expression analysis in the testes, the highest site of Ptch2 expression (Carpenter et al., 1998). 
Hhip1 (Chuang, 2003), Ptch1 (Goodrich et al., 1997), and MtPtch1 (Milenkovic et al., 1999) 
mice have all been previously described. For timed pregnant analyses, noon of the day on which 
a vaginal plug was detected was considered E0.5. Precise embryo staging was achieved by 
assessment of somite number at the time of dissection. For each analysis, a minimum of 3 
embryos were analyzed and representative images are shown. 
 For transgenic analysis of the Ptch2 enhancer, the Ptch2 enhancer region 
(chr4:116,768,296-116,768,754) was PCR amplified from C57Bl/6J genomic DNA, sequence 
verified and cloned upstream of a modified Hsp68-lacZ reporter construct containing a single 
copy of the chicken beta-globin insulator. Transient transgenics were generated via pronuclear 
injection and collected at E10.5. PCR genotyping and X-gal staining were performed as 
previously described (Vokes et al., 2007). 
 
Chick in ovo neural tube electroporations 
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Electroporations were performed as previously described (Allen et al., 2011). In brief, DNA (1.0 
µg/µl) was injected into the neural tubes of Hamburger-Hamilton stage 10-12 chicken embryos 




Immunofluorescence was performed essentially as previously described (Allen et al., 2011). 
Neural patterning analysis was performed at the forelimb level in E9.5 and E10.5 embryos. The 
following antibodies were used: mouse IgG1 anti-NKX6.1 (1:20, Developmental Studies 
Hybridoma Bank [DSHB]), mouse IgG2a anti-PAX3 (1:20, DSHB), rabbit IgG anti-DBX1 
(1:1000, gift from Dr. Yasushi Nagakawa), mouse IgG1 anti-FOXA2 (1:20, DSHB), rabbit IgG 
anti-FOXA2 (1:500, Cell Signaling), mouse IgG2b anti-NKX2.2 (1:20, DSHB), rabbit IgG anti-
OLIG2 (1:1000, Millipore), mouse IgG1 anti-SHH (1:20, DSHB), rabbit IgG anti-Cleaved 
Caspase-3 (1:200, Cell Signaling), rabbit IgG anti-Phospho-Histone H3 (1:1000, Millipore), 
mouse IgG1 anti-MNR2 (1:20, DSHB), mouse IgG2b anti-ISL1 (1:20, DSHB), mouse IgG2a 
anti-EVX1 (1:20, DSHB), and mouse IgG1 anti-EN1 (1:20, DSHB). Nuclei were visualized with 
DAPI (1:30,000, Molecular Probes). Alexa 488, 555, and 633 secondary antibodies (1:500, 
Molecular Probes) were visualized on a Leica upright SP5X confocal microscope. 
 
Cellular localization of HH pathway components 
NIH/3T3 fibroblasts were plated at 150,000 cells/well on coverslips and transfected 16-24 hours 
later. 6 hours post-transfection, cells were placed into low serum (0.5%) media and fixed 48 
hours later in 4% PFA for immunofluorescent analysis. 
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Luciferase assays 
Luciferase assays were adapted from a previously published protocol (Nybakken et al., 2005). 
Mouse NIH/3T3 fibroblasts were plated at 25,000 cells/well on gelatinized 24-well plates and 
transfected 16-24 hours later with 150ng of a ptc∆136-GL3 luciferase reporter (Nybakken et al., 
2005; Chen et al., 1999), 50ng of pSV-β-galactosidase (Promega), and 100 ng of control (pCIG) 
or experimental constructs using Lipofectamine 2000 (Invitrogen). After 48 hours, cells were 
placed in low serum (0.5%) media with 25µl of conditioned media from control (pCDNA3) or 
NSHH transfected (NShh-pCDNA3) COS7 cells. Luciferase (Luciferase Assay System kit, 
Promega) and β-galactosidase (BetaFluor β-galactosidase Assay Kit, Novagen) activity were 
measured after 48 hours. Luciferase values were normalized to β-galactosidase activity and 
expressed as fold induction relative to control treated cells. 
 Signaling assays in Ptch1-/- MEFs (a gift from Dr. M.P. Scott) were performed as 
described with the following modifications. Ptch1-/- MEFs were plated at 50,000 cells per well 
and secreted placental alkaline phosphatase was used as a transfection control (Alkaline 
Phosphatase Yellow pNPP Liquid Substrate for ELISA, Sigma-Aldrich). 
 
Immunoprecipitation 
COS7 cells were plated at 1x106 cells/100 mm-dish and transfected the next day with expression 
plasmids for the indicated proteins. Immunoprecipitations and western blot analyses were 
performed as previously described (Okada et al., 2006) In brief, PTCH::HA proteins were 
immunoprecipitated using a mouse anti-HA antibody (SIGMA H3663). Western blot analyses 
were then performed using mouse anti-HA, rabbit anti-GFP (Molecular Probes A11122), goat 
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anti-Gas1 (R&D AF2644), and mouse anti-Actin (SIGMA A5441) to reveal the input and IP 
levels. 
 
In situ hybridization 
In situ hybridization was performed essentially as described (Wilkinson, 1992) using digoxigenin 
labeled probes on 20µm sections collected at the forelimb level of E9.5 and E10.5 embryos. 
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2.7 Figures 
 
Figure 2-1. PTCH2 is a direct transcriptional target that antagonizes HH signaling in 
NIH/3T3 cells and in the developing chick neural tube. (A) Ptch2 regulatory landscape 
highlighting two discrete Gli1 binding events positioned at -0.5 kb and +2.2 kb relative to TSS. 
(B) Zoom in view of -0.5 kb region assayed for enhancer activity (blue bar). Computationally 
predicted Gli binding sites (GBS) are shown in black (nonconserved) and red (conserved). Multi-
species conservation (cons.) is shown below. (C) Transient transgenic analysis of Ptch2(-0.5 kb) 
regulatory region shows neural specific activity at E10.5. The number of embryos expressing 
transgene out of total transgenic positives is shown in upper right hand corner. (D) Transverse 
section taken from region indicated in (C, black bar) shows reporter activity restricted to the 
ventral neural tube. (E) HH-responsive luciferase reporter activity measured in NIH/3T3 
	   97	  
fibroblasts stimulated with either control media (white bars) or NSHH-conditioned media (grey 
bars), and co-transfected with the indicated constructs. Each condition was performed in 
triplicate and data are represented as mean +/- SEM (representative assay shown), p-values 
measured by two-tailed Student’s t-test. (F-U) Hamburger-Hamilton stage 19-22 chick neural 
tubes electroporated with pCIG (F-I), Ptch1::HA-pCIG (J-M), Ptch2::HA-pCIG (N-Q), and 
Ptch1ΔL2::HA-pCIG (R-U) sectioned at the wing level and stained with antibodies raised against 
NKX6.1 (red, F, G, J, K, N, O, R, S) or PAX7 (red, H, I, L, M, P, Q, T, U). Nuclear EGFP 
expression (G, I, K, M, O, Q, S, U) labels electroporated cells. Arrows indicate repression of 
NKX6.1 expression (J, K, N, O, R, S) or ectopic expression of PAX7 (L, M, P, Q, T, U). 
Arrowheads indicate ventrally located electroporated cells that maintain NKX6.1 expression (J, 
K, N, O) or lack ectopic PAX7 expression (L, M, P, Q). Scale bars: (F, H) 50µm. 
 
 
Figure 2-2. Gross morphology of E10.5 embryos defective in ligand-dependent feedback 
inhibition of HH signaling. Whole mount images of wiltype (A), Ptch2-/- (B), Ptch2-/-;Hhip1-/- 
(C), MT-Ptch1;Ptch1-/- (D), MT-Ptch1;Ptch1-/-;Ptch2-/- (E), MT-Ptch1;Ptch1-/-;Ptch2-/-;Hhip1+/- 
(F), and MT-Ptch1;Ptch1-/-;Ptch2-/-;Hhip1-/- (G) embryos at E10.5. Note the exencephaly present 
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Figure 2-3. Normal SHH-mediated ventral neural patterning in Ptch2-/- embryos. DAPI 
staining (A-C) and neural patterning analysis of E10.5 embryos sectioned at the forelimb level 
detects expression of SHH (green; D-F), FOXA2, NKX2.2, OLIG2 (red, green, and magenta 
respectively; G-I), NKX6.1, DBX1, and PAX3 (red, green, and magenta; respectively; J-L) in 
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Figure 2-4. Normal SHH-mediated ventral neural patterning in E10.5 Ptch2-/-;Hhip1-/- 
mouse embryos. Immunofluorescent analysis of neural patterning in E10.5 mouse forelimb 
sections detects expression of NKX6.1, DBX1, PAX3 (red, green and magenta, respectively; A-
E), FOXA2, NKX2.2, and OLIG2 (red, green and magenta, respectively; F-J) in wildtype (A, F), 
Ptch2-/- (B, G), Hhip1-/- (C, H), Ptch2-/-;Hhip1+/- (D, I), and Ptch2-/-,Hhip1-/- (E, J) embryos. 
Scale bars: (A, F) 50µm. 
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Figure 2-5. Expansion of SHH-dependent ventral progenitor domains in E10.5 mouse 
embryos lacking both PTCH2 and PTCH1 feedback antagonism. (A-H) Neural patterning 
analysis in E10.5 forelimb sections using antibodies against NKX6.1, DBX1, PAX3 (red, green 
and magenta, respectively; A-D), FOXA2, NKX2.2, and OLIG2 (red, green and magenta, 
respectively; E-H) in wildtype (A, E), MT-Ptch1;Ptch1-/- (B, F), MtPtch1;Ptch1-/-;Ptch2+/- (C, 
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G), and MT-Ptch1;Ptch1-/-;Ptch2-/- (D, H) embryos. Insets show NKX2.2 channel alone (E-H). 
Arrows indicate dorsal expansion of NKX2.2+ cells in MT-Ptch1;Ptch1-/-;Ptch2-/- embryos (H). 
(I-K) Quantitation of FOXA2+ cell number (I), NKX2.2+ cell number (J), and NKX6.1 domain 
size as a % of total D-V neural tube length (K). Data are represented as mean +/- SEM calculated 
from at least three embryos per genotype. P-value determined by two-tailed Student’s t-test. 
Scale bars: (A, E) 50µm. 
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Figure 2-6. Ptch2 and Hhip1 transcripts are up-regulated in the absence of PTCH1-
feedback inhibition. RNA in situ hybridization detects expression of Shh (A-D), Ptch1 (E-H), 
Ptch2 (I-L), and Hhip1 (M-P) transcripts at the forelimb level of wildtype (A,C,E,G,I,K,M,O) 
and MT-Ptch1;Ptch1-/- (B,D,F,H,J,L,N,P) embryos at E9.5 (A,B,E,F,I,J,M,N) and E10.5 
(C,D,G,H,K,L,O,P). The Shh expression domain is expanded in MT-Ptch1;Ptch1-/- (B,D) 
compared to wildtype (A,C) embryos. The wildtype gradient of Ptch1 expression (E,G) is lost in 
MT-Ptch1;Ptch1-/- embryos (F,H), where low Ptch1 expression is detected from the MT-Ptch1 
transgene. Note the dorsal expansion and greater intensity of Ptch2 and Hhip1 expression in the 
neural tube of MT-Ptch1;Ptch1-/- (J,L and N,P, respectively) compared to wildtype (I,K and M,O, 
respectively) embryos. Insets in O,P highlight increased Hhip1 expression in the paraxial 
mesoderm surrounding the notochord of MT-Ptch1;Ptch1-/- embryos. Scale bar: (A,C) 200μm. 
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Figure 2-7. Severe neural tube ventralization in E10.5 MT-Ptch1;Ptch1-/-;Ptch2-/-;Hhip1-/- 
embryos. Antibody detection of NKX6.1, DBX1, PAX3 (red, green, and magenta respectively; 
A-D, I-L), FOXA2, NKX2.2, OLIG2 (red, green, and magenta respectively; E-H, M-P), SHH 
(5E1) and FOXA2 (green and red respectively; Q-U) in E10.5 forelimb sections from wildtype 
(A, E, I, M, Q), MT-Ptch1;Ptch1-/- (R), MT-Ptch1;Ptch1-/-;Ptch2-/- (B, F, S), MT-Ptch1;Ptch1-/-
;Hhip1-/- (J, N, T), MT-Ptch1;Ptch1-/-;Ptch2-/-;Hhip1+/- (C, G), MT-Ptch1;Ptch1-/-;Hhip1-/-
;Ptch2+/- (K, O), and MT-Ptch1;Ptch1-/-;Ptch2-/-;Hhip1-/- (D, H, L, P, U) embryos. Arrows 
indicate NKX2.2+ cells within the OLIG2 domain (F) and OLIG2+ cells in the NKX2.2 domain 
(G). Insets are representative of less severe phenotypes that are observed in MT-Ptch1;Ptch1-/-
;Hhip1-/-;Ptch2+/- embryos (K, O). Scale bars: (A, K, O) 50µm. 
 
 
Figure 2-8. Ubiquitous expression of FOXA2 and NKX2.2 and dorsal restriction of OLIG2 
expression in E10.5 MT-Ptch1;Ptch1-/-;Ptch2-/-;Hhip1-/- embryos. Antibody detection of 
FOXA2 (red; A, D, E, H, I, L), NKX2.2 (green; B, D, F, H, J, L), and OLIG2 (magenta; C, D, G, 
H, K, L) in E10.5 forelimb sections from wildtype (A-D) and MT-Ptch1;Ptch1-/-;Ptch2-/-;Hhip1-/- 
(E-L) embryos. Merged images are shown in D-L. Scale bar: (A) 50µm. 
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Figure 2-9. Severe reduction of mature neuronal populations in E10.5 MT-Ptch1;Ptch1-/-
;Ptch2-/-;Hhip1-/- embryos. Immunofluorescent analysis of neural patterning in E10.5 mouse 
forelimb sections detects expression of ISL1, EN1 (green and red respectively; A-E), MNR2, and 
EVX1 (red and green respectively; F-J) in Ptch2-/-;Hhip1-/- (A, F), MT-Ptch1;Ptch1-/- (B, G), 
MT-Ptch1;Ptch1-/-;Ptch2-/- (C, H), MT-Ptch1;Ptch1-/-;Ptch2-/-;Hhip1+/- (D, I), and MT-
Ptch1;Ptch1-/-;Ptch2-/-;Hhip1-/- (E, J) embryos. DAPI staining (blue) is included in A-E. Scale 
bar: (A) 50µm. 
 
 
Figure 2-10. Altered neural tube morphology in E10.5 embryos lacking PTCH2, HHIP1, 
and PTCH1-feedback inhibition. DAPI staining (A, F) and antibody detection of FOXA2 (red; 
B, E, G, J), NKX2.2 (green; C, E, H, J), and OLIG2 (magenta; D, E, I, J) in E10.5 forelimb 
sections from MT-Ptch1;Ptch1-/-;Ptch2-/-;Hhip1-/- embryos. Merged images shown in E, J. 
Arrows denote abnormal neural tube invaginations (A-E) and arrowheads indicate cells that have 
budded off of the neuroepithelium and into the luminal space (F-J). Scale bar: (A) 50µm. 
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Figure 2-11. Loss of PTCH2, HHIP1, and PTCH1-feedback antagonism decreases neural 
progenitor proliferation and increases apoptosis. Immunostaining using antibodies raised 
against Phospho-histone H3 (PH3; A-E) and Cleaved Caspase 3 (CC3; F-J) in E10.5 forelimb 
sections collected from wildtype (A, F), MT-Ptch1;Ptch1-/- (B, G), MT-Ptch1;Ptch1-/-;Ptch2-/- 
(C, H), MT-Ptch1;Ptch1-/-;Hhip1-/- (D, I), and MT-Ptch1;Ptch1-/-;Ptch2-/-;Hhip1-/- (E, J) embryos. 
DAPI staining is shown in blue (A-J). Note the decreased proliferation in the ventral neural tube 
(E) and increased apoptosis outside the neural tube (J) in embryos lacking HH feedback 
inhibition. Scale bars: (A, F) 50µm. 
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Figure 2-12.  Expansion of ventral progenitor domains occurs prior to floorplate expression 
of SHH in E8.5 LDA mutants. DAPI staining (A-E) and neural patterning analysis of E8.5 
embryos (9-12 somites) detects expression of NKX6.1, PAX3 (red, green respectively; F-J), 
FOXA2, and SHH (red, green respectively; K-O) in Ptch2-/-;Hhip1-/- (F, K), MT-Ptch1;Ptch1-/- 
(G, L), MT-Ptch1;Ptch1-/-;Ptch2-/- (H, M), MT-Ptch1;Ptch1-/-;Ptch2-/-;Hhip1+/- (I, N), and MT-
Ptch1;Ptch1-/-;Ptch2-/-;Hhip1-/- (J, O) embryos. Arrows indicate FOXA2 expression at the dorsal-
most region of the neural tube (M, N). Scale bars: (A) 50µm. 
 
	   109	  
           
	   110	  
Figure 2-13. Overlapping and distinct mechanisms of HH pathway antagonism by PTCH1, 
PTCH2, and HHIP1. (A) HH-responsive luciferase reporter activity measured from NIH/3T3 
fibroblasts stimulated with constitutively active SmoM2 and co-transfected with the indicated 
constructs. Each condition was performed in triplicate and data are represented as mean +/- SEM 
(n.s., not significant, P>.05 two-tailed Student’s t-test, representative assay shown). (B-E) HH-
responsive luciferase reporter activity measured from Ptch1-/- mouse embryonic fibroblasts 
(MEFs) transfected with the indicated constructs. Each condition was performed in triplicate and 
data expressed as luciferase reporter activity normalized to cells transfected with empty vector 
alone (pCIG) and represented as mean +/- SEM. Treatment with control- (white bars) or SHH-
conditioned media (grey bars) is indicated in (E).  (F) COS7 cells were transfected with the 
indicated constructs and lysates were immunoprecipitated with anti-HA antibody and blotted 
with anti-GFP or anti-GAS1 antibodies. (G-O) Immunofluorescent detection of HA (green; G, J, 
M) and Acetylated Tubulin (ACTUB, red; H, K, N) in NIH/3T3 cells expressing PTCH1::HA 
(G-I), PTCH2::HA (J-L), and HHIP1::HA (M-O). Merged images with DAPI staining (blue) 
shown in (I, L, O). Insets show ciliary localization of PTCH2::HA in Ptch1-/- MEFs (J-L). Scale 
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Figure 2-14. Model of cell surface regulation of HH signaling. In the absence of HH ligands 
(top panel) PTCH1 represses SMO activity (LIA). At the onset of HH signaling (middle panel), 
HH binding to PTCH1 and to the obligate HH co-receptors GAS1, CDON and BOC results in 
de-repression of SMO function and initiation of a signal transduction cascade that culminates in 
GLI-mediated modulation of transcriptional targets. This initiates a negative feedback 
mechanism at the cell surface that includes the down-regulation of Gas1, Cdon and Boc, and up-
regulation of Ptch1, Ptch2 and Hhip1. PTCH1, PTCH2 and HHIP1 binding to HH ligands 
(bottom panel) competes with productive ligand-receptor interactions to alter the balance 
between bound and unbound PTCH1 resulting in cell autonomous modulation of SMO activity. 
Additionally, ligand sequestration by cell surface HH antagonists results in non-cell autonomous 
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 Vertebrate Hedgehog (HH) signaling is controlled by several ligand-binding antagonists 
including PTCH1, PTCH2, and Hedgehog-interacting protein 1 (HHIP1), whose collective 
action is essential for proper HH pathway activity. However, the molecular mechanisms 
employed by these inhibitors remain poorly understood. Here we investigate the mechanisms 
underlying HHIP1 antagonism of HH signaling. Strikingly, we find that HHIP1 non-cell 
autonomously inhibits HH-dependent neural progenitor patterning and proliferation. We further 
demonstrate that this non-cell autonomous antagonism of HH signaling results from the secretion 
of HHIP1 that is modulated by cell type-specific interactions with heparan sulfate (HS). These 
interactions are mediated by an HS-binding motif in the cysteine rich domain of HHIP1 that is 
required for its localization to the neuroepithelial basement membrane to effectively antagonize 
HH pathway function. Finally, we show that endogenous, secreted HHIP1 localization to HS-
containing basement membranes regulates HH ligand distribution. Overall, the secreted activity 
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3.2 Introduction   
 Hedgehog (HH) signaling is indispensible for embryogenesis (McMahon et al., 2003). 
Secreted HH ligands act over long distances to produce distinct cellular responses, depending on 
both the concentration and duration of HH ligand exposure (McMahon et al., 2003; Dessaud et 
al., 2007; Martí et al., 1995; Ericson et al., 1997). HH pathway activity is tightly controlled by 
complex feedback mechanisms involving a diverse array of cell surface-associated ligand-
binding proteins, including the HH co-receptors GAS1, CDON, and BOC and the HH pathway 
antagonists PTCH1, PTCH2, and HHIP1 (Tenzen et al., 2006; Allen et al., 2011; Jeong and 
McMahon, 2005; Holtz et al., 2013; Beachy et al., 2010). These molecules constitute a complex 
feedback network that controls the magnitude and range of HH signaling (Holtz et al., 2013; 
Chen and Struhl, 1996; Jeong and McMahon, 2005; Milenkovic et al., 1999; Tenzen et al., 2006; 
Allen et al., 2007). 
The canonical HH receptor Patched (PTC in Drosophila; PTCH1 in vertebrates) is a 
direct transcriptional HH pathway target (Goodrich et al., 1996; Forbes et al., 1993; Alexandre et 
al., 1996; Agren et al., 2004; Vokes et al., 2007). In Drosophila, PTC accumulation at the cell 
surface binds and sequesters HH ligands, limiting signaling in cells distal to the HH source 
(Chen and Struhl, 1996). In vertebrates, HH-dependent patterning requires not only PTCH1, but 
two additional, vertebrate-specific feedback antagonists: the PTCH1-homologue, PTCH2, and 
HH-interacting protein 1 (HHIP1) (Chuang and McMahon, 1999; Motoyama et al., 1998; 
Carpenter et al., 1998; Koudijs et al., 2008; 2005). PTCH1 and PTCH2 act redundantly in 
multiple cells and tissues, including the developing skin (Adolphe et al., 2014; Alfaro et al., 
2014). while, HH-dependent ventral neural patterning is severely disrupted following the 
combined removal of PTCH2, HHIP1, and PTCH1-feedback inhibition (Holtz et al., 2013; Jeong 
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and McMahon, 2005; Milenkovic et al., 1999). These data suggest that PTCH1, PTCH2, and 
HHIP1 play overlapping and essential roles to limit HH ligand signaling during embryonic 
development. 
While PTCH2 and HHIP1 perform overlapping functions with PTCH1 in the developing 
nervous system, they exhibit distinct requirements in different tissues. For example, Ptch2-/- mice 
are viable and fertile, yet aged adult males develop significant alopecia and epidermal 
hyperplasia (Nieuwenhuis et al., 2006). Additionally, Hhip1-/- mice die at birth due to severe 
defects in lung branching morphogenesis that results from unrestrained HH pathway activity in 
the developing lung mesenchyme (Chuang, 2003). Despite Ptch1 and Ptch2 expression in the 
embryonic lung (Bellusci et al., 1997b; Pepicelli et al., 1998), these molecules fail to compensate 
for the absence of HHIP1 as occurs during ventral neural patterning. Moreover, Hhip1-/- embryos 
display developmental defects in the pancreas, spleen, and stomach (Kawahira et al., 2003). 
These observations argue that PTCH2 and HHIP1 are not simply redundant with PTCH1, but 
that they perform distinct functions to fulfill essential, tissue-specific roles within the vertebrate 
lineage. However, the mechanisms that account for these non-redundant activities, especially 
with regard to HHIP1, remain largely unknown. 
Hhip1 is a direct transcriptional HH pathway target that encodes for a cell surface-
associated protein which binds all three mammalian HH ligands with high affinity (Chuang and 
McMahon, 1999; Pathi et al., 2001; Bishop et al., 2009; Bosanac et al., 2009; Vokes et al., 2007). 
HHIP1 possesses several conserved functional domains including an N-terminal Cysteine Rich 
Domain (CRD), a 6-bladed β-propeller region, two membrane-proximal EGF repeats, and a C-
terminal hydrophobic motif (Chuang and McMahon, 1999). Crystallographic studies identified 
the β-propeller domain of HHIP1 as the HH ligand-binding domain (Bosanac et al., 2009; 
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Bishop et al., 2009). HHIP1 is proposed to act as a membrane-bound competitive inhibitor of HH 
signaling (Chuang and McMahon, 1999; Bishop et al., 2009); however, both PTCH1 and PTCH2 
share this activity. Thus, the molecular features that distinguish HHIP1 from PTCH1 and PTCH2 
have yet to be discerned. 
Here we investigate the molecular mechanisms of HHIP1 function in HH pathway 
inhibition. Strikingly, we find that, in contrast to PTCH1 and PTCH2, HHIP1 uniquely induces 
non-cell autonomous inhibition of HH-dependent neural progenitor patterning and proliferation. 
Further, we demonstrate that HHIP1 secretion underlies these long-range effects. Using 
biochemical approaches, we define HHIP1 as a secreted HH antagonist that is retained at the cell 
surface through cell type-specific interactions between heparan sulfate (HS) and the N-terminal 
CRD of HHIP1. Importantly, we show that HS-binding promotes long-range HH pathway 
inhibition by localizing HHIP1 to the neuroepithelial basement membrane. Finally we 
demonstrate that endogenous HHIP1 is a secreted protein whose association with HS-containing 
basement membranes regulates HH ligand distribution. Overall, these data redefine HHIP1 as a 
secreted, HS-binding HH pathway antagonist that utilizes a novel and distinct mechanism to 
restrict HH ligand function. 
 
3.3 Results 
HHIP1 non-cell autonomously inhibits HH-dependent neural progenitor specification 
To interrogate PTCH1-, PTCH2- and HHIP1-mediated antagonism of HH signal 
transduction, we utilized a gain-of-function approach in the developing chicken neural tube to 
investigate their effects on HH-dependent ventral neural patterning (Fig. 3-1). Nuclear EGFP 
expression from a bicistronic IRES-EGFPNLS construct (pCIG) labels electroporated cells, 
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providing spatial resolution when analyzing the effects of a given protein on HH-dependent 
neural patterning. Expression of EGFP alone (pCIG) does not affect neural patterning as assessed 
by antibody detection of the positive HH target, NKX6.1, and the negative HH target PAX7 (Fig. 
3-1, A-E) in embryos collected 24 hours post electroporation (24hpe). Similar to previous results, 
electroporation of Ptch2 or Ptch1∆L2, a ligand-insensitive construct that functions as a 
constitutive repressor (Briscoe et al., 2001), results in cell autonomous loss of NKX6.1 (Fig. 3-1, 
F-H and K-M, arrows) and ectopic PAX7 expression (Fig. 3-1, I-J and N-O, arrows), indicative 
of reduced HH signaling (Holtz et al., 2013). Hhip1 electroporation also represses NKX6.1 
expression in ventral progenitors (Fig. 3-1, P-R) and induces ectopic PAX7 expression (Fig. 3-1, 
S-T) at 24hpe. Strikingly, these effects arise non-cell autonomously; most ventral progenitors 
that lose NKX6.1 expression are not EGFP+ (Fig. 3-1, P-R, white line). Additionally, many 
ectopic PAX7+ cells do not co-express EGFP and are found ventral to the EGFP+, HHIP1-
expressing cells (Fig. 3-1, S-T, arrowhead). This contrasts with the strictly cell autonomous 
inhibition produced by PTCH2 and PTCH1∆L2 expression (Fig. 3-1, A-O). 
Analysis of neural patterning at 48hpe indicates that both PTCH2 and PTCH1∆L2 cell 
autonomously repress NKX6.1 (Fig. 3-2, F-H and K-M, arrows) and induce ventral expansion of 
PAX7 (Fig. 3-2, I-J and N-O). In contrast, Hhip1 electroporation causes a significant growth 
defect that is most evident in the ventral neural tube, leading to a significant reduction in the 
number of ventral, but not dorsal progenitors compared to Ptch2- and Ptch1∆L2-electroporated 
embryos (Fig. 3-2, P-R, brackets; and Fig. 3-2, U-V). Thus, HHIP1 antagonizes both HH-
dependent neural patterning and ventral neural tube growth in a non-cell autonomous manner.  
 
HHIP1 inhibits neural progenitor proliferation in a non-cell autonomous manner 
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To determine the cause of this HHIP1-mediated growth defect, we examined apoptosis 
and proliferation in neural progenitors, processes that are regulated by HH signaling (Cayuso et 
al., 2006; Charrier et al., 2001; Saade et al., 2013; Thibert et al., 2003). While both PTCH1ΔL2 
and HHIP1 expression transiently induce apoptosis to similar extents at 24hpe (Fig. 3-3, E-F and 
I-J), Hhip1 electroporation significantly reduces the number of mitotic, phospho-histone H3+ 
(PH3+) cells on the electroporated side of the neural tube at both 24hpe and 48hpe compared to 
pCIG and Ptch1∆L2 (Fig. 3-4). Strikingly, while most HHIP1-electroporated cells are found in the 
dorsal neural tube, we observe the greatest reduction in proliferation ventrally (Fig. 3-4, I-L, 
brackets; quantified in Fig. 3-4 N). Thus, HHIP1 expression inhibits both neural progenitor 
patterning and proliferation in a non-cell autonomous manner. 
 
Cell autonomous activation of HH signaling does not block the non-cell autonomous effects of 
HHIP1 
To further investigate the non-cell autonomous effects of HHIP1 expression, we co-
electroporated Hhip1 with a constitutively active Smo construct, SmoM2 (Xie et al., 1998). Since 
SMOM2 is downstream and refractory to HHIP1 inhibition, we reasoned that this would rescue 
any cell autonomous HH inhibition caused by HHIP1 (Holtz et al., 2013). Indeed, SmoM2 
electroporation cell autonomously induces ectopic NKX6.1+ cells (Fig. 3-5, B and C, yellow 
arrows) and represses PAX7 expression (Fig. 3-5, D and E, yellow arrows) at 48hpe. 
Co-electroporation of Hhip1 with SmoM2 also induces ectopic NKX6.1 and represses 
PAX7 expression (Fig. 3-5, G-J, yellow arrows), indicating cell autonomous rescue of HHIP1 
inhibition. However, we also detected a significant, non-cell autonomous loss of NKX6.1 and a 
ventral expansion of PAX7 expression in the ventral neural tube at 24hpe and 48hpe (Fig. 3-5, 
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G-J; Fig. 3-6, A-E, white line), which does not occur in embryos co-electroporated with Ptch2 
and SmoM2 (Fig. 3-6, P-T). These data support the notion that HHIP1 non-cell autonomously 
inhibits HH signaling in the chicken neural tube. 
 
HHIP1 is a secreted protein 
 To determine how HHIP1 expression produces non-cell autonomous effects, we 
investigated whether HHIP1 functions as a secreted HH antagonist. Previous studies using COS7 
cells classified HHIP1 as a type-I transmembrane protein with a C-terminal 22 amino acid 
transmembrane domain (Chuang and McMahon, 1999). However, a subsequent report identified 
the presence of overexpressed HHIP1 in cell supernatants (Coulombe et al., 2004). Surprisingly, 
we observed significant accumulation of N-terminally HA-tagged HHIP1 (HA::HHIP1) in 
supernatants when expressed in HH-responsive NIH/3T3 fibroblasts (Fig. 3-7 A). In contrast, a 
HHIP1 chimera in which the putative C-terminal membrane anchor is replaced with the 
transmembrane domain from the CD4 protein (HA::HHIP1::CD4) is not secreted (Maddon et al., 
1985)(Fig. 3-7 A). Thus, the CD4 transmembrane domain is sufficient to anchor HHIP1 to the 
cell surface. As a positive control, we also detected secreted CDON protein (HA::CDONΔTMCD) 
in NIH/3T3 cell supernatants (Fig. 3-7 A). These data suggest that HHIP1 can be secreted from 
cells. 
 
Membrane anchoring abrogates the non-cell autonomous effects of HHIP1 
To test whether the non-cell autonomous effects of HHIP1 in the neural tube result from 
HHIP1 secretion, we compared the activity of secreted HHIP1 protein, and membrane-tethered 
HHIP1::CD4. Importantly, HHIP1 and HHIP1::CD4 function equivalently to antagonize HH-
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mediated pathway activation in NIH/3T3 cells (Fig. 3-7 B); thus, membrane anchoring of HHIP1 
does not compromise its cell autonomous inhibitory activity. 
We next analyzed neural patterning in embryos electroporated with either Hhip1 or 
Hhip1::CD4 at 24hpe. HHIP1 non-cell autonomously inhibits NKX6.1 and induces ectopic 
PAX7 expression at 24hpe (Fig. 3-7, I-L, white lines). In contrast, HHIP1::CD4 antagonizes 
NKX6.1 and induces PAX7 expression exclusively in a cell autonomous manner at 24hpe (Fig. 
3-7, N-Q, arrows). At 48hpe, the most prominent effect of HHIP1 expression is a significant 
growth defect in the ventral neural tube; however, membrane anchoring of HHIP1 partially 
rescues the growth of ventral neural progenitors at 48hpe based on gross tissue morphology (Fig. 
3-8, G and L) and quantitation of PH3+ cells at 24hpe (Fig. 3-8 A). Further, HHIP1::CD4 cell 
autonomously inhibits expression of the high-level HH target, NKX2.2 (Fig. 3-8, M-N, arrows) 
and induces persistent ectopic expression of PAX7 at 48hpe (Fig. 3-8, O-P, arrows), 
demonstrating effective antagonism of HH signaling. Overall, these data suggest that the non-cell 
autonomous effects of HHIP1 on both patterning and proliferation of neural progenitors arise 
from HHIP1 secretion. 
 
HHIP1 associates with the cell surface through cell type-specific interactions with heparan 
sulfate 
 To resolve our data demonstrating HHIP1 secretion in NIH/3T3 cells with previously 
published data showing cellular retention of HHIP1 in COS7 cells (Chuang and McMahon, 
1999), we directly compared HA::HHIP1 secretion from NIH/3T3 and COS-7 cells. HA::HHIP1 
robustly accumulates in NIH/3T3 cell supernatants (Fig. 3-9 A). However, HA::HHIP1 secretion 
is significantly reduced in supernatants collected from COS-7 cells, despite increased 
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HA::HHIP1 expression (Fig. 3-9, A and B). In fact, in some instances we failed to detect 
significant HA::HHIP1 secretion from COS-7 cells (Fig. 6 F). Consistent with previous reports, a 
HHIP1 protein lacking the putative C-terminal 22 amino acid membrane spanning helix, 
HA::HHIP1ΔC22, accumulates in COS-7 cell supernatants (Fig. 3-9, A and B) (Chuang and 
McMahon, 1999). Importantly, COS-7 cells are not generally defective in protein secretion based 
on the robust secretion of HA::CDONΔTMCD (Fig. 3-9 A). Overall, these data suggest that the 
balance between membrane retention and release of HHIP1 depends on the cellular context. 
 To test whether HHIP1 was proteolytically cleaved in NIH/3T3 cells, we generated dual-
tagged HHIP1 constructs that possess an N-terminal HA tag and either a C-terminal MYC or V5 
epitope (Fig. 3-9 C). Both HA::HHIP1::MYC and HA::HHIP1::V5 accumulate in NIH/3T3 cell 
supernatants as full-length proteins based on western blot detection of HA and MYC/V5  (Fig. 3-
9, D-F), demonstrating that proteolytic cleavage of HHIP1 is not a requirement for secretion. 
HHIP1 has also been implicated as a glycosylphosphatidylinositol (GPI)-anchored protein 
(Bosanac et al., 2009); however, phosphatidylinositol phospholipase C (PI-PLC) treatment fails 
to release HA::HHIP1 or HA::HHIP1::CD4 from the cell surface of COS-7 cells while a GPI-
anchored version of the HH co-receptor CDON (HA::CDON::GPI), is effectively released from 
the cell surface by PI-PLC treatment (Fig. 3-10). 
 To examine whether HHIP1 is retained at the cell surface through ionic interactions we 
treated COS-7 cells expressing HA::HHIP1 with buffers possessing increasing NaCl 
concentrations. Surprisingly, we detected HA::HHIP1 release from COS-7 cells with as little as 
300mM NaCl, which increases substantially after incubation with 500mM NaCl (Fig. 3-11 A). 
As a control, HA::HHIP1::CD4 remains associated with the cell pellet at all NaCl concentrations 
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tested (Fig. 3-11 A). These data are consistent with HHIP1 being anchored to the cell surface 
through intermolecular interactions. 
 To identify the binding partner responsible for membrane retention of HHIP1, we first 
sought to determine whether HHIP1 is retained at the cell surface through interactions with 
heparan sulfate (HS), an abundant glycosaminoglycan (GAG) that has been implicated in 
multiple aspects of HH signal transduction (Häcker et al., 2005; Lin, 2004; Perrimon and 
Bernfield, 2000). First, we attempted to disrupt HHIP1 retention at the cell surface in COS-7 
cells using heparin, a structural analog of HS (Esko and Lindahl, 2001). Incubation with as little 
as 100nM heparin effectively competes HA::HHIP1 from the cell surface of COS-7 cells, while 
HA::HHIP1::CD4 is refractory to competition with up to 10µM heparin (Fig. 3-11 B). This 
effect is specific to heparin as we only achieved minimal HHIP1 release with a 1000-fold excess 
of Chondroitin Sulfate A or a 100-fold excess of Dermatan Sulfate (Fig. 3-11, C and D). 
 To determine whether HHIP1 membrane retention is affected by cell type-specific 
modifications in HS composition, which vary between cell types and over developmental time, 
we isolated HS from both NIH/3T3 and COS-7 cells to perform cell surface competition assays 
(Allen and Rapraeger, 2003; Esko and Lindahl, 2001; Rubin et al., 2002). Since COS-7 cells 
largely retain HHIP1 we reasoned that COS-7 HS would preferentially bind and thus more 
effectively compete HHIP1 from the cell surface than HS isolated from NIH/3T3 cells. As 
expected, COS-7 GAGs more effectively compete HHIP1 from the cell surface than NIH/3T3 
GAGs (Fig. 3-11 E). After enriching for HS by Chondroitinase ABC treatment, we observed 
HHIP1 release with as little as 2µg/ml of COS-7 HS, which is more effective than a 10-fold 
excess of NIH/3T3 HS (Fig. 3-11 F). Collectively, these data suggest that HHIP1 is retained at 
the cell surface through cell type-specific interactions with HS. 
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HHIP1 binds to HS through basic amino acids in the N-terminal CRD 
 To determine the HS-binding motif in HHIP1, we initially focused on the HHIP1 C-
terminus, which was previously implicated in HHIP1 surface retention (Chuang and McMahon, 
1999) (Fig. 3-9 A). Molecular modeling of the C-terminal 30 amino acids identifies a putative 
HS-binding site comprised of 4 arginine residues (R671, R673, R674, R678) (Fig. 3-12, A and 
B). Interestingly, this analysis also revealed that the C-terminal helix is amphipathic, and is thus 
unlikely to form a transmembrane domain (Fig. 3-12 A).  
We performed heparin-agarose chromatography to investigate HHIP1-HS interactions. 
HA::HHIP1 binds to heparin-agarose with a peak elution of 550mM NaCl (Fig. 3-12 C). 
Deletion of the C-terminal 30 amino acids (HHIP1ΔC30), containing the potential HS-binding 
motif, shifts the elution peak to 450mM NaCl, indicating reduced heparin binding (Fig. 3-12 C). 
However, site-directed mutagenesis of the 4 arginines to alanines (HA::HHIP1C4R->4A) does not 
affect heparin binding (Fig. 3-12 D). Additionally, replacing the C-terminus with a heterologous 
transmembrane domain (HA::HHIP1::CD4) restores heparin binding (Fig. 3-12 E). These data 
suggest that additional motifs are required for HS-binding and surface retention. 
 The EGF domains and the β-propeller region are largely dispensable for heparin binding 
(Fig. 3-12, F and G). However, deletion of the N-terminal CRD of HHIP1 (HA::HHIP1ΔCRD) 
shifts the elution peak to 400 mM NaCl (Fig. 3-12 H). Importantly, Surface Plasmon Resonance 
(SPR) studies confirm a direct interaction between purified HHIP1 with heparin (Kd=100nM) 
that is reduced 50-fold upon deletion of the N-terminal CRD (Kd=5000nM) (Fig. 3-13, A and B). 
Similar results are observed with SPR analysis of HHIP1 and HS interactions (Fig. 3-13, D and 
E). Additionally, the purified HHIP1 CRD directly binds both heparin and HS (Fig. 3-13, C and 
F). Molecular modeling of the CRD domain reveals a positively charged region at the surface 
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(Fig. 3-14 A), including a potential HS-binding site comprised of several basic arginine and 
lysine residues (Fig. 3-14 B). Based on this model, we investigated two clusters of basic amino 
acids that comprise the putative HS-binding moiety (Fig. 3-14, C and D). Mutation of 4 arginines 
to alanines in the first basic cluster (HA::HHIP1ΔHS1) shifts the heparin elution peak to 450mM 
NaCl (Fig. 3-14 E). Additionally, replacing the central KRR motif of cluster 2 with alanine 
residues (HA::HHIP1ΔHS2) weakens heparin binding and produces an elution peak of 400mM 
NaCl (Fig. 3-14 F). A double mutant construct, HA::HHIP1ΔHS1/2, (Fig. 3-14 D), elutes at a peak 
of 350mM NaCl (Fig. 3-14 G), suggesting that these two motifs cooperate to bind HS. Strikingly, 
HA::HHIP1ΔHS1, HA::HHIP1ΔHS2, and HA::HHIP1ΔHS1/2 proteins accumulate in COS-7 cell 
supernatants (Fig. 3-14 H). Collectively, these data suggest that HHIP1 is retained at the cell 
surface through interactions between HS and basic amino acids present within the HHIP1-CRD. 
 
HHIP1 interactions with HS promote basement membrane localization and HH pathway 
antagonism in the chicken neural tube 
 To determine the functional role of the HHIP1-HS interaction, we assessed signaling in 
NIH/3T3 cells. HHIP1ΔHS1/2 antagonizes Sonic HH (SHH)-mediated pathway activity in 
NIH/3T3 cells equivalently to wildtype HHIP1 (Fig. 3-14 I). Surprisingly, HHIP1ΔHS1/2 
expression in the developing chicken neural tube produces limited non-cell autonomous 
inhibition of SHH signaling (Fig. 3-15, G-J, white lines). Additionally, at 48hpe HHIP1ΔHS1/2 
expression does not alter ventral neural tube growth as assessed by DAPI staining and the size of 
the NKX6.1+ domain (Fig. 3-15, P-R). HHIP1ΔHS1/2 does not affect neural progenitor 
proliferation at 24hpe and 48hpe (Fig. 3-15, U and V), but does induce cell death similar to 
HHIP1 (Fig. 3-16, D-F).  
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 Since HHIP1 and HHIP1ΔHS1/2 function equivalently in cell-based assays, we reasoned 
that HS-binding might control the tissue localization of HHIP1 in the neural tube to promote 
long-range HH inhibition. Towards this end, we stained embryos electroporated with Hhip1 and 
Hhip1ΔHS1/2 with an anti-HHIP1 antibody that does not detect the endogenous chicken HHIP1 
protein (Fig. 3-17, A-E). Intriguingly, HHIP1 protein primarily localizes to the basal side of the 
neuroepithelium when expressed in the chicken neural tube and co-localizes with the basement 
membrane (BM) component Laminin (Fig. 3-17, F-J, arrowheads). We also observe co-
localization between HHIP1 and Laminin in the surface ectoderm (Fig. 3-17, F-J, arrows, insets). 
Strikingly, HHIP1ΔHS1/2 fails to localize to the basal side of the epithelium and surface ectoderm 
and remains associated with electroporated cells (Fig. 3-17, K-O), similar to the localization of 
membrane-anchored HHIP1::CD4 (Fig. 3-17, P-T). Quantitation of these data demonstrate that 
while HHIP1 and HHIP1ΔHS1, are expressed at equal levels, HHIP1ΔHS1,2 is significantly less 
enriched in the BM compared to HHIP1 (Fig. 3-17, U and V) Collectively, these data indicate 
that HS-binding mediates HHIP1 localization to the neural tube BM and is required to promote 
long-range inhibition of HH signaling. 
 
Endogenous HHIP1 protein is secreted and associates with the basement membrane in the 
developing neuroepithelium 
 We next sought to determine the localization of endogenous HHIP1 protein in the neural 
tube. Using whole mount X-Gal staining of Hhip1+/- mouse embryos, which express a lacZ 
reporter from the endogenous Hhip1 locus, we initially detect Hhip1 expression in the 
developing heart and body wall at E8.5 (Fig. 3-18 A, red arrow). At E9.5, we observe Hhip1 
expression in several locations including the paraxial mesoderm, lung, and intestine, consistent 
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with published Hhip1 expression data (Fig. 3-18 B) (Chuang and McMahon, 1999; Chuang, 
2003). Our group and others have previously published in situ hybridization data showing low 
levels of Hhip1 expression within ventral neural progenitors in the embryonic spinal cord at 
E10.5 (Chuang and McMahon, 1999; Holtz et al., 2013). Interestingly, while Hhip1 expression 
in ventral neuronal cells is too low to detect by X-gal stain, we do observe reporter expression in 
the roof plate of the developing spinal cord at E10.5 and E11.5 (Fig. 3-18 C and D, red 
arrowheads; Fig. 3-20 A, red arrows), consistent with previously published data in Xenopus 
(Cornesse et al., 2005). Using in situ hybridization, we validated Hhip1 expression within the 
paraxial mesoderm and roof plate, and also detected weaker expression in ventral neural 
progenitors at E10.5 (Fig. 3-18 E, arrow, red arrowhead, and black arrowhead, respectively). 
Interestingly, the membrane-bound HH antagonist, PTCH2, is not expressed in the developing 
roof plate (Fig. 3-18 F). While we confirm the roof plate expression of Hhip1 by 
immunofluorescence, we do not detect HHIP1 protein by immunofluorescence at this axial level 
at E10.5 and E11.5 (Fig. 3-19, arrows). 
Interestingly, we detect strong Hhip1 expression in the developing diencephalon at E10.5 
and E11.5 (Fig. 3-18 C, black arrow; Fig. 3-20, A and B, arrows and arrowheads). HH signaling 
plays a critical role in the growth and patterning of the developing midbrain and mutations in the 
HH pathway produce diencephalic defects in humans (Ishibashi and McMahon, 2002; Szabó et 
al., 2009; Ericson et al., 1995; Roessler et al., 2003; Dale et al., 1997; Zhao et al., 2012; Treier et 
al., 2001). At the level of Rathke’s Pouch, Hhip1 is expressed in more dorsal regions of the 
diencephalon (Fig. 3-20, A-C, arrowheads), and at the midline caudal to the developing pituitary 
(Fig. 3-20, A, B, and D, arrows). In wildtype embryos, HHIP1 protein is not readily observed 
within the neuroepithelium of the dorsal diencephalon, but instead accumulates basally at a 
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significant distance from its site of production (Fig. 3-20, E-H, arrows). Importantly, HHIP1 
signal is not detected in Hhip1-/- embryos, confirming antibody specificity (Fig. 3-20, I-L). 
Consistent with our analysis in the chicken neural tube, endogenous HHIP1 protein co-localizes 
with Laminin in the BM (Fig. 3-20, M and N, arrows). Strikingly, we also observe an association 
between HHIP1 and the HS-decorated BM protein, Perlecan (HSPG2; Fig. 3-20, O and P, 
arrows). Importantly, HHIP1 does not associate with axonal projections as assessed by labeling 
with TUJ1 (Fig. 3-21, A-C, arrows). 
 To validate the distribution of secreted HHIP1 protein, we generated a novel HHIP1 
antibody. Notably, this reagent also specifically detects HHIP1 protein in the neuroepithelial BM 
near the source of SHH ligand production in the ventral diencephalon (Fig. 3-20, Q-X, arrows). 
Interestingly, we observed accumulation of SHH ligand within the BM at a distance from the 
SHH source that co-localizes with HHIP1 in discrete puncta (Fig. 3-20, S-T; Fig. 3-22, A-D, 
arrows). Strikingly, this accumulation of SHH is lost in Hhip1-/- embryos, demonstrating that 
HHIP1 can interact with and affect the distribution of SHH ligand in the neuroeptihelial BM (Fig. 
3-20, W-X; Fig. 3-22, E-H). Collectively, these data demonstrate that endogenous HHIP1 protein 
is secreted and associates with HS-containing BM of the developing neuroepithelium. 
 
Endogenous HHIP1 is produced and secreted by lung mesenchymal fibroblasts 
 To determine whether endogenous HHIP1 protein is secreted and associates with BM 
outside of the neuroepithelium, we investigated HHIP1 distribution in the developing lung, 
where HHIP1 is critical for branching morphogenesis (Chuang, 2003). Hhip1-/- lungs collected at 
E12.5 and E14.5 possess only two rudimentary lung lobes instead of the normal five and largely 
fail to undergo secondary branching morphogenesis (Fig. 3-23, A-D) (Chuang, 2003). Consistent 
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with previous reports, Hhip1 is exclusively expressed by mesenchymal fibroblasts proximal to 
the lung epithelium, but is excluded from the epithelium itself as determined by β-Galactosidase 
(β-Gal) expression in Hhip1+/- lungs (Fig. 3-23, E-H, arrows) (Chuang, 2003). HHIP1 protein 
co-localizes with β-Gal in the lung mesenchyme; however, we also detect HHIP1 protein on the 
basal side of epithelial cells that does not co-localize with β-Gal (Fig. 3-23 E-H, arrowheads). 
This signal is specific for HHIP1 as it is absent in Hhip1-/- embryos (Fig. 3-23, I-L). The 
epithelial HHIP1 protein staining co-localizes with the BM markers Laminin and Perlecan (Fig. 
3-23, M-T, arrowheads). Interestingly, HHIP1 is only detected in regions where Perlecan is 
present (Fig. 3-23, Q-T, arrows). Taken together, these data indicate that endogenous HHIP1 
protein is produced and secreted by lung mesenchymal fibroblasts and accumulates in the HS-
containing BM of the lung epithelium. 
 
3.4 Discussion 
HHIP1 is a secreted antagonist of vertebrate Hedgehog signaling 
 Secreted, ligand-binding antagonists are common components of morphogen signaling 
pathways, including Noggin and Chordin in the BMP pathway (Zimmerman et al., 1996; Smith 
and Harland, 1992; Smith et al., 1993; Piccolo et al., 1996); Lefty inhibition of Nodal signaling 
(Meno et al., 1996; Chen and Shen, 2004); WIF-1 and a large family of secreted frizzled 
receptors that function as WNT pathway antagonists (Wang et al., 1997; Leyns et al., 1997; 
Cruciat and Niehrs, 2013; Hsieh et al., 1999); and Cerberus, which binds to and antagonizes the 
activity of BMP, Nodal, and WNT ligands (Piccolo et al., 1999; Bouwmeester et al., 1996). Thus, 
it is surprising that the ligand-binding HH pathway antagonists described to date act exclusively 
as membrane bound inhibitors (Chuang and McMahon, 1999; Carpenter et al., 1998; Marigo et 
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al., 1996; Stone et al., 1996). Here we present functional and biochemical evidence to redefine 
HHIP1, previously thought to be a transmembrane-anchored protein, as a secreted antagonist of 
vertebrate HH signaling. Importantly, this is supported by a recent, complementary study 
demonstrating that HHIP1 acts as a secreted HH pathway inhibitor  (Kwong et al., 2014).  
 
Heparan sulfate regulation of HH pathway activity 
 HS regulates the activity of numerous key developmental signaling pathways including, 
FGF, WNT, BMP, and HH (Yan and Lin, 2009). Following genetic studies in flies that identified 
a role for HS in the trafficking of HH ligands (Bellaiche et al., 1998; The et al., 1999), 
subsequent work demonstrated multiple and complex roles for HS in HH ligand trafficking; 
proteolytic processing and release of HH ligands; and HH signal transduction (Gallet et al., 2003; 
Desbordes and Sanson, 2003; Rubin et al., 2002; Lum et al., 2003; Han et al., 2004; Dierker et al., 
2009; Ohlig et al., 2012). To this point studies have been restricted to direct interactions of HH 
ligands with HS (Whalen et al., 2013), which affects neural progenitor proliferation in flies (Park 
et al., 2003) and mice (Rubin et al., 2002; Chan et al., 2009; Witt et al., 2013), as well as 
oligodendrocyte specification in the developing spinal cord (Danesin et al., 2006; Oustah et al., 
2014; Touahri et al., 2012). 
 Our study identifies a novel role for HS in HH signaling through its interactions with 
HHIP1. Further, our data suggest that HS acts to regulate the extracellular distribution of HHIP1 
as mutagenesis of the HS-binding site stimulates significant release of HHIP1 from the cell 
surface. Importantly, and counterintuitively, interference of HHIP1-HS interactions limits long-
range inhibition of HH signaling in the chicken neural tube. Interactions with HS are not required 
for HHIP1 activity in cell culture; instead, we find that HS-binding is required to localize HHIP1 
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to the BM of the neuroepithelium to promote long-range inhibition of HH signaling. This role for 
HS in regulating the tissue distribution of HHIP1 is consistent with previous studies in Drosphila, 
where disruption of HS biosynthesis prevents the distribution of HH ligands away from their 
source of production in the wing imaginal disc and in the developing embryo (Bellaiche et al., 
1998; The et al., 1999). Our data suggest that HS regulates both HHIP1 and HH ligand diffusion 
within a target field. Alternatively, HS may stabilize and concentrate HHIP1 in the BM to reach 
the threshold levels required for effective antagonism (Lin, 2004).  
HHIP1 interacts with HS with high affinity compared to SHH ligand (HHIP1 Kd 622nM 
vs. SHH Kd 14.5 µM) (Whalen et al., 2013). The weaker SHH-HS affinity is consistent with a 
“rolling” interaction that promotes the establishment of the HH morphogen gradient. The strong 
HHIP1-HS interaction indicates that HHIP1 is likely to become fixed within an HS-rich 
environment, consistent with our observation of endogenous HHIP1sequestration of SHH ligand 
within the neuroepithelial BM. However, the diversity of HS across cell types and tissues 
suggests that these interactions will vary in a tissue- and context-specific manner. Importantly, 
the role of HS in regulating HH-dependent signaling in vertebrates must now be considered in 
the context of effects on both HH ligand and HHIP1 distribution within a tissue. 
 
Secreted HHIP1 association with HS-containing BM in multiple organs during embryogenesis  
 In exploring the molecular properties of HHIP1, we determined the extracellular 
distribution of endogenous, secreted HHIP1 protein within the BM of the developing 
neuroepithelium and lung. The functional route utilized by HH ligands during vertebrate tissue 
development is largely unexplored. In Drosophila, both apical and basal gradients of HH ligand 
produce distinct functional consequences in receiving cells (Ayers et al., 2012; 2010). In 
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vertebrates, HH ligands have been visualized in the neuroepithelial BM by antibody detection 
(Allen et al., 2007; Gritli-Linde et al., 2001) and by using a Shh::GFP fusion knock-in allele 
(Chamberlain et al., 2008). The presence of HHIP1 within this tissue compartment and the 
redistribution of SHH observed in Hhip1-/- embryos implicates the BM as one functional route 
utilized by HH ligands to distribute within the neural tube. Notably, the roof plate expression of 
Hhip1 in the spinal cord is analogous to notochord expression of the BMP antagonists Noggin, 
Chordin and Follistatin (McMahon et al., 1998; Liem at al., 2000), consistent with a role for 
secreted antagonists in the regulation of morphogen function during neural patterning. 
 In addition to the neuroepithelium, we also observed HHIP1 accumulation in the BM of 
the developing lung endoderm. This suggests that HHIP1 localization to the BM is a general 
strategy to antagonize HH pathway activity during embryogenesis. Notably, in both cases, 
HHIP1 distributes towards the source of HH ligand production. The strong HHIP1-HH ligand 
interaction in addition to the unique HS-rich environment of the BM may provide the driving 
forces for the tissue distribution of HHIP1. 
Interestingly, the unique requirement for HHIP1 during lung development compared to 
PTCH1/2 may reflect the need for a secreted HH antagonist to orchestrate lung branching 
morphogenesis (Chuang, 2003). In the embryonic lung, epithelial-derived HH ligands traverse 
the basement membrane to signal to the underlying mesenchyme, resulting in repression of 
Fgf10 expression, a key mediator of epithelial outgrowth (Pepicelli et al., 1998; Litingtung et al., 
1998; Chuang, 2003; Sekine et al., 1999; Bellusci et al., 1997a; Min et al., 1998). Paradoxically, 
Fgf10 expression is maintained within the mesenchyme adjacent to the sites of highest Shh 
expression at growing bud tips due to the induction of Hhip1 expression (Chuang, 2003; Bellusci 
et al., 1997b; Bitgood and McMahon, 1995; Urase et al., 1996). HHIP1 protein localization 
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within the lung BM may restrict SHH ligand exit from the epithelial compartment, thus 
preserving Fgf10 expression in the adjacent mesenchyme, providing a molecular mechanism to 
explain the unique genetic requirement for Hhip1 in lung branching morphogenesis. 
These data also have implications for understanding human lung diseases as HHIP1 has 
also been implicated in a wide variety of human lung pathologies including chronic obstructive 
pulmonary disease (COPD), emphysema, asthma, and lung cancer; thus, HH pathway inhibition 
by secreted HHIP1 might also have significant implications for the regulation of HH signaling in 
adult tissues, and in human lung pathologies (Pillai et al., 2009; Van Durme et al., 2010; Zhou et 
al., 2012; Young et al., 2010; Li et al., 2011; Castaldi et al., 2014). 
 
3.5 Materials and Methods 
Chicken in ovo neural tube electroporations 
Electroporations were performed as previously described (Holtz et al., 2013; Tenzen et al., 2006). 
In brief, DNA (1.0 µg/µl) mixed with Fast Green (50 ng/µl) was injected into Hamburger-
Hamilton stage 11-13 embryos. Embryos were dissected 24 and 48 hours post electroporation 
(hpe), fixed in 4% PFA, and processed for immunofluorescent analysis. Electroporated cells 
were marked by constructs expressing either nuclear-localized EGFP (pCIG) or tdTomato 
(pCIT). mPtch2, mPtch1∆L2, and all mHhip1 constructs were cloned into pCIG. SmoM2 cDNA 
(Xie et al., 1998) was cloned into pCIT. For co-electroporations, each construct was injected at a 
concentration of 0.5 µg/µl. PH3+ cells were quantified from 3 or more sections isolated from at 
least 4 separate embryos per condition.  
 
HHIP1 constructs 
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All Hhip1 constructs were derived from a full-length mouse Hhip1 cDNA (generously provided 
by Dr. Pao-Tien Chuang, UCSF). Hhip1∆C22 encodes for a protein that lacks aa A679-V700 of 
full-length HHIP1, while HHIP1::CD4 replaced these resides with aa V394-C417 of the mouse 
CD4 protein (Maddon et al., 1985). An N-terminal HA tag (YPYDVPDYA) was inserted 
between residues F25 and G26 preceded by a residual ClaI site. For the dual-tagged Hhip1 
constructs, C-terminal MYC (EQKLISEEDL) and V5 (GKPIPNPLLGLDST) tags were added 
following a flexible linker (GSG) to enhance visualization by western blot analysis. Hhip1 
deletion constructs and HS-binding mutants were generated using the QuikChange II XL Site-
Directed Mutagenesis Kit (Agilent).  
 
Immunofluorescence  
Immunofluorescent analysis of neural patterning was performed at the wing bud axial level at 
both 24hpe and 48 hpe (Holtz et al., 2013). The following antibodies were used: mouse IgG1 
anti-NKX6.1 (1:20, Developmental Studies Hybridoma Bank [DSHB]), mouse IgG1 anti-PAX7 
(1:20, DSHB), rabbit IgG anti-cleaved caspase-3 (1:200, Cell Signaling), rabbit IgG anti-
phospho-Histone H3 (1:1000, Millipore), mouse IgG2b anti-NKX2.2 (1:20, DSHB), goat IgG 
anti-HHIP1 (1:200, R&D Systems), rabbit IgG anti-Laminin (1:500, Abcam), rabbit IgG anti-β-
Gal (1:5,000, MP Biomedicals), rabbit IgG, mouse IgG1 anti-SHH (1:20, DSHB), rat IgG anti-
HSPG2 (1:500, Millipore) and mouse IgG anti-E-Cadherin (1:500, BD Laboratories). Nuclei 
were visualized with DAPI (1:30,000, Molecular Probes). Alexa 488, 555, and 633 secondary 
antibodies (1:500, Molecular Probes) were used to detect protein localization. Slides were 
mounted in Shandon Immu-Mount (Thermo Scientific). Images were captured on a Leica upright 
SP5X confocal microscope at room temperature using the LAS AF software. Leica 63x  (Type: 
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HC PL APO CS2; N.A.: 1.2) and 25x (Type: HCX IRAPO L; N.A.: .95) water immersion 
objectives were used. Fluorescent intensities were quantified using ImageJ from data isolated 
under identical imaging conditions. Two sections from at least three embryos were analyzed in 
each condition. Total HHIP1 fluorescent intensity was normalized to GFP fluorescence to 
control for electroporation efficiency. Direct comparisons of endogenous HHIP1 protein stains 




Luciferase reporter assays to read out HH pathway activity were performed as previously 
described (Holtz et al., 2013; Nybakken et al., 2005). In brief, NIH/3T3 cells were seeded onto 
24-well plates and transfected 16-24 h later with a ptc∆136-GL3 luciferase reporter construct 
(Chen et al., 1999; Nybakken et al., 2005), pSV-β-galactosidase (Promega), and either empty 
vector or experimental constructs. After 48 h, cells were placed in low serum media in addition 
to either control- or NSHH-conditioned medium. Luciferase activity (Luciferase Assay System 
kit, Promega) was read 48 h later and normalized to β-galactosidase activity (BetaFluor β-
galactosidase Assay Kit, Novagen). Data were expressed as fold induction relative to control 
treated cells. 
 
Western Blot Analysis 
Western blot analysis was performed according to standard methods. Briefly, cells were lysed 48 
hours post-transfection in RIPA buffer (50mM Tris-HCl [pH 7.2], 150mM NaCl, 0.1% TX-100, 
1% sodium deoxycholate, 5mM EDTA) containing Complete Mini Protease Inhibitor Cocktail 
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(Roche), centrifuged at 20,000 x g for 30 min at 4°C, and analyzed by SDS-PAGE. Proteins 
were transferred to PVDF and probed with the following antibodies: mouse IgG1 anti-HA 
(1:1000, Covance), rabbit IgG anti-MYC (1:5000, Bethyl Labs), and rabbit IgG anti-V5 (1:1000, 
Bethyl Labs). Cell supernatants and washes from HHIP1 cell surface competition experiments 
were centrifuged at 20,000 x g for 5 min at room temperature prior to SDS-PAGE. NaCl washes 
from cell surface competition experiments underwent buffer exchange into RIPA buffer and 
washes from GAG competition experiments were concentrated 4-fold prior to SDS-PAGE using 
Nanosep 30K Omega columns (PALL Life Sciences). Western blot intensities were quantified 
using ImageJ.  
 
Glycosaminoglycan isolation 
GAG preparations were performed as previously described (Karlsson and Björnsson, 2001; Allen 
and Rapraeger, 2003). COS-7 and NIH/3T3 cells were grown to confluency, washed with 1x 
PBS, and incubated with 0.25% Trypsin-EDTA for 30 min at 37°C. Cell-trypsin mixtures were 
boiled for 30 min and centrifuged at 1,500 x g for 5 min at room temperature. Supernatants were 
isolated and proteins were precipitated in 6% TCA for 1 h on ice. Proteins were pelleted by 
centrifugation at 10,000 x g for 30 min at 4°C. GAGs were precipitated from the remaining 
supernatant by overnight incubation with 5 volumes of ethanol at -20°C and pelleted by 
centrifugation at 10,000 x g for 30 min at 4°C. GAG pellets were resuspended in 50mM Tris-
HCl (pH 8.0) and GAGs were quantified by alcian blue precipitation (Karlsson and Björnsson, 
2001). To enrich for heparan sulfate, GAGs were incubated with 0.25 units of Chondroitinase 
ABC (Sigma) overnight at 37°C followed by alcian blue quantitation. 
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Heparin-agarose chromatography 
COS-7 cells expressing HA-tagged Hhip1 constructs were lysed in column buffer (50mM Tris-
HCl [pH 7.2], 150mM NaCl, 5mM EDTA) with 1% NP-40 containing complete mini protease 
inhibitor cocktail (Roche) and clarified by centrifugation at 20,000 x g for 30 min at 4°C. 
Columns were loaded with 2 ml of heparin-agarose (Sigma) and equilibrated with 10 ml of 
column buffer. Lysates were diluted 1:25 in column buffer and loaded onto the column. The 
column was washed with 10 ml of column buffer and HHIP1 proteins were eluted in a step 
gradient (4 ml per elution) of column buffer possessing increasing concentrations of NaCl. 
Eluates were assayed for the presence of HA-tagged HHIP1 protein by dot blot analysis. The 
intensity of each dot was quantified using Image J software and plotted as the relative amount of 
signal compared to the total intensity measured for all elutions. 
 
Molecular modeling and structural analysis 
Models of the C-terminal 30 residues (residues 671-700) and the N-terminal 196 residues 
(residues 18-213) of human HHIP1, respectively, were generated using the Full-chain Protein 
Structure Prediction Server ROBETTA with the default RosettaCM protocol (Raman et al., 
2009). Electrostatic potentials were calculated with APBS (Baker et al., 2001) and structure 
representations were drawn with PYMOL (The PyMOL Molecular Graphics System, Version 
1.7.0.3 Schrödinger, LLC.). 
Expression and purification of HHIP1 constructs 
Human HHIP1 constructs (UniProt ID: Q96QV1) consisting of the N-terminal domain (HHIPN; 
39-209), β-propeller and EGF repeats (217-670; (Bishop et al., 2009) and ΔC-helix full-length 
(18-670) were fused C-terminally with either a hexa-histidine or a BirA recognition sequence 
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and cloned into the pHLsec vector (Aricescu et al., 2006). Expression was performed by 
transient transfection in HEK-293T cells (using a semi-automated procedure (Zhao et al., 2011) 
in the presence of the class I α-mannosidase inhibitor, kifunensine (Chang et al., 2007). 3-4 days 
post-transfection, conditioned medium was harvested, buffer exchanged into PBS and purified 
by immobilized metal affinity chromatography using TALON beads (ClonTech). Proteins were 
then further purified using size-exclusion chromatography (Superdex 16/60 column, GE 
Healthcare) in a buffer of 10 mM HEPES pH 7.5, 150 mM NaCl. 
 
Hhip1 antibody generation 
Rabbits were immunized against human HHIP1 protein (aa212-670) that was purified as 
described above. Injections, animal husbandry, and serum production was performed at the 
Pocono Rabbit Farm & Laboratory (Canadensis, PA) using the 70 day antibody production 
package. Polyclonal HHIP1 antibodies were purified from serum using Protein-A agarose 
chromatography.  
HHIP1-GAG Surface Plasmon Resonance Binding Studies 
Surface Plasmon Resonance (SPR) experiments were performed using a Biacore T200 machine 
(GE Healthcare) in 10 mM HEPES pH 7.5, 120 mM NaCl, 0.05% (v/v) polysorbate 20, at 25 °C. 
Proteins were buffer exchanged into running buffer and concentrations calculated from the 
absorbance at 280 nm using molar extinction coefficient values. Heparin (Iduron; average 
molecular weight >9,000 Da) and heparan sulfate (HS) from porcine mucosa (Iduron) were 
biotinylated using EZ-link Biotin-LC-Hydrazide (Thermo Fisher Scientific) as described 
previously (Malinauskas et al., 2011) Biotinylated GAGs were immobilized upon a CM5 sensor 
chip to which 3,000 RU of streptavidin were coupled via primary amines. After each binding 
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experiment, the chip was regenerated with 1.5 M NaCl at 30 ul/min for 120s. HHIP1 proteins 
were injected at a flow rate of 5 µL/min for binding studies. The signal from experimental flow 
cells was processed, and corrected by subtraction of a blank and reference signal from a blank 
flow cell. In all experiments, the experimental trace returned to baseline after each regeneration. 
All data were analysed using SCRUBBER2 (Biologic) and GraphPad Prism Version 6.04 
(GraphPad Software, La Jolla California USA). Best-fit binding curves were calculated using 
non-linear curve fitting of a one-site - total binding model (Y = Bmax*X / (Kd+X) + NS*X + 
Background, where X is analyte concentration and the amount of non-specific binding is 
assumed to be proportional to the concentration of analyte, hence NS is the slope of non-specific 
binding). The background value was constrained to zero as the data had been previously 
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3.7 Figures 
 
Figure 3-1. Ectopic HHIP1 expression non-cell autonomously inhibits neural progenitor 
patterning. Embryonic chicken neural tubes electroporated at Hamburger-Hamilton stage 11-13 
with pCIG (A-E), mPtch2-pCIG (F-J), mPtch1ΔL2-pCIG (K-O), or mHhip1-pCIG (P-T) and 
dissected 24 hours post electroporation (hpe). Transverse sections from the wing axial level were 
stained with antibodies directed against NKX6.1 (red; B, C, G, H, L, M, Q, R) and PAX7 (red; D, 
E, I, J, N, O, S, T). Nuclei are stained with DAPI (grey; A, F, K, P). Nuclear EGFP expression 
labels electroporated cells (green; C, E, H, J, M, O, R, T). Arrows indicate repression of NKX6.1 
expression (G, H, L, M) or ectopic PAX7 expression (I, J, N, O). Insets show individual green 
channels (E, J, O, T). White lines highlight non-cell autonomous NKX6.1 repression (Q, R) and 
ectopic PAX7 expression (S, T). Arrowheads demarcate the ventral most electroporated cell (S, 
T). Scale bars (A), 50µm. 
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Figure 3-2. Ectopic HHIP1 expression causes significant neural tube growth defects. 
Embryonic chicken neural tubes electroporated at Hamburger-Hamilton stage 11-13 with pCIG 
(A-E), mPtch2-pCIG (F-J), mPtch1ΔL2-pCIG (K-O), or mHhip1-pCIG (P-T) and dissected 48 
hours post electroporation (hpe). Transverse sections from the wing axial level were stained with 
antibodies directed against NKX6.1 (red; B, C, G, H, L, M, Q, R) and PAX7 (red; D, E, I, J, N, 
O, S, T). Nuclei are stained with DAPI (grey; A, F, K, P). Nuclear EGFP expression labels 
electroporated cells (green; C, E, H, J, M, O, R, T). Arrows indicate repression of NKX6.1 
expression (G, H, L, M) or ectopic expression of PAX7 (I, J, N, O). Arrowheads denote ventrally 
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electroporated cells that maintain (Ptch2; G-H) or repress (Ptch1∆L2; L-M) NKX6.1 expression. 
Brackets highlight ventral neural tube size in embryos electroporated with Hhip1 (P-R). (U-V) 
Quantitation of cell numbers in the ventral (U) and dorsal (V) neural tubes of embryos 
electroporated with the indicated constructs and expressed as the relative number of cells on the 
electroporated compared to the unelectroporated side of the tissue. Data are presented as mean 




Figure 3-3. PTCH1∆L2 and HHIP1 expression transiently induce apoptosis in the neural 
tube. Chicken embryos electroporated at stage 11-13 with pCIG (A-D), mPtch1ΔL2-pCIG (E-H), 
and mHhip1-pCIG (I-L) and collected at 24hpe (A, B, E, F, I, J) or 48hpe (C, D, G, H, K, L) 
were sectioned at the wing axial level and stained with cleaved caspase-3 (CC3, red; A-L). 
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Figure 3-4. HHIP1 expression inhibits HH-dependent neuronal progenitor proliferation in 
a non-cell autonomous manner. Electroporation of pCIG (A-D), mPtch1ΔL2-pCIG (E-H), or 
mHhip1-pCIG (I-L) in HH stage 11-13 chicken embryos. Embryos were dissected 24 hours post 
electroporation (hpe), sectioned at the wing axial level, and stained with a Phospho-histone H3 
antibody (PH3, red; A-L). Nuclear EGFP expression labels electroporated cells (green; A-L). 
DAPI staining reveals nuclei (blue; B, D, F, H, J, and L). Dotted lines (A-L) bisect the neural 
tube into dorsal and ventral halves. Arrows (I-L) highlight PH3+ cells on the unelectroporated 
side of the neural tube while brackets (I-L) denote the lack of PH3+ cells resulting from HHIP1 
expression. (M-N) Quantitation of total PH3+ cells (M) or PH3+ cells binned into either the 
dorsal or ventral half of the tissue (N) at 24hpe and 48hpe. Data are presented as mean +/- SEM. 
P-values determined by two-tailed student’s t-test. (A, C), 50µm. 
 
 
Figure 3-5. HHIP1 non-cell autonomously inhibits HH-dependent neural patterning when 
co-expressed with SMOM2. (A-J) Immunofluorescent analysis of neural patterning in chicken 
embryos electroporated at stage 11-13 with SmoM2-pCIT (A-J) and co-electroporated with either 
pCIG (A-E) or mHhip1-pCIG (F-J). Transverse sections collected at the wing axial level were 
stained with NKX6.1 (magenta; B, C, G, H) and PAX7 (magenta; D, E, I, J). DAPI stains nuclei 
(grey; A, F). Electroporated cells are labeled with nuclear EGFP and tdTomato (tdTom; C, E, H, 
J). Insets (E, J) show individual green channels (EGFP). Yellow arrows denote ectopic NKX6.1 
expression (B, C, G, H) or repression of PAX7 (D, E, I, J) resulting from SMOM2 expression. 
Vertical lines denote non-cell autonomous inhibition of NKX6.1 expression (G, H) or ectopic 
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Figure 3-6.  PTCH2 does not induce non-cell autonomous inhibition of HH-dependent 
neural patterning when co-electroporated with SMOM2. Chicken embryos co-electroporated 
at stage 11-13 with either pCIG (F-J), mHhip1-pCIG (A-E, K-O) or mPtch2-pCIG (P-T) and co-
electroporated with SmoM2-pCIT (A-T) were collected at 24hpe (A-E) and 48hpe (F-T). 
Transverse sections at the wing axial level were stained with antibodies raised against NKX6.1 
(magenta; B, C, G, H, K, M, Q, R) and PAX7 (magenta; D, E, I, J, N, O, S, T). Electroporated 
cells are labeled with EGFP and tdTomato (tdTom; C, E, H, J, M, O, R, T). DAPI staining labels 
nuclei (grey; A, F, K, P). Yellow arrows indicate cell autonomous expansion of NKX6.1 (B, C, 
G, H, L, M, Q, R) or repression of PAX7 (D, E, I, J, N, O, S, T) resulting from SMOM2 
expression. White lines indicate non-cell autonomous repression of NKX6.1 (B, C, L, M) or 
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Figure 3-7. HHIP1 secretion mediates its non-cell autonomous effects in the developing 
neural tube. (A) Western blot analysis of cell lysates (bottom panels) and supernatants (top 
panel) collected from NIH/3T3 fibroblasts expressing HA-tagged HHIP1 proteins and probed 
with an anti-HA antibody. HA::CDONΔTMCD is included as a secreted protein control. Anti-β-
tubulin (βTUB) is used as a loading control. (B) HH-responsive luciferase reporter activity 
measured in NIH/3T3 cells stimulated with either control-conditioned media (white bars) or 
NSHH-conditioned media (grey bars) and transfected with the indicated constructs. Data are 
presented as mean +/- SEM. P-values are determined by two-tailed student’s t-tests. (C-Q) 
Neural patterning analysis of chicken embryos electroporated at stage 11-13 with pCIG (C-G), 
mHhip1-pCIG (H-L), and mHhip1::CD4-pCIG (M-Q) and collected at 24hpe. Embryos were 
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sectioned at the wing axial level and stained with antibodies against NKX6.1 (red; D, E, I, J, N, 
O) and PAX7 (red; F, G, K, L, P, Q). DAPI staining detects nuclei (grey; C, H, M). 
Electroporated cells are labeled with nuclear EGFP (E, G, J, L, O, Q). Insets show individual 
green channels (G, L, Q). White lines highlight non-cell autonomous NKX6.1 repression (I, J) 
and ectopic PAX7 expression (K, L). Arrowheads demarcate the ventral most electroporated cell 
(K, L). White arrows indicate cell autonomous inhibition of NKX6.1 expression (N, O), and 
ectopic PAX7 expression (P, Q) resulting from mHHIP1::CD4 expression. Insets in (N, O) 
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Figure 3-8. Membrane anchoring of HHIP1 limits long-range inhibition of HH-dependent 
patterning at 48hpe. (A) Quantitation of PH3+ cells in embryos electroporated with the 
indicated constructs at stage 11-13 and collected at 24hpe. Data are presented as mean +/- SEM. 
P-values calculated using Student’s two-tailed t-test. (B-P) Transverse sections at the wing axial 
level from chicken embryos electroporated with pCIG (B-F), mHhip1-pCIG (G-K) and 
mHhip1::CD4-pCIG (L-P) and collected at 48hpe. Sections were immunostained to detect 
expression of NKX2.2 (red; C, D, H, I, M, N) and PAX7 (red; E, F, J, K, O, P). DAPI staining 
marks nuclei (grey; P, G, L). Nuclear EGFP expression identifies electroporated cells (D, F, I, K, 
N, P). Arrows indicate cell autonomous repression of NKX2.2 (M, N) or expansion of PAX7 
expression (O, P). Scale bar (B), 50µm. 
	   153	  
 
 
Figure 3-9. HHIP1 is secreted in a cell-type specific manner independent of proteolytic 
cleavage. (A) Western blot analysis of cell lysates (bottom panels) and supernatants (top panel) 
collected from NIH/3T3 and COS-7 cells expressing HA-tagged HHIP1 protein. 
HA::CDONΔTMCD is included as a secreted protein control. (B) Quantitation of HHIP1 secretion 
from NIH/3T3 and COS-7 cells. Data are presented as mean +/- SEM. P-values determined by 
two-tailed Student’s t-test. (C) Schematic of dual-tagged HHIP1 constructs. (D-F) Immunoblot 
detection of dual-tagged HHIP1 constructs in supernatants (top panel) and lysates (bottom 
panels) collected from NIH/3T3 cells and probed with anti-HA (D), anti-MYC (E), and anti-V5 
(F) antibodies. 
                                  
 
Figure 3-10. HHIP1 is not a GPI-anchored protein. COS-7 cells expressing the indicated HA-
tagged constructs were treated with PI-PLC for 20 minutes. Both the lysates (bottom panels) and 
washes (top panel) were analyzed by western blot using an anti-HA antibody. Note that PI-PLC 
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treatment releases CDON::HA::GPI from cells while HA::HHIP1 and HA::HHIP1::CD4 remain 









Figure 3-11. HHIP1 is retained at the cell surface through cell-type specific interactions 
with heparan sulfate. (A) COS-7 cells expressing HA::HHIP1 were washed for 20 minutes with 
solutions containing increasing NaCl concentrations. Both the washes (top panel) and cell lysates 
(bottom panels) were assayed by western blot analysis for HHIP1 expression. (B-D) As in (A), 
except using washes containing increasing Heparin (B), Chondroitin Sulfate A (C), or Dermatan 
Sulfate (D) concentrations. (E, F) As in (A-D), except using washes containing 
glycosaminoglycans isolated from NIH/3T3 and COS-7 cells pre- (E) and post- (F) 
Chondroitinase ABC (Ch’ase ABC) treatment. Anti-β-tubulin (βTUB) is used as a loading 
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Figure 3-12. HHIP1 associates with HS through the N-terminal CRD. (A) Representative 
structural model of the HHIP1 C-terminal 30 residues shown as ribbons (left) and electrostatic 
potential (right). Four N-terminal arginines are highlighted (dotted circle). Electrostatic potential 
is calculated from -10 kbT/ec (red, acidic) to 10 kbT/ec (blue, basic). Selected residues are 
depicted in stick representation. (B) Cartoon depiction of HA::HHIP1 (top). Sequence analysis 
identifies a cluster of basic residues (blue) in the C-terminal 30 amino acids that were 
mutagenized to alanines (orange) to generate HHIP1C4R-4A (bottom). (C-H) Heparin-agarose 
chromatography was used to measure heparin-binding affinities for HA::HHIP1 (C-H), 
HA::HHIP1ΔC30 (C) HA::HHIP1C4R->4A (D), HA::HHIP1::CD4 (E), HA::HHIP1ΔEGF1,2 (F), and 
HA::HHIP1Δβprop (G), and HA::HHIP1ΔCRD (H). NaCl concentrations (in mM) corresponding to 
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Figure 3-13. The HHIP1-CRD directly interacts with Heparin and HS. Representative 
surface plasmon resonance (SPR) binding experiments demonstrating direct interactions between 
HHIP1(18-670) (A, D), HHIP1(212-670) (B, E), and HHIP1(18-211) (C, F) with Heparin (A-C) and HS 
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Figure 3-14. Identification of specific residues that mediate HS-binding and cell surface 
retention of HHIP1. (A) Representative model of the HHIP1 CRD. Left panel: ribbon 
representation in rainbow coloring from blue (N-terminus) to red (C-terminus). Potential 
disulphide bridges are shown in Roman numerals. Right: electrostatic potential from -10 kbT/ec 
(red, acidic) to 10 kbT/ec (blue, basic). (B) Close-up view of the potential HHIP1-CRD HS-
binding site shown in stick representation in atomic coloring (carbon: cyan, nitrogen: blue, 
oxygen: red, sulfur: yellow). (C) Cartoon depiction of HA::HHIP1. (D) Sequence analysis 
identifies two clusters of basic residues (blue) in the CRD that were mutagenized to alanines 
(orange) to generate HA::HHIP1ΔHS1, HA::HHIP1ΔHS2, and HA::HHIP1ΔHS1/2. (E-G) Heparin-
binding of HA::HHIP1 (E-G),  HA::HHIP1ΔHS1 (E), HA::HHIP1ΔHS2 (F), and HA::HHIP1ΔHS1/2 
(G) was assessed by heparin-agarose chromatography. NaCl elution peaks (in mM) are indicated 
above each curve. (H) Immunoblot analysis of COS-7 cell lysates (bottom panels) and 
supernatants (top panels) expressing HA-tagged HHIP1 HS-binding mutants. Of note, in addition 
to the expected 75kDa HHIP1 band, we also observe the presence of a 100kDa form in some of 
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the HS-binding mutants. (I) HH-responsive luciferase reporter activity measured from NIH/3T3 
cells stimulated with either control-conditioned media (white bars) or NSHH-conditioned media 
(grey bars) and transfected with the indicated constructs. Data are presented as mean +/- SEM. P-
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Figure 3-15. HHIP1-HS interaction promotes long-range inhibition of HH-dependent 
patterning and proliferation. (A-T) Hamburger-Hamilton stage 11-13 chicken embryos 
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electroporated with mHhip1-pCIG (A-E, K-O) and mHhip1ΔHS1/2-pCIG (F-J, P-T) were collected 
at 24hpe (A-J) and 48hpe (K-T), sectioned at the wing axial level, and immunostained with 
antibodies raised against NKX6.1 (red; B, C, G, H, L, M, Q, R) and PAX7 (red; D, E, I, J, N, O, 
S, T). Electroporated cells express nuclear EGFP (green; C, E, H, J, M, O, R, T). DAPI stains 
nuclei (grey; A, F, K, P). White lines indicate non-cell autonomous repression of NKX6.1 
expression (B, C, G, H) and ectopic expansion of PAX7 (D, E, I, J). White arrowheads 
demarcate the ventral most electroporated cell (D, E, I, J). Brackets in (K-M, P-R) denote the 
size of the NKX6.1+ domain. (U, V) Quantitation of PH3+ cells in embryos electroporated with 
the indicated constructs and collected at 24hpe (U) and 48hpe (V). Data are presented as mean 




        
 
Figure 3-16. Ectopic HHIP1ΔHS1/2 expression induces neuronal progenitor apoptosis. 
Immunofluorescent staining with antibodies against cleaved caspase 3 (CC3) (red; B, C, E, F) in 
chicken embryos electroporated at HH stage 11-13 with mHhip1-pCIG (A-C) and mHhip1ΔHS1/2-
pCIG (D-F) and collected at 24hpe. Embryos were sectioned at the wing bud axial level. Nuclear 
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Figure 3-17. HS-binding is required to localize HHIP1 to the neuroepithelial basement 
membrane. Immunofluorescent detection of HHIP1 (red; B, C, E, G, H, J, L, M, O, Q, R, T) and 
Laminin (cyan; D, E, I, J, N, O, S, T) in embryos electroporated with pCIG (A-E), mHhip1-pCIG 
(F-J), mHhip1ΔHS1/2-pCIG (K-O), and mHhip1::CD4-pCIG (P-T) and isolated 24hpe. DAPI 
stains nuclei (grey; A, F, K, P). Nuclear EGFP labels electroporated cells (green; C, E, H, J, M, 
O, R, T). (G-J) Note HHIP1 co-localization with Laminin in the neural tube (arrowheads) and 
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surface ectoderm (arrows, insets). (U) Quantitation of HHIP1 fluorescent intensity normalized to 
GFP expression. (V) Data in U binned into signal measured within the basement membrane or 
neural progenitors. Data is presented as mean +/- SEM. P-values determined by Student’s two-







Figure 3-18. Spatial and temporal analysis of Hhip1 expression in mouse embryos. (A-D) 
Whole mount X-gal staining of Hhip1+/- embryos collected at E8.5 (A), E9.5 (B), and E10.5 (C, 
D). (E, F) RNA in situ hybridization detects expression of Hhip1 (E) and Ptch2 (F) transcripts in 
E10.5 wildtype mouse embryos sectioned at the forelimb level. Red arrows (A, B) indicate 
Hhip1 expression in the developing heart and body wall. Black arrow (C) demonstrate reporter 
expression in the diencephalon. Red arrowheads (D, E) demarcate Hhip1 expression in the roof 
plate. Black arrows (E, F) indicate Hhip1 (G) and Ptch2 (H) expression in the paraxial mesoderm. 
ht, heart; ba, branchial arch; lu, lung; int, intestine; pm, paraxial mesoderm. Scale bars (A-D), 
1mm. Scale bar (E), 200µm. 
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Figure 3-19. Hhip1 is expressed in the roof plate of the developing mouse spinal cord. 
Mouse embryos isolated at E10.5 (A-R) and E11.5 (S-JJ) sectioned at the forelimb axial level 
and stained with antibodies to detect HHIP1 (green; A, C-F, G, I-L, M, O-R, S, U-X, Y, AA-DD, 
EE, GG-JJ) and β-Galactosidase (β-Gal, red; B-F, H-L, N-R, T-X, Z-DD, FF-JJ). DAPI staining 
reveals nuclei (blue; D, F, J, L, P, R, V, X, BB, DD, HH, JJ). Arrows (G-R, Y-JJ) denote the site 
of Hhip1 expression in the roof plate. Arrowheads (N-P) highlight β-Gal expression in the 
paraxial mesoderm. Scale bars (A, E, G, K, M, Q, S, W, Y, CC, EE, II), 50µm. 
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Figure 3-20. Endogenous HHIP1 protein is secreted and accumulates in the basement 
membrane of the developing diencephalon. (A, B) Whole mount X-gal staining of E11.5 
Hhip1+/- mouse embryos. (C-X) Immunofluorescent detection of β-Galactosidase (β-Gal, red; C-
L), HHIP1 (green; E-X), Laminin (red; M, N), HSPG2 (red; O, P), and SHH (red; Q-X) in E11.5 
Hhip1+/+ (E-H, M-P, Q-T), Hhip1+/- (C, D), and Hhip1-/- (I-L, U-X) mouse embryos sectioned at 
the axial level of the diencephalon. DAPI reveals nuclei (blue; C, D, F-H, J-L, N, P, R, T, V, X). 
Arrows (A, B, D) indicate Hhip1 expression in the ventral diencephalon. Arrowheads (A-C) 
demarcate HHIP1 production in more dorsal regions of the diencephalon. Dashed lines (A, B) 
represent axial level of images depicted in C, D. White box (C) corresponds to area analyzed in 
panels E, F, I, J. White box (D) demonstrates region presented in G, K, M-P, Q-X. Yellow box 
(D) denotes area analyzed in H, L. Asterisks (C, F, J) demarcates Rathke’s pouch. Brackets (E, F, 
I, J) highlight area of HHIP1 production. Arrows (E-H, M-P, Q-T) depict the presence of HHIP1 
protein in the neuroepithelial basement membrane that co-localizes with Laminin (M, N), 
HSPG2 (O, P), and SHH (Q-T). HHIP1 protein signal is absent in Hhip1-/- embryos (arrows, I-L, 
U-X). Note the accumulation of SHH in the neuroepithelial basement membrane (arrows, S, T) 
that is absent in Hhip1-/- embryos (W, X). White boxes (R, V) demonstrate area of higher 
magnification presented in S, T, W, X. Yellow asterisks (S, T, W, X) highlight region of SHH 
production. A commercial HHIP1 antibody (R&D) was used in E-P while a newly developed 
HHIP1 antibody was used in Q-X. Scale bars (A, B), 1mm. Scale bars (C, E, G, I, K, M, Q, S, U, 
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Figure 3-21. HHIP1 does not co-loclaize with axonal processes. E11.5 wildtype mouse 
embryos sectioned at the axial level of the diencephalon and stained with antibodies against 
HHIP1 (green; B, C) and TUJ1 (red; A-C). DAPI labels nuclei (blue; C). Arrows (A-C) 





Figure 3-22. HHIP1 co-localizes with SHH in discrete puncta in the neuroepithelial BM. 
Immunofluorescent detection of SHH (red; A, C, D, E, G, H) and HHIP1 (green; B-D, F-H) in 
the diencephalon of E11.5 wildtype (A-D) and Hhip1-/- (E-H) mouse embryos. DAPI labels 
nuclei (blue; D, H). Arrows (A-D) depict co-localization of HHIP1 and SHH in puncta within the 
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Figure 3-23. Endogenous HHIP1 protein is secreted and accumulates in the epithelial 
basement membrane in the embryonic lung. (A-D) Wholemount images of E12.5 (A-B) and 
E14.5 (C-D) mouse lungs isolated from Hhip1+/- (A, C) and Hhip1-/- (B, D) embryos. (E-T) 
Immunofluorescent detection of β-Galactosidase (β-Gal, red; E, G, H, I, K, L), HHIP1 (green; F-
H, J-L, M, O, P, Q, S, T), Laminin (magenta; N-P), E-Cadherin (ECAD, red; P), and HSPG2 
(red; R-T) in sections isolated from E14.5 Hhip1+/- (E-H, M-T) and Hhip1-/- (I-L) lungs. DAPI 
staining reveals nuclei (blue; H, L, P, T). Arrows demonstrate overlap between HHIP1 and β-Gal 
(E-H) or HSPG2 (Q-T) protein expression in the lung mesenchyme. Arrowheads highlight 
HHIP1 protein staining in the epithelial basement membrane (E-H, M-T). A commercial HHIP1 
antibody (R&D) was used in E-P while a newly developed HHIP1 antibody was used in Q-T. 
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Discussion and Future Directions 
 
4.1 A Collective Requirement for PTCH2-, HHIP1-, and PTCH1-Feedback Inhibition 
During Vertebrate Embryogenesis 
4.1.1 Summary of Key Findings 
 Data presented in Chapter II demonstrate that PTCH2 plays overlapping roles with 
PTCH1 and HHIP1 to antagonize HH signaling during vertebrate development. Importantly, 
recent reports support these findings in other experimental systems. In one study, neuralized 
embryoid bodies (NEBs) generated from Ptch1-/-;Ptch2-/- embryonic stem cells (ESCs) 
demonstrated greater HH pathway activation than NEBs produced from Ptch1-/- ESCs (Alfaro et 
al., 2014). Overlapping roles for PTCH2 and PTCH1 were also recently demonstrated in the 
context of skin development and tumorigenesis. In mouse models with conditional inactivation 
of Ptch1 (Ptch1f/f) in the skin using a K14-Cre or a K5-Cre transgene, further loss of Ptch2 lead 
to more severe defects in hair follicle (HF) morphogenesis and epidermal differentiation than 
conditional deletion of Ptch1 alone (Adolphe et al., 2014). Moreover, K14-
CreERT2;Ptch1f/f;Ptch2-/- adult animals treated with tamoxifen to delete Ptch1 in the skin 
developed more advanced BCC-like lesions than K14-CreERT2;Ptch1f/f mice (Adolphe et al., 
2014). A separate study similarly demonstrated overlapping roles for PTCH1 and PTCH2 during 
limb development. In this context, Prx1-Cre;Ptch1f/-;Ptch2-/- mice exhibited greater HH pathway 
	   180	  
activation and more severe defects in limb outgrowth than Prx1-Cre;Ptch1f/- animals (Zhulyn et 
al., 2015). Taken together, these studies present compelling evidence that PTCH2 plays 
overlapping roles with PTCH1 to restrict HH signaling in multiple contexts during 
embryogenesis and tissue homeostasis, demonstrating that redundancy between the Patched 
receptors is likely a global mechanism to regulate HH pathway activity in vertebrates. 
The most striking result from my analysis in the developing spinal cord is the severe 
neural tube ventralization observed in MT-Ptch1;Ptch1-/-;Ptch2-/-;Hhip1-/- embryos. In this 
context, the highest-level HH targets, FOXA2 and NKX2.2, are expressed throughout the dorsal-
ventral axis of the tissue, reflecting constitutive HH pathway activation within the neural tube. 
This suggests that PTCH1, PTCH2, and HHIP1 comprise an essential network of cell surface HH 
pathway antagonists that are collectively required to inhibit ligand-dependent HH signaling 
during vertebrate embryogenesis. Thus, the activity of PTC-feedback inhibition in Drosophila 
has been distributed amongst three partially redundant feedback antagonists in vertebrates. These 
observations resolve the conflicting reports as to the requirement for LDA of HH signaling 
during Drosophila and mouse tissue patterning. 
 These data are reminiscent of the collective requirement for GAS1, CDON, and BOC to 
promote ligand-dependent HH signaling during vertebrate embryogenesis (Allen et al., 2011; 
Izzi et al., 2011). While loss of any single co-receptor produces little to no defects in HH-
dependent ventral neural patterning, Gas1;Cdon;Boc triple mutants display a near complete loss 
of HH signaling, comparable to Smo mutant embryos (Allen et al., 2011). Similarly, while loss of 
feedback up-regulation of any single antagonist results in, at most, a subtle expansion of HH-
dependent ventral cell fates, combined loss of PTCH2-, HHIP1-, and PTCH1-feedback inhibition 
results in constitutive HH pathway activity throughout the neural tube. Collectively, these results 
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define two sets of essential, yet opposing cell surface HH-binding receptors that are required to 
precisely regulate ligand-dependent HH signaling during vertebrate embryogenesis. 
 Mechanistically, I present evidence that PTCH2 utilizes similar molecular mechanisms as 
PTCH1 to restrict HH pathway activity. First, PTCH2 acts upstream of SMO to antagonize 
ligand-dependent HH pathway activity (LDA) when expressed in NIH/3T3 cells. Moreover, 
PTCH2 can directly antagonize SMO activity (LIA) when expressed in Ptch1-/- MEFs, albeit 
with reduced activity compared to PTCH1. Moreover, PTCH2 is responsive to SHH ligand in 
this context. Consistent with this, PTCH2 can interact with the HH co-receptors GAS1, CDON, 
and BOC. Finally, PTCH2 localizes to the primary cilium similar to PTCH1 and more recent 
evidence demonstrates that PTCH2 can prevent the ciliary accumulation of SMO (Zhulyn et al., 
2015). 
 
4.1.2 Future Directions 
A Role for PTCH2 to Inhibit SMO Activity During Early Embryogenesis 
The ability of PTCH2 to antagonize SMO activity is surprising considering the 
constitutive activation of HH signaling observed in Ptch1-/- embryos (Goodrich et al., 1997). 
Moreover, I have not detected any differences between Ptch1-/- and Ptch1-/-;Ptch2-/- embryos 
isolated at E9.5, suggesting that PTCH2 possesses a limited capacity to antagonize SMO activity 
during early development (data not shown). This may reflect a difference in timing, as Ptch2 
may not be induced early enough to counteract the severe HH pathway activation observed in 
Ptch1-/- embryos. It would be interesting to analyze the role of PTCH2 in neural patterning upon 
conditional deletion of Ptch1 in the spinal cord at later stages of HH dependent ventral neural 
patterning using a tamoxifen inducible Cre recombinase, similar to the approach used in the 
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developing limb (Zhulyn et al., 2015). This may bypass the need to use the MT-Ptch1 transgene 
and could help to determine whether PTCH2 does indeed function to antagonize SMO activity in 
this context. Nevertheless, the MT-Ptch1;Ptch1-/- model does provide a powerful tool to test the 
role of candidate molecules to antagonize HH signal transduction. This sensitized background 
could be used to test whether other HH-interacting components, loss of which may not produce 
overt phenotypes on their own, also participate to restrict HH pathway activity in the ventral 
neural tube, similar to PTCH2 and HHIP1.  
 
Structure-Function Analysis of PTCH1 and PTCH2 
Throughout my dissertation, I have taken advantage of several assays to dissect the 
molecular and cellular mechanisms employed by cell surface HH pathway antagonists. These 
tools provide a unique opportunity to dissect the structural requirements underlying the ability of 
PTCH1 and PTCH2 to inhibit ligand-dependent HH signaling (LDA); to antagonize SMO 
activity (LIA); to respond to HH ligands; to localize to the primary cilium; and to interact with 
the HH co-receptors. This analysis is particularly important considering that the RND motif is 
the only known functional domain that is linked with PTCH1/2-mediated inhibition of SMO 
(Taipale et al., 2002; Holtz et al., 2013; Alfaro et al., 2014).  
During the course of my studies, I have performed a preliminary structure-function 
analysis of the PTCH1 C-terminus (Fig. 4-1). While the C-terminal tail of PTCH1 is involved in 
protein turnover (Kawamura et al., 2008; Xingwu Lu, 2006), it is thought that this region is 
largely dispensable for HH pathway inhibition in vertebrates. This is due to the viability of the 
spontaneous Mesenchymal Dysplasia (Mes) mouse mutant, which was mapped to the PTCH1 C-
terminal tail, truncating this region from 273 to 50 amino acids (Makino, 2001). Surprisingly, my 
	   183	  
preliminary data shows that complete truncation of the C-terminus renders PTCH1 incapable of 
SMO inhibition, demonstrating the requirement for this region in LIA (Fig. 4-1, A and B). I have 
narrowed this region down to a 28 amino acid region stretch in the C-terminal tail (Fig. 4-1 A). 
Moreover, truncation of the C-terminal tail results in a compromised response to SHH ligand 
(Fig. 4-1 C), which could be related to enhanced stability of these constructs. Further work is 
needed to map this functional domain in greater detail and to determine the role of this region in 
regards to other aspects of PTCH1 function. In the future, a similar approach could be used to 
interrogate other structural requirements within PTCH1 and PTCH2, including the N-terminus, 
the third large intracellular loop, etc.  
Another important question involves the mechanism and functional significance of ciliary 
localization of PTCH1/2. The current model assumes that PTCH1 acts within the membrane of 
the primary cilium to prevent SMO ciliary accumulation and activation (Rohatgi et al., 2007); 
however, this has yet to be tested functionally. A variety of cilia localization sequences (CLS) 
can target membrane proteins to the primary cilium (Nachury et al., 2010). Of these CLS motifs, 
PTCH1 and PTCH2 possess two A/Q boxes [defined as AxA/SxQ (Berbari et al., 2008)], the 
first of which is conserved with Drosphila PTC, which does not localize to the cilium when 
expressed in NIH/3T3 cells compared to PTCH1 and PTCH2 (Fig. 4-2, A-I). Interestingly, 
mutagenesis of the second A/Q box in PTCH1 (PTCH1ΔCLS) compromises trafficking to the 
primary cilium (Fig. 4-2, J-L). Surprisingly, PTCH1ΔCLS maintains the ability to antagonize SMO 
with slightly reduced activity, but is incapable of antagonizing ligand-dependent HH signaling in 
NIH/3T3 cells (Fig. 4-2, M and N). These results suggest that ciliary localization of PTCH1 may 
play a role to inhibit ligand-dependent HH signaling. Since current models suggest that 
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productive HH ligand-receptor interactions occur in the ciliary membrane (Rohatgi et al., 2007), 
proximity to the primary cilium could be a critical aspect of LDA. 
This idea is supported by an in-depth analysis of the PTCH2 RND mutants defined in 
Chapter II. Surprisingly, PTCH2G465V mutant protein also fails to localize to the primary 
cilium compared to the other PTCH1 and PTCH2 RND mutant constructs when expressed in 
NIH/3T3 cells (Fig. 4-3, A-L, arrows). While this construct antagonizes SMO equivalent to 
PTCH2D469Y (Fig. 2-13 D), it fails to inhibit SHH-mediated pathway activity in NIH/3T3 cells 
(Fig. 4-3 N). In contrast, the other PTCH1- and PTCH2-RND mutants are indistinguishable from 
their wildtype counterparts in NIH/3T3 cell assays (Fig. 4-3, M and N).  Taken together, these 
data suggest that Patched ciliary localization may play a role in both LIA and LDA of HH 
signaling. However, further work is needed to define the mechanisms and functional significance 
of Patched ciliary targeting. 
The analyses described above could be complemented with an unbiased approach using 
Drosophila PTC (dmPTC), which does not localize to the primary cilium and is incapable of 
antagonizing SMO activity when expressed in Ptch1-/- MEFs (Fig. 4-2). This provides an 
opportunity to identify novel PTCH1 functional domains through generating PTCH1/dmPTC 
chimeras to identify regions of PTCH1 that are capable of transforming dmPTC into a vertebrate 
SMO inhibitor. Moreover, candidate CLS motifs can be introduced into dmPTC to determine 
whether they are sufficient for ciliary targeting of heterologous receptors. If ciliary localized 
dmPTC is capable of inhibiting SMO activity, this would suggest that both vertebrate and 
invertebrate Patched proteins possess fundamentally similar catalytic activities. An additional 
approach could involve generating PTCH1/DISP1 chimeras, to determine the molecular basis of 
the divergent activities of these RND permeases in HH signaling. 
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Examining the Cell Surface Hedgehog Interactome 
The cell surface HH pathway machinery is thought to function within the context of a 
complex interaction network. PTCH1 has been shown to form distinct complexes with the HH 
co-receptors, GAS1, CDON, and BOC (Izzi et al., 2011). Moreover, the co-receptors can also 
interact with each other and can self-associate (Bae et al., 2011). Similarly, we show that PTCH2 
interacts with all three HH co-receptors (Holtz et al., 2013); however, the functional significance 
of these interactions remains unknown. While the PTCH1-interacting domains have been 
mapped to the FNIII(1) and FNIII(2) in CDON/BOC, the corresponding regions of PTCH1/2 and 
GAS1 are unknown (Izzi et al., 2011). Co-immunoprecipitation studies will help to delineate the 
GAS1/CDON/BOC interacting domains in PTCH1/2. Subsequent cell signaling assays will help 
to determine the role of these interactions to mediate ligand-dependent HH pathway activation. 
These receptor complexes should be reconstituted in Ptch1-/-;Cdon-/-;Boc-/- MEFs to prevent 
interactions with the endogenous co-receptors. Moreover, further deletion of Gas1 by 
CRISPR/CAS9 mediated genome editing may also be necessary to precisely interrogate the 
functional significance of these interactions (previous attempts to generate Ptch1;Gas1 double 
mutants have failed due to their close proximity on chromosome 13).  
Moreover, we have no reason to believe that all of the PTCH1-interaction partners have 
been identified. Proteomics approaches could be used to isolate novel HH pathway components 
that interact with PTCH1. Towards this end, I have generated Ptch1-/- and Cdon-/- MEF lines 
stably expressing HA-tagged PTCH1 and CDON, respectively (Fig. 4-4, A and B). 
Immunoprecipitation using an HA antibody followed by mass spectrometry could be used to 
isolate novel HH receptor components, using the parental MEF line as a negative control. Since 
these MEF lines are HH responsive, it would be interesting to perform these experiments before 
	   186	  
and after exposure to HH ligand to determine how the HH receptor complex changes in response 
to signaling over time. Any novel interacting partners could then be tested in functional assays, 
with promising candidates followed up through loss-of-function studies in the mouse. 
 
4.2 Novel Role for HHIP1 as a Secreted, Heparan Sulfate-Binding Antagonist of Vertebrate 
HH Signaling that Regulates HH Ligand Distribution 
4.2.1 Summary of Key Findings 
Prior to my studies, HHIP1 was classified as a type-I transmembrane anchored protein 
that functions at the cell surface to competitively inhibit ligand-dependent HH signaling (Chuang 
and McMahon, 1999; Jeong and McMahon, 2005). Data presented in Chapter III re-define 
HHIP1 as a secreted antagonist of HH signaling due to its ability to impact HH signaling over 
long distances when expressed in the developing chicken neural tube. Strikingly, anchoring 
HHIP1 to the cell surface using a heterologous transmembrane domain precludes these non-cell 
autonomous effects, demonstrating that HHIP1 secretion underlies long-range inhibition of HH-
dependent patterning and proliferation. Moreover, I provide biochemical evidence that HHIP1 is 
a secreted protein that associates with the cell surface through cell-type specific interactions with 
HS. Biochemical studies demonstrate that these interactions are mediated by basic amino acids 
within the HHIP1 N-terminal CRD. Overall, these data provide the first description of a secreted 
HH pathway antagonist, which has recently been corroborated through complementary 
approaches (Kwong et al., 2014). 
 The novel interaction between HHIP1 and HS is important considering that HS regulates 
HH signaling during vertebrate and invertebrate embryogenesis (Whalen et al., 2013; Bellaiche 
et al., 1998; The et al., 1999; Rubin et al., 2002; Chang et al., 2011). Mutagenesis of the HS-
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binding site within the HHIP1-CRD (HHIP1ΔHS1,2) leads to enhanced HHIP1 secretion from 
cells. Paradoxically, HHIP1ΔHS1,2 is significantly compromised in its ability to influence HH 
signaling over long distances in the developing chick neural tube. This is not due to 
compromised protein activity, but instead reflects a failure to localize to the basement membrane 
(BM) of the neuroepithelium. Therefore, HHIP1-HS interactions likely play two key roles: (1) to 
alter the balance between secretion and cell surface retention of HHIP1 in producing cells and 
(2) to control the tissue distribution of HHIP1 to epithelial basement membranes to promote 
effective HH pathway inhibition. These data are consistent with previous studies in Drosophila 
that demonstrate an essential role for HS to control the tissue distribution of HH ligands  
(Bellaiche et al., 1998; The et al., 1999; Han et al., 2004a; b). 
  Importantly, I demonstrate that endogenous HHIP1 protein is localized to the basement 
membrane in the developing neuroepithelium, consistent with our gain-of-function analysis in 
the chicken neural tube. While I did not detect HHIP1 protein within the developing spinal cord, 
likely due to low expression levels in this region, Hhip1 is expressed in the roof plate of the 
embryonic spinal cord. This dorsal HHIP1 expression in relation to the ventral production of 
SHH is reminiscent of the expression of secreted BMP inhibitors in the notochord, which 
counteracts BMP ligands produced dorsally in the roof plate (McMahon et al., 1998; Liem et al., 
2000); however, more sensitive tools will be required to determine the localization of HHIP1 
protein at this axial level.  
Hhip1 is also expressed in more rostral regions of the neural tube in the developing 
diencephalon, enabling visualization of endogenous HHIP1 protein distribution. Strikingly, I 
detected HHIP1 protein localization to the basement membrane over 200µm away from its 
source of production. This demonstrates that HHIP1 protein is secreted in vivo and accumulates 
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in the neuroepithelial basement membrane. Moreover, I also observed co-localization of 
endogenous HHIP1 and SHH ligand in discrete puncta within this tissue compartment. 
Intriguingly, loss of HHIP1 prevents the distal accumulation of SHH in the basement membrane, 
demonstrating that HHIP1 can directly impact the tissue distribution of SHH. Importantly, these 
data also implicate the basement membrane as one of the functional routes utilized by SHH to 
distribute within a tissue. This compartmentalization provides an efficient mechanism to spatially 
regulate the activity of HH ligands in the developing nervous system, especially when 
considering that each neural progenitor maintains contact with the basement membrane in this 
pseudostratified epithelium. 
Finally, I also observed endogenous, secreted HHIP1 protein in the developing lung. In 
this context, HHIP1 is produced by mesenchymal fibroblasts and accumulates within the BM of 
the developing lung epithelium. This suggests that the localization of HHIP1 to BM may be a 
generalizable aspect of HHIP1-mediated inhibition of HH signaling. Importantly, HHIP1 plays 
an essential, non-redundant role to antagonize HH signaling in the developing lung, as Hhip1-/- 
embryos die at birth due to severe defects in lung branching morphogenesis (Chuang, 2003). 
Despite the presence of PTCH1 feedback up-regulation in the developing lung mesenchyme, 
PTCH1 fails to compensate for the absence of HHIP1 as occurs during neural patterning 
(Bellusci et al., 1997; Chuang, 2003; Jeong and McMahon, 2005; Holtz et al., 2013). One 
intriguing idea is that the secreted activity of HHIP1 underlies its unique requirement in the lung, 
compared to PTCH1 and PTCH2, which are strictly membrane-bound. This idea can be tested in 
explant models and using novel genetic tools (described below). 
 
4.2.2 Future Directions 
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How is HHIP1 Recruited to Basement Membranes In Vivo? 
 Several key questions remain concerning the secretion and tissue distribution of HHIP1. 
While disrupting HS-interactions prevents the BM localization of HHIP1 in the chicken neural 
tube, it remains to be determined whether this mechanism functions to recruit endogenous 
HHIP1 to the BM in the neuroepithelium and lung. Strikingly, I demonstrated that HHIP1 co-
localizes with the predominant BM HSPG, Perlecan, in the developing neuroepithelium and 
lung. In fact, I detected HHIP1 accumulation around lung fibroblasts that express Perlecan, 
suggesting that this may be the relevant core HSPG that controls HHIP1 distribution. It will be 
critical to determine whether endogenous HHIP1 interacts with endogenous Perlecan through co-
immunoprecipitation studies. Moreover, this can be combined with heparanase treatment to 
determine to what extent this interaction is mediated through HS.  
Perlecan mutant mice (Hspg2-/-) mice display several developmental defects. A subset of 
these animals exhibits early lethality at E10.5 with severe defects in head development 
(Arikawa-Hirasawa et al., 1999). The rest die at birth and exhibit exencephaly to varying degrees 
in addition to skeletal dysplasia (Arikawa-Hirasawa et al., 1999; Costell et al., 1999). It would be 
interesting to determine whether Perlecan loss alters the tissue distribution of HHIP1 protein in 
the neural tube and lung of Hspg2-/- mice. To date, the glypicans, a family of 6 GPI-anchored 
HS-decorated proteins, are the only vertebrate HSPGs that have been demonstrated to regulate 
HH pathway activity (Williams et al., 2010; Capurro et al., 2008; Li et al., 2011a); thus, an 
analysis of HH-dependent developmental processes in the neural tube, limb, face, and lung of 
Hspg2-/- mice could provide important insights HSPG-regulation of HH signaling during 
embryogenesis. This type of analysis could be extended to the other glypican family members 
(GPC1, 2, 4, and 6), which possess the ability to regulate HH signal transduction (Williams et al., 
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2010). Moreover, a detailed structure-function analysis of the opposing actions of GPC3 and 
GPC5 to antagonize and to promote HH signaling, respectively, using cell based assays and 
chicken in ovo neural tube electroporations would provide valuable insight into HSPG-mediated 
regulation of HH signaling (Capurro et al., 2008; Li et al., 2011a). 
A Requirement for a Secreted HHIP1 in the Developing Lung? 
 I show through gain-of-function approaches that HHIP1 secretion and interactions with 
HS are required to effectively antagonize HH signaling in the the developing neural tube. 
However, HHIP1 activity is entirely redundant with PTCH1/2 during neural patterning; thus, it 
will be important to test these properties in the context of a developing tissue that depends on 
HHIP1 activity. The lung represents the ideal system to interrogate these questions. One 
approach involves rescue experiments in Hhip1-/- lung explants, which exhibit defects in 
branching morphogenesis in culture (Chuang, 2003). I have previously attempted to introduce 
HHIP1 constructs into lung explants by electroporation. While the lung epithelium was amenable 
to electroporation, I was unable to achieve construct expression in the lung mesenchyme (data 
not shown), the site of endogenous HHIP1 production (Chuang, 2003). A viral transduction 
system may prove more useful to introduce HHIP1, HHIP1ΔHS1,2, and HHIP1::CD4 into the lung 
mesenchyme to determine how these different constructs rescue the lung branching defects. 
Moreover, driving expression of these constructs with a HH-responsive enhancer could restrict 
HHIP1 expression to the appropriate regions of the lung mesenchyme, since Hhip1 is a direct 
HH target gene (Chuang and McMahon, 1999; Vokes et al., 2008; 2007). 
 Previous studies have generated transgenes expressing either full-length Hhip1 or a 
secreted form of Hhip1 lacking the C-terminal 22 amino acids to study the role of HHIP1 in vivo  
(Madison et al., 2005; Zacharias et al., 2011; Treier et al., 2001; Chuang, 2003). Another 
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approach to address the role of secreted HHIP1 would involve engineering novel mouse models 
to replace the C-terminal 22 amino acids with a CD4 domain at the endogenous Hhip1 locus. 
Moreover, point mutations in the HS-binding site within the HHIP1 CRD could be introduced at 
the endogenous locus to test the role of HHIP1-HS interactions in vivo. Generation of these 
alleles may be facilitated using CRISPR/CAS9 genome engineering (Cong et al., 2013; Yang et 
al., 2014; 2013). Lung branching defects observed in Hhip1CD4/CD4 or Hhip1 ΔHS/ΔHS mice would 
directly demonstrate a role for HHIP1 secretion and HS-binding to regulate lung branching 
morphogenesis. Moreover, an analysis of HHIP1 protein distribution in the diencephalon and 
lung in these models would help to determine whether HS-interactions recruit HHIP1 to 
epithelial basement membranes in vivo. 
 
Exploring the Tissue Specific Roles for HHIP1 in Embryonic and Adult Tissues 
 In addition, a conditional Hhip1 allele would prove invaluable to further examine the role 
of HHIP1 in embryonic and adult tissues. One striking result is that Hhip1 is highly expressed in 
the developing roof plate and paraxial mesoderm, but is weakly expressed in ventral neuronal 
progenitors. Currently, it is assumed that the Hhip1 produced in ventral progenitors acts to 
restrict HH signaling during ventral neural patterning; however, it is likely that HHIP1 produced 
in the roof plate and paraxial mesoderm could also play a role (Jeong and McMahon, 2005). To 
test this, Hhip1 could be conditionally ablated in these different tissue compartments to see if 
they contribute to regulating HH-dependent ventral patterning. Using a GDF7-Cre line, Hhip1 
can be specifically ablated in the developing roof plate (Lee et al., 2000). An expansion of 
ventral HH-dependent cell fates in MT-Ptch1;Ptch1-/-;Hhip1f/-;Gdf7-Cre embryos, which lack 
PTCH1-feedback inhibition combined with specific ablation of Hhip1 in the roof plate, would 
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determine whether HHIP1 is produced and secreted from the roof plate to inhibit HH signaling at 
a distance in the ventral neural tube. Moreover, Hhip1 can be deleted in the paraxial mesoderm 
using a Dll1-Cre transgene to determine whether HHIP1 produced in the paraxial mesoderm can 
inhibit HH signaling in ventral progenitors (Wehn et al., 2009). These data would demonstrate 
novel tissue interactions that regulate HH signaling during embryogenesis. 
 Throughout the course of my studies, I have also observed that Hhip1 expression persists 
into adulthood in several tissues (Fig. 4-5). The most striking examples of this are in the adult 
lung and intestine. In E18.5 lung tissue, I detect HHIP1 protein expression in PDGFRα-
expressing mesenchymal cells in the alveoli (Fig. 4-5, A-D, arrowheads). I also detect HHIP1 
expression in myofibroblast-like cells surrounding the larger airways (Fig. 4-5, E-H, arrows). 
Additionally, HHIP1 is largely excluded from Aquaporin-5+ type I cells and Surfactant Protein 
C+ type II cells (Fig. 4-5, I-P). This expression pattern is similar in the adult lung (data not 
shown). Interestingly, I also observe strong Hhip1 expression in mesenchymal cells within the 
adult intestine (Fig. 4-5, Q-X); however, the identity of these HHIP1-expressing cells remains 
unknown. Since Hhip1-/- embryos do not survive post-natally, a conditional allele will be 
essential to determine the role of HHIP1 in the lung, stomach, and in other tissues during 
adulthood. 
 
Hhip1 Mice as a Model for Human Lung Diseases 
 The persistence of Hhip1 expression in the adult lung is intriguingly considering that 
HHIP1 has been implicated in a variety of human lung diseases, including chronic obstructive 
pulmonary disease (COPD), asthma, and lung cancer (Pillai et al., 2009; Van Durme et al., 2010; 
Zhou et al., 2012; Young et al., 2010; Li et al., 2011b; Castaldi et al., 2014). One intriguing idea 
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involves the use of Hhip1+/- mice or mice with conditional ablation of Hhip1 in the adult lung as 
a model for these various lung diseases. Indeed, my preliminary data demonstrates structural 
abnormalities in a subset of Hhip1+/- lungs, including delayed branching morphogenesis and 
mesenchymal thickening (data not shown). COPD is characterized by two distinct pathologies. 
This includes chronic bronchitis, which involves inflammation and remodeling of the larger 
airways of the lung, and emphysema, or a loss of distal lung tissue resulting in a decreased area 
for gas exchange (Tuder and Petrache, 2012). Interestingly, my preliminary data suggests that 
Hhip1 is expressed in the mature lung in regions affected by COPD (Fig. 4-5).  
COPD is primarily a disease related to long term tobacco use (Tuder and Petrache, 2012); 
thus, the most widely used model to study COPD involves exposing mice to cigarette smoke. 
This recapitulates many aspects of the disease, including airway remodeling and fibrosis in 
addition to loss of alveolar structures (Churg et al., 2008; Wright et al., 2008). It would be 
interesting to monitor the expression of Hhip1 and other HH pathway components throughout 
the development of COPD in this model. Moreover, an accelerated development of disease 
pathology in Hhip1+/- mice or in conditional Hhip1 mutants compared to wildtype controls would 
demonstrate the importance of HHIP1 in COPD progression, which could potentially be 
mitigated through use of pharmacologic HH pathway inhibitors. A similar approach could be 
used in other mouse models of lung disease where HH signaling has been implicated, including 
in bleomyin-induced lung fibrosis (Farrokhi Moshai et al., 2014). 
 
A Novel Interaction Between HHIP1 and HH Ligands? 
Many questions remain concerning the molecular and biochemical mechanisms 
underlying HHIP1 function. One key aspect involves the ability of HHIP1 to bind HH ligands. 
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Two crystallographic studies demonstrated that HHIP1 lacking the N-terminal CRD (HHIP1ΔN) 
binds to SHH through the β-propeller domain (Bosanac et al., 2009; Bishop et al., 2009). An 
aspartic acid residue (D383) within this region is essential to coordinate with the zinc ion present 
within HH ligands (Bishop et al., 2009). Replacing this negative residue with a positively 
charged arginine (D383N) completely abolishes the physical interaction between HHIP1ΔN and 
SHH (Bishop et al., 2009). Based on these data, I generated the analogous mutation in full length 
HHIP1 (HHIP1D383R) to test in chicken electroporation experiments (Fig. 4-6). Strikingly, 
HHIP1D383R is still capable of inhibiting HH-dependent patterning and growth, albeit in a cell 
autonomous manner  (Fig. 4-6, arrows). These data implicate a novel interaction between the 
HHIP1 CRD and HH ligands; however, one caveat to these studies is the presence of endogenous 
HHIP1 in the chicken neural tube, which could interact with HHIP1D383R.  
Intriguingly, structural studies have demonstrated that the CRDs present in other proteins 
can directly bind to lipophilic molecules. For example, the CRD in Frizzled receptors bind to the 
palmitoleyl group of Wnt ligands and the SMO CRD can interact with oxysterols (Janda et al., 
2012; Bazan et al., 2012; Myers et al., 2013; Nachtergaele et al., 2013; Nedelcu et al., 2013). 
One hypothesis involves the HHIP1 CRD interacting with HH ligands either through the 
cholesterol or palmitate moieties. This should be followed up through biochemical and 
crystallographic studies combined with cell signaling and chicken electroporation assays. 
Moreover, recent evidence demonstrates that the secreted GPI-hydrolase and Wnt inhibitor, 
Notum, can bind to and cleave the palmitoleate residue from Wnt ligands to inhibit signaling 
(Kakugawa et al., 2015). It will be interesting to determine whether HHIP1 can alter the 
structural properties of HH ligands in a similar manner. 
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HHIP1 as a Multimodal Inhibitor of Morphogen Signaling 
While HHIP1 is primarily thought to act as an inhibitor of HH signaling in mammals, 
there is evidence that HHIP1 might influence other cell signaling pathways. Interestingly, studies 
in Xenopus demonstrate that WNT, FGF, and BMP signaling can regulate Hhip1 expression 
(Cornesse et al., 2005). Subsequent gain- and loss-of-function studies demonstrated that HHIP1 
could interfere with FGF8-dependent induction of Xbra expression and MAPK-phosphorylation 
(Cornesse et al., 2005). Moreover, HHIP1 could block the ability of WNT8 ligand to induce 
secondary axis formation in Xenopus embryos (Cornesse et al., 2005). Intriguingly, WNT3A was 
refractory to HHIP1-inhibition, demonstrating ligand specificity in the ability of HHIP1 to 
impact WNT signaling (Cornesse et al., 2005). These experiments suggest that HHIP1 might act 
as a multi-modal inhibitor of morphogen signaling, similar to Cerberus, which antagonizes the 
activity of BMP, Nodal, and WNT ligand (Piccolo et al., 1999; Bouwmeester et al., 1996). 
Several lines of inquiry should be pursued to test whether HHIP1 can antagonize WNT or 
FGF signaling in mammals. One simple experiment would be to test whether HHIP1 can 
antagonize these pathways in cell signaling assays. This should be performed using a variety of 
different WNT and FGF ligands to test the specificity of these interactions. These data could be 
followed up through biochemical studies to determine whether HHIP1 physically interacts with 
these signaling ligands or their corresponding receptors. These interaction domains could then be 
mapped using the HHIP1 domain mutants generated in Chapter III. Finally, a careful 
examination of WNT- and FGF-dependent developmental processes in Hhip1-/- animals may 
provide in vivo evidence that HHIP1 can impact these signaling pathways. 
 
Exploring Additional HHIP-Related Proteins in Vertebrate HH Signaling 
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In addition to HHIP1, vertebrates possess two additional HHIP1-like proteins, HHIP1L1 
and HHIP1L2 (Pei and Grishin, 2012). These were identified through sequence homology and 
share roughly 30% amino acid identity with HHIP1 (data now shown). Both HHIP1L1 and 
HHIP1L2 possess a conserved N-terminal CRD and a β-propeller domain, but lack the two C-
terminal EGF repeats. It would be interesting to determine whether these molecules can 
influence HH signaling or other signaling pathways. While HHIP1L1/2 lack key residues that are 
required for HHIP1 interactions with HH ligands, it is possible that these proteins could interact 
with HH in a mechanism that is distinct from that of HHIP1. Initially, this should be approached 
through cell signaling assays and chicken electroporation experiments. If overexpression of these 
molecules does influence HH-dependent ventral neural patterning, it would be important to 
follow up these studies through targeted mouse mutants to determine their roles in vivo. This 
would demonstrate that HHIP1 proteins comprise a family of HH pathway components that are 
critical to regulate HH signal transduction during vertebrate embryogenesis. 
Overall, data presented in this dissertation demonstrate that the cell surface HH pathway 
antagonists, PTCH1, PTCH2, and HHIP1, play overlapping and essential roles to restrict HH 
signaling during vertebrate embryogenesis. In addition, I provide evidence to re-define HHIP1 as 
a secreted antagonist of HH signaling that controls the localization of HH ligands during 
development. Moreover, I find that HHIP1 associates with HS to localize to epithelial basement 
membranes in several tissues during embryogenesis. These results provide novel mechanistic 
insights into how HH signaling is antagonized during vertebrate embryogenesis and provide a 
foundation for further investigation into the role of HH pathway inhibitors during development, 
tissue homeostasis, and disease processes. 
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4.3 Materials and Methods 
Luciferase assays 
Ptch1-/- mouse embryonic fibroblasts (MEFs; a gift from Dr. M.P. Scott) were plated at 
50,000 cells per well on gelatinized 24-well plates and transfected 16-24 hours later with 150ng 
of a ptc∆136-GL3 luciferase reporter (Chen et al., 1999; Nybakken et al., 2005), 100ng of a 
secreted placental alkaline phosphatase construct, and varying amounts of control (pCIG) or 
experimental constructs using Lipofectamine 2000 (Invitrogen). After 48 hours, cells were 
changed into low serum media (0.5%) to stimulate ciliogenesis and HH signaling. After another 
48 hours, 100μl of medium was removed from each well and transferred to a 96-well clear 
bottom plate, heat inactivated at 65°C for 1 hour to deactivate the endogenous alkaline 
phosphatase activity, and then 100μl of alkaline phosphatase substrate was added per well 
(Alkaline Phosphatase Yellow pNPP Liquid Substrate for ELISA, Sigma-Aldrich). Absorbance 
at 405nm was read 2 hours later. Cells were also lysed and the luciferase activity was measured 
using the Luciferase Assay System (Promega). Luciferase values were normalized to alkaline 
phosphatase activity to control for transfection efficiency. Each condition was performed in 
triplicate. To measure responsiveness to SHH ligand, varying amounts of either control- or 
NSHH-conditioned medium were added when cells were switched into low serum medium. 
NIH/3T3 cell Luciferase assays were adapted from a previously published protocol 
(Nybakken et al., 2005; Holtz et al., 2013). Mouse NIH/3T3 fibroblasts were plated at 25,000 
cells/well on gelatinized 24-well plates and transfected 16-24 hours later with 150ng of a 
ptc∆136-GL3 luciferase reporter (Chen et al., 1999; Nybakken et al., 2005), 50ng of pSV-β-
galactosidase (Promega), and 100 ng of control (pCIG) or experimental constructs using 
Lipofectamine 2000 (Invitrogen). After 48 hours, cells were placed in low serum (0.5%) media 
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with 25μl of conditioned media from control (pCDNA3) or NSHH transfected (NShh-pCDNA3) 
COS7 cells. Luciferase (Luciferase Assay System kit, Promega) and β-galactosidase (BetaFluor 
β-galactosidase Assay Kit, Novagen) activity were measured after 48 hours. Luciferase values 
were normalized to β-galactosidase activity and expressed as fold induction relative to control 
treated cells. 
 
Cellular localization of HH pathway components 
NIH/3T3 fibroblasts were plated at 150,000 cells/well on coverslips and transfected 16-24 hours 
later. 6 hours post-transfection, cells were placed into low serum (0.5%) media and fixed 48 
hours later in 4% PFA for immunofluorescent analysis. 
 
Chicken in ovo neural tube electroporations 
Electroporations were performed as previously described (Holtz et al., 2013; Tenzen et al., 
2006). In brief, DNA (1.0 µg/µl) mixed with Fast Green (50 ng/µl) was injected into Hamburger-
Hamilton stage 11-13 embryos and then subjected to electroporation. Embryos were dissected 24 
hours post electroporation (hpe), fixed in 4% PFA, and processed for immunofluorescent 
analysis. Chicken embryos were sectioned at the wing axial level. Electroporated cells were 
marked by constructs expressing nuclear-localized EGFP (pCIG). 
  
Immunofluorescence 
Immunofluorescence was performed essentially as previously described (Holtz et al., 2013). The 
following antibodies were used: mouse IgG1 anti-NKX6.1 (1:20, Developmental Studies 
Hybridoma Bank [DSHB]), mouse IgG1 anti-PAX7 (1:20, DSHB), mouse IgG1 anti-HA 
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(1:1000, Covance), mouse IgG2b anti-Acetylated Tubulin (1:2500, Sigma-Aldrich), goat IgG 
anti-HHIP1 (1:200, R&D Systems), rabbit IgG anti-Aquaporin 5 (1:1000, Abcam), rabbit anti-
Surfactant Protein C (1:100, Seven Hills Bioreagents), and rabbit IgG anti-β-galactosidase 
(1:10,000, MP Biomedicals). Nuclei were visualized with DAPI (1:30,000, Molecular Probes). 
Alexa 488 and 555 secondary antibodies (1:500, Molecular Probes) were visualized on a Leica 
upright SP5X confocal microscope. 
 
Western Blot Analysis 
Western blot analysis was performed according to standard methods. Briefly, MEFs were lysed 
in RIPA buffer (50mM Tris-HCl [pH 7.2], 150mM NaCl, 0.1% TX-100, 1% sodium 
deoxycholate, 5mM EDTA) containing Complete Mini Protease Inhibitor Cocktail (Roche), 
centrifuged at 20,000 x g for 30 min at 4°C, and analyzed by SDS-PAGE. Proteins were 
transferred to PVDF and probed with a mouse IgG1 anti-HA antibody (1:1000, Covance). 
 
Immunoprecipitation 
 1mg of MEF lysates were brought to a concentration of 2mg/ml and pre-cleared with 
30µl bead volume of Protein G-Agarose (Roche) for 1 hour at 4°C. Anti-HA antibody (mouse 
IgG1, Covance) was added to the pre-cleared lysates at 1:200 overnight at 4°C. Immune 
complexes were pulled down using 30µl bead volume of Protein G-Agarose for 1 hour at 4°C. 
The beads were washed 5x 10 minutes in wash buffer at 4°C  (1% NP-40, 50mM Tris-HCl, 
150mM NaCl, 5mM EDTA, pH 7.2) and proteins were eluted from the beads with laemmli 
buffer for SDS-PAGE analysis.  
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4.4 Figures 
 
Figure 4-1. The PTCH1 C-terminal tail is essential for SMO inhibition. (A) Cartoon 
schematics of PTCH1 C-terminal tail deletion constructs. The number of amino acids remaining 
in the C-terminal tail is depicted below each construct. (B) HH-responsive luciferase reporter 
activity measured from Ptch1-/- mouse embryonic fibroblasts (MEFs) transfected with the 
indicated constructs. Data expressed as luciferase reporter activity normalized to cells transfected 
with empty vector alone (pCIG) and represented as mean +/- SEM. (C) As in B, including 
treatment with different amounts of NSHH-conditioned media. P-values determined by Student’s 
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Figure 4-2. Identification of a cilia localization motif in PTCH1 that is required its full 
activity. (A-L) Immunofluorescent detection of HA (green; A, C, D, F, G, I, J, L) and Acetylated 
Tubulin (ACTUB, red; B, C, E, F, H, I, K, L) in NIH/3T3 cells transfected with Ptch1::HA (A-
C), Ptch2::HA (D-F), Ptch1ΔCLS (G-I), or dmPtc::HA (J-L). DAPI labels nuclei (blue; C, F, I, L). 
(M) Ptch1-/- MEFs transfected with a HH-responsive luciferase reporter and co-transfected with 
the indicated constructs. Luciferase reporter activity is normalized to cells transfected with empy 
vector alone and presented as mean +/- SEM. (N) HH-responsive luciferase reporter activity 
measured from NIH/3T3 fibroblasts stimulated with either control- or NSHH-conditioned media 
and co-transfected with the indicated constructs. Data represented as mean +/- SEM (n.s., not 
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Figure 4-3. PTCH2G465V fails to localize to the primary cilium to antagonize ligand-
dependent HH signaling. (A-L) NIH/3T3 cells transfected with Ptch1G495V::HA (A-B), 
Ptch1D499Y::HA (D-F), Ptch2G465V::HA (G-I), Ptch2D469Y::HA (J-L) and stained with 
antibodies to detect the expression of HA (green; A, C, D, F, G, I, J, L) and Acetylated Tubulin 
(ACTUB, red; B, C, E, F, H, I, K, L). Nuclei are stained with DAPI (blue; C, F, I, L). Arrows 
(G-I) denote lack of ciliary localization of PTCH2G465V. (M, N) HH-responsive luciferase 
reporter activity measured from NIH/3T3 fibroblasts transfected with the indicated constructs 
and treated with with either control- or NSHH-conditioned media. Data presented as mean +/- 
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Figure 4-4. Initial analysis of PTCH1 and CDON stable cell lines. Western blot analysis of 
lysates from Ptch1-/- (A) and Cdon-/- (B) MEF lines stably expressing PTCH1::HA and 
CDON::HA, respectively, compared to the parental MEF lines. (B) Immunoprecipitation using 
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Figure 4-5. HHIP1 protein detection in mature tissues. Immunofluorescent detection of 
HHIP1 (green; A, C, D, E, G, H, I, K, L, M, O, P, Q, S, T, U, W, X), PDGFRα (red; B-D, F-H), 
Aquaporin 5 (AQP5, red; J-L), Surfactant Protein C (SFTPC, red; N-P), and β-galactosidase 
(βGAL, red; R-T, V-X) in E18.5 wildtype lungs (A-P) and adult Hhip1+/- intestines (Q-X). DAPI 
labels nuclei (blue; D, H, L, P, T, X). Arrowheads (A-D) highlight co-localization between 
HHIP1 and PDGFRα expression. Arrows (E-H) demonstrate HHIP1 expression in 
myofibroblast-like cells surrounding the larger airways. Scale bar (A): 50µm. 












Figure 4-6. HHIP1D383R antagonizes HH-dependent ventral neural patterning in the 
chicken neural tube. Hamburger-Hamilton stage 11-13 embryos were electroporated with 
Hhip1D383R-pCIG and isolated 24 hours post-electroporation (24hpe). Embryos were sectioned at 
the wing axial level and stained with antibodies to detect expression of NKX6.1 (red; B, C) and 
PAX7 (red; D, E). Nuclear EGFP expression labels electroporated cells (green; C, E). DAPI 
reveals nuclei (grey; A). Arrows denote repression of NKX6.1 (B, C) or ectopic expression of 
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